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Abstract 
Background: Respiratory Syncytial Virus (RSV) is a common cause of 
bronchiolitis during infancy; virtually all children are infected with this virus by 
the age of 2 years. Although the majority have a self-limiting, mild infection, 1-
3% have disease severe enough to warrant hospital admission. These 
children have an abundance of neutrophils (>80% of bronchoalveolar lavage 
cells) within their airways. There is however, a lack of detailed investigation 
into their role in viral infection. Our group has previously shown RSV 
associated with ex vivo neutrophils from infected infants. To explore this 
observation further, I have modelled and visualised the RSV-neutrophil 
interaction, hypothesising that neutrophils play a role in the innate viral 
response in the airway. 
 
Aims: The aims of this thesis were to (i) establish an in vitro model of RSV-
neutrophil interaction, (ii) determine whether RSV is taken up into the 
neutrophil, (iii) determine if RSV productively replicates inside the neutrophil, 
(iv) compare neutrophil-RSV interaction in adult and infant neutrophils and (v) 
investigate the response of the neutrophil to RSV. 
 
Methods: An in vitro model of RSV-neutrophil interaction was established 
using highly purified adult and cord blood neutrophils. Neutrophils were 
analysed by quantitative RT-PCR, western blot, and by confocal microscopy 
using indirect immunocytochemistry. In addition, ex vivo BAL neutrophils from 
RSV infected infants were examined by confocal microscopy. Following 
validation of this model, confirming the presence of virus within the neutrophil, 
a human gene microarray was performed.  
 
Results: Interaction of neutrophils with RSV was modelled in vitro and 
demonstrated by PCR analysis and western blot. RSV N gene expression 
revealed maximal neutrophil uptake at 4 hours. A time course over 20 hours 
showed no increase in RSV expression, implying that active RSV replication 
was not occurring. Confocal microscopy revealed internalisation of RSV, with 
virus distributed throughout the cytoplasm. Imaging of ex vivo neutrophils 
extracted from bronchoalveolar lavage of RSV-infected infants showed a 
similar distribution. RSV induced significant change in neutrophil gene 
expression with over 1000 differentially expressed genes being identified. 
Pathway analysis revealed an RNA virus specific transcriptional response. 
Results for key molecules were subsequently validated by RT-PCR.  
 
Conclusions: Neutrophils do not allow RSV to replicate within them. In 
contrast, following interaction with RSV, they alter their gene expression 
profiles through the modulation of interferon responses and other pathways, 
thereby inhibiting viral replication. Evidence presented in this thesis supports 
a novel role for neutrophils as innate cells at the frontline of antiviral immunity 
in RSV disease. 
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Chapter 1 General Introduction 
1.1 Respiratory Syncytial Virus 
Since its discovery in 1956, respiratory syncytial virus (RSV) has been 
recognised as a pathogen causing a significant burden of disease to the 
paediatric population. It is an important cause of severe respiratory illness in 
infants and young children and the leading cause of bronchiolitis. Despite 
increasing understanding of the immunology and pathology of the virus, the 
number of admissions to hospital continues to rise. In the UK, admissions 
coded as acute bronchiolitis increased from 21 330 in 2004/5 to 34 668 in 
2012/13 (1).  
 
RSV was first identified in chimpanzees with symptoms of an upper 
respiratory tract infection (2). It was initially named Chimpanzee Coryzal 
Agent (CCA). In 1957, a virus which was indistinguishable from CCA, was 
isolated from throat swabs from two separate infants by Chanock and Finberg 
(3). These three isolates were grouped and named respiratory syncytial virus 
because of the ability they showed in culture to cause epithelial cells to fuse 
forming syncytia.  
1.1.1 Classification 
RSV is an RNA virus of the Paramyxoviridae family. The Paramyxoviridae 
family is subdivided into Paramyxovirinae and Pneumovirinae. The 
Pneumovirinae family is split into the Pneumovirus and Metapneumovirus 
genus, with RSV belonging to the Pneumovirus genus.  Avian pneumovirus 
and human metapneumovirus belong to the Metapneumovirus genus. RSV 
contains more genes/proteins than any other member of the Paramyxoviridae 
family.  
1.1.2 Structure 
RSV is a negative-sense, single-stranded RNA virus consisting of 15,191 
base pairs. The genome is found encapsidated by the nucleocapsid N protein 
and has 10 genes encoding 11 proteins. The virus, which is 150-300nm in 
diameter, is enveloped in a lipid bilayer, and has 3 surface glycoproteins: the 
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large glycoprotein G, fusion protein F and small hydrophobic protein SH. 
These viral glycoproteins form separate homo-oligomers that appear as short 
surface spikes (Figure 1-1). RSV lacks neuraminidase or haemagglutinin 
activity. 
 
 
 
Figure 1-1 Schematic representation of an RSV virion identifying key proteins  
The RSV virion is composed of a lipid bilayer which encapsulates the negative sense single 
stranded RNA. There are 3 surface glycoproteins, G, F, and SH. Inside the lipid bilayer is the 
matrix protein (M). The nucleocapsid is made up of 4 proteins, L, M, N and P.  
 
Lipid envelope 
The F protein, typical of a paramxyoviridae F protein, directs the fusion 
between the virus and the host plasma membrane. In addition, it is capable of 
attaching to neighbouring cells and promoting syncytia formation. The G 
protein is the major attachment protein, containing a single hydrophobic 
region. It is a type II transmembrane glycoprotein. The SH protein is a 
transmembrane protein which appears to be a viroporin, a small viral protein 
which can modify membrane permeability and affect budding (4). The non-
glycosylated matrix protein M has a role in virus particle formation. 
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Ribonucleocapsid  
The nucleocapsid, contained inside the lipid bilayer, is 12-15nm in diameter 
and made of 4 nucleocapsid proteins which replicate and transcribe the RSV 
genome, these are the nucleocapsid protein N, the phosphoprotein P, the 
anti-termination factor M2-1 and the large polymerase subunit L. M2 is the 
second matrix protein encoding both M2-1 (elongation factor) and M2-2 
(transcription regulation) 
 
Non-structural proteins 
NS1 and NS2 are non-structural proteins that are unique to the Pneumovirus 
genus. These proteins act cooperatively to interfere with innate immune 
responses including interferon induction and signalling. They suppress the 
activation and nuclear translocation of the IFN-regulatory factor IRF-3 (5).  
NS1 and NS2 have also been shown to activate antiapoptotic genes of the 
host cell, thereby prolonging the life of the cell and increasing viral yield (6).  
1.1.3 Viral replicative cycle 
Attachment and viral entry are mediated by the G and F glycoproteins. Much 
of our understanding of RSV cell entry is inferred from our knowledge of other 
enveloped viruses. These can be grouped into two broad categories; those 
that require acidic pH for fusion and entry and those that fuse at neutral pH. 
The latter group include the paramyxovirus family, including RSV, which enter 
irrespective of drugs that inhibit acidification (7, 8). Entry to host cells 
therefore is presumed to be by plasma membrane fusion of the viral envelope 
and the cell plasma membrane (9). There is some evidence, discussed in 
detail in Chapter 4, that entry can occur by endocytosis, both clathrin-
mediated and macropinocytosis (10, 11). Transcription and replication of the 
genome occurs in the cytoplasm. RSV mRNAs and proteins can be detected 
at 4–6 hours post infection of epithelial cells, reaching a peak by 15–20 hours 
(12). Progeny virus begins by 10–12 hours post infection, and continues until 
the cells die by 30–48 hours (13). 
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1.2 Respiratory Syncytial Virus bronchiolitis 
Viral bronchiolitis occurs predominantly in infants under the age of one year 
and is the commonest reason for hospitalisation in this age group. 
Approximately 1 in 5 infants will develop bronchiolitis in their first year of life. 
RSV is the leading cause of bronchiolitis, resulting in up to 80% of cases.  
1.2.1 Epidemiology 
RSV is a common infection during infancy; virtually all children will be infected 
by the age of 2 years (14).  Although the majority have a self-limiting, mild 
infection, 1-3% of all infants have disease severe enough to warrant 
admission to hospital (15-18). Most of these hospitalised children are 
previously healthy, although several groups of infants are predisposed to 
severe RSV infection; premature or extremely low birth weight infants, and 
those with chronic lung disease, congenital heart disease or 
immunodeficiency (19-21). Incomplete development of the airway and airway 
hyperreactivity may contribute to the increased risk of disease seen in preterm 
infants. Pulmonary hypertension and cyanosis are associated with worse 
outcome in those infants with pre-existent heart disease (22). RSV epidemics 
occur annually. In temperate climes this occurs during the winter season. In 
Liverpool, at Alder Hey Children’s Hospital, peak RSV bronchiolitis is seen 
between November and January (Figure 1-2). 
1.2.2 Incidence  
RSV is believed to be the most important acute lower respiratory infection 
(ALRI) causing viral pathogen worldwide. In 2010, a systematic review was 
carried out, funded by the World Health Organisation (WHO) and Bill and 
Melinda Gates Foundation, which included unpublished data and produced a 
global estimate of RSV burden of disease (23). They estimated the incidence 
of RSV-associated ALRI in under 5 year olds to be 33.8 (95% CI 19.3-46.2) 
million new episodes in 2005. Severe RSV requiring a hospital admission 
accounted for 3.4 (2.8-4.3) million of these episodes. It was estimated that 66 
000 – 199 000 under 5 year olds died from RSV associated ALRI in 2005, 
99% of these deaths occurring in developing countries. RSV has been a  
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Figure 1-2 Number of RSV/week at Alder Hey Hospital   
Line graph showing number of RSV isolates/week from 1st week of October to end of February during 2008-2014 at Alder Hey Children’s Hospital, Liverpool 
Image generated from data collated by the Microbiology department at Alder Hey Children’s Hospital, Liverpool 
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priority for many national health organisations for over 20 years, with 
renewed attention in 2000 following the establishment of the Millennium 
Development Goals, which included reduction in child mortality (23). The 
WHO have also recognised the importance of vaccine development for RSV 
and their ‘Product Development for Vaccines Advisory Committee’ (PDVAC) 
have identified it as a priority area (24).  
1.2.3 Spread of RSV 
RSV is one of the most contagious human pathogens (25). It is spread by 
droplet and secretion transmission between individuals in close contact. The 
incubation period is between two to eight days. By two years of age, almost 
all children will have had an RSV infection at least once (26).  
1.2.4 Clinical presentation 
Initial symptoms are generally those of an upper respiratory tract infection 
with coryza, rhinitis and cough (27). A third of children develop otitis media 
(28). Symptoms can progress over 3-4 days to involvement of the 
bronchioles leading to dyspnoea, subcostal recession and poor feeding. 
When examined, chest auscultation may reveal wheeze and/or crackles. 
Infants younger than 6 weeks of age may present with apnoea and no other 
clinical signs. Bronchiolitis can lead to acute respiratory failure, characterised 
by hypoxia and carbon dioxide retention. The acute illness improves over 5-7 
days but a persistent cough lasting for more than two weeks occurs in 50% 
of children (29).  
1.2.5 Delayed respiratory sequelae of RSV bronchiolitis 
In some children, a ‘post bronchiolitis syndrome’ occurs characterised by 
months of episodic wheeze, typically with other viral infections. Stein et al 
showed that RSV bronchiolitis carried the highest independent risk ratio for 
asthma (30). The Tucson study, a longitudinal study investigating 
development of asthma, revealed that RSV significantly increased the risk for 
wheezing in the first 10 years of life but that was no longer significant at 13 
years of age (30). However, in 2007 Simoes et al offered the first evidence 
that RSV causes recurrent wheezing. A prospective, multicentre, double-
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cohort, follow-up study in 27 centres recruited 421 pre-term infants, who 
either did or did not received prophylactic palivizumab. The recruits were 
followed up for two years, and an association between palivizumab 
prophylaxis and improved respiratory outcomes was statistically significant 
even after adjustment for confounding factors. The authors concluded that 
preventing RSV LRTI using palivizumab may reduce subsequent recurrent 
wheezing in pre-term infants (31). In 2013 Blanken et al showed that 
palivizumab treatment resulted in a significant reduction in wheezing 
during the first year of life, even after the end of treatment, thus 
implicating RSV as an important cause of recurrent wheeze during the 
first year of life in such infants. 
1.2.6 Management 
Supportive care is the mainstay of treatment. Children are admitted to 
hospital if they have apnoea, take less than 75% of usual feed volume, 
and/or have severe respiratory distress and/or hypoxia. Care is given in the 
form of hydration (nasogastric feeds or intravenous fluid), and/or 
supplemental oxygen for hypoxaemia. To date, no treatments for 
bronchiolitis have been shown to be efficacious, despite many being trialled, 
including antibiotics, hypertonic saline, adrenaline, salbutamol, montelukast, 
ipratropium bromide or systemic inhaled corticosteroids for bronchiolitis (32). 
However, there are a number of new promising anti-virals coming through 
(33). In particular, oral GS-5806, an oral RSV-entry inhibitor, has shown 
promising results in an RSV challenge model using healthy adults; reducing 
viral load and severity of clinical disease (34). 
1.2.7 Prophylaxis 
Palivizumab is a humanised monoclonal antibody (IgG11K) that is used to 
prevent RSV infection in high-risk infants. It is directed towards an epitope in 
the ‘A’ antigenic site on the F protein, the protein responsible for fusing the 
virus with the host cell (35, 36). The half-life of palivizumab is 18 – 21 days 
and therefore it must be given monthly to maintain protection over the winter 
months/RSV season (35). It is licensed in the UK only for certain high-risk 
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infants for whom RSV infection is likely to cause significant illness or death 
(37). These are: 
• Preterm infants who have chronic lung disease (defined as oxygen 
dependency for at least 28 days from birth). Eligibility however, depends 
on their gestational age at birth and their corrected age at the start of 
the RSV season.   
• Pre-term infants who have haemodynamically significant, acyanotic 
congenital heart disease.  
• Infants < 24 months with severe combined immunodeficiency disorder.  
• Infants on long term ventilation under certain conditions (38).  
1.3 Innate immune response in RSV bronchiolitis  
Inoculation of RSV into the nose or eyes results in virus entering the 
nasopharynx. Once within the respiratory tract, it can be trapped by mucus 
lining the airways. Over several days the virus can spread to the lower 
airways. The mechanism by which this occurs is not known but may be due 
to spread along the epithelium or through aspiration of the nasopharyngeal 
secretions. It is the ciliated cells of the small bronchioles and type 1 
pneumocytes in the alveoli that are infected, with the basal cells being 
spared (39).  
1.3.1 Viral recognition 
Viral infection of epithelial cells leads to recognition of viral components 
within these cells by pattern recognition receptors (PRRs). RNA viruses are 
detected by two kinds of PRR; cytoplasmic recognition receptors such as 
retinoic acid-inducible gene I-like receptor (RIG-1), and Toll-like receptors 
(TLRs). RIG-1 is a highly inducible cytoplasmic RNA helicase that signals 
antiviral responses after binding dsRNA (40, 41). In contrast to TLRs, these 
receptors are cytoplasmic and can therefore recognise intracellular virus 
(42). TLRs are membrane bound receptors. In RSV infection, TLR 3 and TLR 
4 are thought to mediate RSV signalling (43-45). This signalling takes the 
form of nuclear factor KB (NFKB) activation and cytokine secretion. TLR2 and 
TLR6 have also been implicated in the control of RSV replication, as well as 
in the production of inflammatory cytokines by leucocytes, and neutrophil 
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migration into the lungs (46).  RSV can modulate changes in the expression 
of these TLRs, enhancing inflammatory responses, for example in epithelial 
cells an upregulation of TLR4 has been described (47). In addition, 
neutrophils from BAL of RSV infected pre-term infants express higher levels 
of TLR4 than healthy infants (48).   
1.3.2 Inflammatory response 
NFKB is translocated to the nucleus upon activation of PRRs, leading to the 
production and secretion of cytokines and chemokines (illustrated below in 
Figure 1-3 by airway epithelium infected with RSV). Of particular significance 
to viral infection are type I interferons (IFNs). Not only produced by epithelial 
cells, they are also produced by plasmacytoid dendritic cells (pDCs) and 
macrophages in response to TLR and RIG-1 activation by virus. Type I IFNs 
bind to cell surface receptors activating signalling pathways, promoting an 
anti-viral response. Downstream signalling molecules vary depending on the 
cell type but transcription of over 100 IFN stimulating genes (ISGs) lead to an 
anti-viral state. STAT1/STAT2 signalling is the best described of these 
pathways. As well as the production of these specific antiviral factors there is 
also expression of CXC and CC chemokines that stimulate the recruitment of 
a number of cells including neutrophils, natural killer (NK) cells, and dendritic 
cells (49). One of the first cells, alongside epithelial cells, to encounter RSV 
in the airways, is the macrophage.  
1.3.3 Macrophages 
Macrophages help to control viral infection through direct interaction with 
helper and cytotoxic T cells and also through the production of cytokines, in 
particular type I IFN (50). In response to RSV they secrete a host of 
cytokines, which in turn activate and recruit neutrophils, lymphocytes and NK 
cells to the site of infection. They destroy invading pathogens by 
phagocytosis and subsequently function as antigen presenting cells (APCs) 
by presenting protein on their cell membrane (51, 52).  
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Figure 1-3 RSV infection modifies the inflammatory environment in the airways. 
This image illustrates how RSV infection of the epithelium modifies the inflammatory 
environment of the airways. RSV infects the ciliated airway epithelial cells, and as a result 
the infected cells mount a defence mechanism. Activation of NFkB by RSV-derived 
molecular patterns precedes secretion of type I IFNs. Engagement of surface PRRs, such 
as TLR4, by RSV induces production of several chemokines and cytokines. These 
messengers trigger an influx of inflammatory cells, including neutrophils. In the meantime 
viral replication is ongoing inside the cells, spreading from cell to cell.  
Adapted from Bueno et al. (2011) (54) 
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1.3.4 Neutrophils  
Neutrophils intensify the cellular response through the production of further 
chemokines (53). Although these cells are numerically the major 
inflammatory cell within the airway in infants with RSV bronchiolitis, their 
specific role is largely undetermined (55). The function of these important 
cells is discussed in more detail in Section 1.6.  
1.3.5 Natural Killer Cells 
Work in mice has revealed that natural killer cells are present in the lung in 
the initial stages of infection and produce abundant quantities of IFN-γ, which 
appears to shape the subsequent T cell response (56). Virus infected cells 
are recognised by decreased MHC class 1 molecule expression.  
1.3.6 Dendritic cells   
Dendritic cells (DCs) link the innate to the adaptive immune response. From 
murine studies it has been shown that plasmacytoid DCs, thought to limit 
viral replication, are recruited early on in infection (57). In contrast myeloid 
DCs increase in number later in the infection and are matured by RSV, and 
subsequently activate naïve T cells (58).  
1.4 Adaptive Response in RSV bronchiolitis 
1.4.1 Humoral response  
Only the two major RSV surface viral glycoproteins (F and G) induce 
antibodies that confer protection (59). Secretory IgA in the mucosa is 
important for local protection in the upper airway but its effect is short-lived. 
Serum-derived RSV antibody (mainly IgG) accesses the lower but not the 
upper airways relatively effectively; in the nasal mucosa access occurs via 
passive transudation (25, 60).  During acute infection, IgM is present within a 
few days and lasts up to 1-2 weeks. IgG appears after a week, peaks after a 
month and declines thereafter. The protection resulting from serum antibody 
production following RSV infection is therefore short-lived (61).  
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Most term newborn babies have RSV neutralising antibodies due to placental 
transfer of maternal immunoglobulin. These antibodies appear to confer a 
degree of protection; correlation has been noted between low cord blood 
RSV antibody titres and severe RSV disease (27) and early RSV disease 
(62). In addition, prophylactic administration of RSV-neutralising antibody 
provides protection to high-risk infants (63, 64).  
1.4.2 Cell-mediated immune response 
Both CD4+ T helper and CD8 cytotoxic T+ cells are recruited to the lung in 
response to RSV infection and are believed to play a critical role in 
terminating acute RSV infection (65, 66). Humans with compromised T cell 
immunity shed virus for months, and in mice depletion of CD4+ and CD8 T+ 
cells also cause prolonged shedding (20). In mice, this T cell depletion 
despite causing prolonged viral replication, reduces pulmonary disease (65).  
1.5 RSV pathogenesis  
RSV infection is usually completely resolved by the innate and adaptive 
immune responses described above (67, 68). However, infection does result 
in widespread alteration in cellular gene expression, and upregulation of 
cytokines and chemokines as the body mounts its immune response. The 
combination of host immune response and viral factors are thought to be 
responsible for RSV induced pathology although their relative contributions 
are debated. 
1.5.1 Infant and viral factors contributing to pathogenesis  
RSV occurs more frequently and severely in younger children, with the peak 
for hospitalisation being 2 months of age. Rhinovirus, influenza, and human 
metapneumovirus commonly infect children less than 6 months of age (69). 
Rhinovirus in particular is associated with wheezing but in infants less than 6 
months old, its incidence is much less than that of RSV (70). It is perhaps the 
unusual ability of RSV to evade maternal antibodies, which allows infection 
of very young infants. Due to the narrow diameter of these infants’ 
bronchiolar airway lumens it has been suggested that they are more 
susceptible to mechanical obstruction and severe disease. In addition, these 
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infants are vulnerable due to the absence of previous exposure and 
consequent lack of immune memory. Reinfection is common, even within the 
same season (26). This is not unique to infants; the same is true for healthy 
adults and even more commonly in exposed adults such as health-care 
workers (68, 71). Reinfection of healthy individuals usually results in disease 
of reduced severity but this ability to re-infect ensures that RSV remains 
present within the population, at all ages.   
 
Individual proteins within the RSV virion contribute to its pathogenicity. RSV 
subverts the antiviral IFN response through two IFN antagonists, NS1 and 
NS2 (72). They inhibit the induction of IFN-alpha/beta by blocking the 
activation of IFN regulatory factor 3 and by inhibiting type I IFN signalling 
through the JAK/STAT pathway (5). The JAK/STAT pathway would 
otherwise amplify the IFN response and upregulate IFN stimulated genes, 
resulting in the antiviral state described in Section 1.3. 
 
RSV F and G surface proteins induce neutralising antibody production and 
are the major antigenic determinants of protection. The G protein differs from 
most other receptor binding proteins of the Paramyxoviridae family with 
respect to its structure and antigenic properties. For not fully elucidated 
reasons, the G protein requires multiple antibodies in order to be efficiently 
neutralised (73). It also influences epithelial and antigen presenting cell 
responses by down-regulating expression of inflammatory mediators through 
the inhibition of the NF-kB-pathway (74) (75).  
 
There is increasing recognition that the magnitude of the viral load correlates 
with disease severity. Nasal viral loads are used in a number of studies as a 
surrogate for lower airway measurement, as the agreement of viral load 
between the two has been shown to be good (76). Higher viral load 
correlates with longer hospital stay, increased risk of intensive care and of 
mechanical ventilation (77, 78). In an adult RSV model, viral load, measured 
by RT-PCR has been shown to correlate with disease severity (79). The 
degree to which this is due to viral damage or an increased immune 
response is not elucidated.  
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1.5.2 Immune pathogenesis 
Disease manifestation of RSV infection varies widely from upper respiratory 
tract infection (URTI), through to lower respiratory tract infection (LRTI), 
which can be mild or life threatening. Although the direct cytopathic effect of 
the virus and viral load likely contribute to these different manifestations, 
several observations lead us to believe that the host’s own immunity plays a 
role in disease severity.  
 
Histopathology of the lung from an infant with RSV who died in a car 
accident rather than as a result of infection, revealed significant numbers of 
immune cells, specifically T lymphocytes, monocytes and neutrophils (39). 
Inflammatory cells were noted in the submuscularis between the arterioles 
and bronchioles, but also identified moving through gaps in smooth muscle. 
This, the author’s conjecture, could impact smooth muscle tone and affect 
airway hyperreactivity. The small airways were noted to contain inflammatory 
cells, fibrin and mucus, suggesting that mechanical obstruction of these 
airways plays a role in disease (39). 
 
Murine studies have suggested that, in addition to clearing infection, T cells 
contribute to disease severity (66). A further mouse study suggested that the 
presence of alveolar lymphocytes correlated with disease severity, with a 
reduction in illness observed after ablation of CD4+ or CD8+ T cells despite 
ongoing RSV replication (65). There are opposing views in the literature 
regarding T cells in human infant disease. Sanchez et al report that T cells 
are not frequently observed in the airway or lung tissue of RSV infected 
infants (80). Lukens et al however report that there is a robust T cell 
activation and response in RSV (81). It is worth noting however that Sanchez 
et al used a group of infants with fatal bronchiolitis, a number of who had pre-
existing medical conditions including Down’s syndrome. Juxtaposed to host 
immunity causing the burden of pathogenesis is that RSV disease is more 
severe and occurs more frequently in immunocompromised individuals for 
example children with low T cell numbers have an increased risk of severe 
disease (82).  
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The failure of the formalin inactivated RSV (FI-RSV) vaccination in the 1960s 
provides further evidence of the potential for immune mediated 
pathogenesis.  This vaccine, given to RSV naive infants, was not protective 
and primed for severe disease on infection with naturally occurring RSV 
infection. When this occurred, 80% required hospitalisation and two infants 
died. Histopathological analysis, supported by subsequent animal data, 
revealed that an atypical antibody response resulted in antigen-antibody 
complexes and complement activation in the lungs (83, 84). In addition, a 
Th2 biased response contributed to immunopathology with an overly robust 
response of virus-specific CD4+ T lymphocytes (85). It is not clear however 
what relevance the pathogenesis of FI-RSV disease has to naturally 
occurring human disease as similar heightened responses do not occur.   
 
There are an abundance of inflammatory cytokines and granulocytes in the 
airways of infants with severe RSV, with the neutrophil being the most 
abundant inflammatory cell, accounting for up to 84% of airway leucocytes 
(55, 86). This is much greater than that seen in influenza virus infection (87). 
There is a high airway concentration of predominantly epithelial derived 
CXCL8, a major neutrophil chemoattractant (49). In a study of the dynamics 
of neutrophil responses in infants admitted to the intensive care unit, the 
appearance of neutrophil precursors in the blood, preceding their influx into 
the lungs, closely followed the peak of virus shedding and was concurrent 
with clinical symptoms. Whether this represented a protective response or a 
contributor to the disease severity cannot be determined (81).  
 
The magnitude of the neutrophil response to RSV infection, which appears 
greater than that for other viral infections, does lead one to deliberate what 
the role of the neutrophil is in RSV disease. Beyond the appreciation that 
they may contribute indirectly to viral clearance through their ability to 
phagocytose RSV infected and apoptotic cells, their contribution to the 
antiviral response within the airways has not been investigated. The extent to 
which RSV neutrophilia is protective versus pathogenic is unclear. 
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1.6 The Neutrophil 
Paul Ehrlich in 1886 first described as ‘polynuclear cells’, the cells we now 
know as polymorphonuclear neutrophil leucocytes, PMNL, PMN or just 
neutrophils (88). When it was recognised that the neutrophil had in fact a 
single multi-lobed nucleus rather than a number of nuclei they were re-
named to the present terminology (89). Initially there was misunderstanding 
as to the role of the neutrophil in inflammation, with the belief that the 
neutrophil spontaneously generated until Waller demonstrated that they 
originated from blood (90). Secondly it was thought that the presence of 
neutrophils, which were now known to produce pus, assisted the growth of 
microorganisms. However, Metchnikoff showed that neutrophils were 
capable of chemotaxis and could phagocytose. He argued that the presence 
of phagocytic cells were beneficial to mammals as a natural immunity against 
infection by microorganism (91). Other scientists in the field initially refuted 
Metchnikoff’s theory on the killing ability of neutrophils but in 1905 he was 
awarded a Nobel Prize for his findings. Previously considered to be short-
lived, phagocytic cells, they are increasingly being found to have more 
complex and far-reaching functions. Their role as the first immune cell to 
respond to invasion by bacteria and fungi has been extensively 
demonstrated and, neutrophil depletion generally results in catastrophic 
consequences to whichever species is being studied. Neutrophils are 
recruited in large numbers to the site of many viral infections and although 
there is evidence that they play a role in anti-viral innate immunity, the 
evidence is limited and more investigation is warranted.   
1.6.1 Structure 
Neutrophils, 10-15μm in diameter (92), consist of 63% cytoplasm, 21% 
nucleus, 15.4% granules and 0.6% mitochondria (93) (Figure 1-4). The 
cytoplasm contains primary (azurophilic) granules, secondary (specific) 
granules and tertiary granules, which contain enzymes and proteins (Table 
1-1). Ingested pathogens are contained within phagosomes that then fuse 
with primary granules, termed lysosomes. The granules can also be released  
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Figure 1-4 Neutrophil granulocyte 
This is a schematic diagram of a neutrophil showing the component parts. The nucleus has 
a characteristic multi-lobed shaped. Within the cytoplasm is the small golgi apparatus, and 
multiple granules. 
 
 
Granule type Content 
Azurophilic 
(primary) 
myeloperoxidase, permeability-increasing protein, 
defensins, neutrophil elastase and cathepsin G 
Specific 
(secondary) 
alkaline phosphatase, lysozyme, NADPH oxidase, 
collagenase, lactoferrin, cathelicidin 
Tertiary cathepsin, gelatinase 
 
Table 1-1 Neutrophil granule types and contents 
The neutrophil contains about 200 granules of 3 different types; azurophilic, specific and 
tertiary.  
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extracellularly along with cytotoxic substances when activated through Fcγ 
receptors.   
 
During the inflammatory response, the neutrophil functions in a variety of 
ways, with regulatory factors at every step. Their killing capability is three 
pronged, and comprises engulfment of the organism (phagocytosis), release 
of secretory granules containing reactive oxygen species (degranulation) and 
release of neutrophil extracellular traps (NETs) capable of trapping 
microorganisms and potentially killing them with the aid of attached 
antimicrobial peptides.   
1.6.2 Pathogen destruction 
That neutrophils are essential for an effective innate immune response, is 
evidenced by the life-threatening conditions associated with congenital 
abnormalities of neutrophil function (94). Their primary role is in their ability 
to act as phagocytic cells. The neutrophil senses chemotactic factors that are 
generated at the site of an infection via plasma membrane receptors on their 
surface. The neutrophil attaches to endothelium by means of binding to P-
selectin and E-selectin via glycosylated ligands. These tethered neutrophils 
roll along the endothelium in the direction of blood flow (95). They squeeze 
through gaps between endothelial cells, a process called transmigration. This 
involves rearrangement of the neutrophil cytoskeleton. They then migrate up 
a chemoattractant gradient by chemotaxis towards the site of infection (96). 
The microorganisms by this stage may have been opsonised by serum 
proteins such as complement or immunoglobulin. The neutrophil will have 
upregulated surface expression of receptors required for phagocytosis. Thus 
primed, they will carry out phagocytosis, degranulation and activation of 
respiratory burst in order to kill the microorganism. Since 2004, the role of 
neutrophil extra-cellular traps (NETs) was recognised as part of the cells 
armoury against invading pathogens. A web of chromatin fibres and serine 
proteases are released, as the neutrophil’s final act, to trap and kill microbes 
extracellularly (97). The neutrophil may augment the inflammatory response 
by production of neutrophil chemoattractants, drawing in additional 
neutrophils, and cytokines activating and recruiting other immune cells. The 
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principle role of the neutrophil is to destroy invading microorganisms and this 
it does most effectively as described above. The paradox however is that in 
order to do so it generates chemicals such as ROS and defensins, which not 
only destroy the invading organism but potentially also damage host tissue 
(98, 99). Thus to limit this damage, controlled cell death or apoptosis, is 
required (100). 
1.6.3 Resolution of inflammation 
Apoptosis is not the only way that the neutrophil contributes to the resolution 
of inflammation. Neutrophils also have anti-inflammatory capabilities through 
their ability to block and scavenge chemokines such as CCL3 and CCL5 
(101), and produce anti-inflammatory cytokines such as IL-1 receptor 
antagonist (IL-1RA) and TGF-β1&2 (102). They can also produce pro-
resolving lipid mediators such as lipoxin A4 (LXA4) that inhibit further 
neutrophil recruitment (103). Furthermore, they contribute to the biosynthesis 
of resolvins, which contribute to inhibit neutrophil transendothelial migration 
(103).  
1.6.4 Neutrophil-derived cytokines 
Chemokines, pro-inflammatory, anti-inflammatory, immunoregulatory, 
angiogenic and fibrogenic cytokines as well as ligands to the TNF 
superfamily are all expressed and produced by the neutrophil (Figure 1-5) 
(102).  Neutrophils produce cytokines either constitutively or upon activation. 
There are a variety of neutrophil receptors, including colony-stimulating 
factor and cytokine receptors, G protein coupled-, FCy and complement 
receptors, and PRRs that trigger this activation. They express all TLRs 
except TLR-3 (104). Neutrophils control the expression and production of 
cytokines through regulation at different levels, including mRNA transcription, 
translation and protein secretion. For example, TNF-related apoptosis-
inducing ligand (TRAIL), CXCL8, CCL20 and IL1- RA are synthesised but 
then stored in intracellular pools, requiring further stimulation by 
secretagogue-like molecules for rapid secretion (105). 
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Figure 1-5 Cytokines expressed and/or produced by human neutrophils  
This figure lists the cytokines that have been validated in human neutrophils through gene 
expression techniques, immunohistochemistry, enzyme-linked immune-adsorbent assays or 
biological assays. * refers to studies only performed at the mRNA level. ? refers to 
controversial data. 
(Taken from Cassatella et al, 2014 (105)) 
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1.6.5 Crosstalk with other immune cells 
Through its ability to produce cytokines and chemokines, the neutrophil can 
recruit discrete cell populations as and when needed. Neutrophils produce 
chemotactic signals that recruit monocytes, dendritic cells, NK cells, and T-
helper type 1 and type 17 cells (106). TNF-alpha is produced by neutrophils, 
which can drive DC and macrophage differentiation. This crosstalk is bi-
directional with products from macrophages and DCs activating neutrophils 
as well. Cell to cell contact between CD11b on neutrophils and DC-SIGN 
(DC-specific ICAM3 grabbing non-integrin) on monocyte derived DCs 
induces maturation (107).  Neutrophils are also a source of BAFF, a member 
of the TNF superfamily, which is needed for B cell function, maturation and 
survival (108). Neutrophils can also modulate NK cell survival, proliferation 
and IFNy production through the release of ROI and granule components 
(109). There is complex interplay between T cells and neutrophils, with 
effects on recruitment to inflamed sites and cell survival (102).   
1.6.6 Neutrophils in viral infection 
A number of factors support a role for phagocytes such as neutrophils in the 
early defence against viruses. It has long been known that viral infections 
can lead to a transient neutropenia (110) and this has been postulated to be 
due to cells being recruited en masse to the site of infection (55, 111). 
Through phagocytosis, virally infected cells and potentially individual virions, 
can be cleared (112). Neutrophils also produce a variety of mediators, 
including some that have anti-viral activities such as TNFα and TRAIL (105). 
More recent data reveals that the neutrophil can respond specifically to viral 
invasion and recognise potentially dangerous ‘non-self’ RNA and DNA, via 
intracellular sensor systems, such as RIG-1 (113). Cassetella et al have 
shown that RIG-1 and melanoma differentiation associated gene 5 (MDA-5) -
mediated signal cascades occur in human neutrophils as evidenced by the 
expression of antiviral and immunomodulatory molecules in response to 
poly(I:C) transfection (114). That neutrophils possess RNA recognition 
receptors, such as RIG-1, MDA-5 and TLR-8, that are non-canonically 
expressed at the mRNA and protein level has since been shown (115).  
  
39 
1.7 Neutrophils and RSV 
On the basis of the studies presented above, it would appear that neutrophils 
have a role at the frontline of antiviral immunity. What is known about their 
contribution in RSV infection?  As referenced previously neutrophils are the 
predominant cell in the airways of infants with RSV bronchiolitis. Epithelial 
cells drive this migration through the production of neutrophil 
chemoattractants in response to RSV, particularly CXCL8 (53, 116-119). 
CXCL8 concentration is elevated in the bronchoalveolar lavage (BAL) fluid of 
severely infected infants and at levels higher than in other viral pulmonary 
infections such as adenovirus and rhinovirus (118, 120, 121). In vitro studies 
show that there is an initial CXCL8 peak two hours after RSV infection 
suggesting establishment of viral infection is not required for this early 
inflammatory response. A further peak is seen at 24 hours with a 
requirement for active viral replication at this later stage (122). There is 
evidence to suggest that CXCL8 correlates with disease severity, the NPA 
CXCL8 mRNA showing a strong dose response correlation (123).  
Neutrophils have been found to represent a median of 93% of cells in the 
upper airway, collected by nasopharyngeal aspiration, and between 76% and 
84% in the lower airway, counted from BAL fluid (55, 86). There is some 
evidence, from in vitro studies, that RSV infection increases neutrophil 
adherence to epithelial cells, which is hypothesised to contribute to epithelial 
damage and detachment (124, 125). Most studies on the role of neutrophils 
in RSV disease have concentrated on the damage inflicted by the neutrophil 
(119, 126). There is one report, albeit published 30 years ago, which 
describes neutrophil mediated cytotoxicity against RSV. Human neutrophils 
were shown to mediate cytotoxicity, in the form of cell lysis, of RSV infected 
epithelial cells (HEP-2) measured by a chromium-51 release assay, in the 
presence of complement. Activation of complement by RSV-infected 
epithelial cells was observed only in the presence of neutrophils, not 
lymphocytes or monocytes (127).  
 
One would expect, given their ability to cause damage, that depleting 
neutrophil numbers would reduce the pathogenesis of RSV disease. In a 
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murine model of RSV, a monoclonal antibody Ly6G was used effectively to 
deplete neutrophils in blood and lungs. Neutrophil depleted mice lost more 
weight and had increased lung damage evidenced by greater bronchiolar 
and alveolar oedema, alveolar haemorrhage, and vasculitis. There was no 
significant change in viral load but there was a reduction in mucin production 
and a change in cytokine expression, with a reduction in Th2 cytokines (128). 
This study, albeit in mice, would suggest that the neutrophil protects against 
lung damage and disease severity rather than causing it.  
 
One further important study, discussed in more detail in Chapter 3, explored 
the in vivo interaction between RSV and neutrophils, and showed that RSV 
proteins and mRNA transcripts are present within blood and bronchoalveolar 
lavage neutrophils from infants with RSV disease (129). Although the 
majority of RSV replication occurs within the respiratory epithelium, these 
findings suggest that RSV replication may also occur within the neutrophil. 
Given that neutrophils are one of the first immune cells to encounter and 
interact with RSV in the lung, are numerously present, and have recently 
been demonstrated to contain viral sensors specific to RNA, this piece of 
work aiming to explore this interaction and characterise any antiviral 
mechanisms is warranted.  
1.8 Aims of the study 
The overall aim of this study is to explore the interaction between neutrophils 
and RSV. Specifically I aim to:  
  
1. Establish an in vitro model of neutrophil-RSV interaction 
2. Determine whether RSV is taken up into the neutrophil 
3. Determine if RSV productively replicates inside the neutrophil  
4. Compare neutrophil-RSV interaction in adult and infant neutrophils 
5. Investigate the response of the neutrophil to RSV 
 
Hypotheses relating to these specific aims are stated in the relevant 
chapters.  
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Chapter 2 Methods and optimisation of an in vitro 
model of neutrophil-RSV interaction  
In order to realise the aims outlined in Chapter One, an in vitro model of RSV 
- neutrophil interaction needed to be established. Sections 2.1 – 2.12 
describe the materials, method and experiments undertaken to optimise this 
in vitro model. Sections 2.13 – 2.17 describe the standard methods and 
materials used for subsequent chapters.   
2.1 Participant recruitment 
Three groups of participants were recruited; healthy adult controls for 
peripheral blood, ventilated RSV infected infants for BAL samples, and term 
infants delivered by caesarean section for cord blood. Ethical approval to 
obtain samples from these participants came from one pre-existing study and 
one new study as described below.   
2.1.1 Mucin study 
This on-going study was originally conceived to investigate inflammation and 
mucus production in the airways of children with a variety of respiratory 
conditions (REC reference mucin study 06/Q1502/142). For my experiments, 
I recruited infants who were ventilated for RSV bronchiolitis at Alder Hey 
Children’s Hospital, Liverpool, UK during 2012/13, 2013/14, and 2014/15 
seasons. Term and pre-term infants ventilated for RSV-positive bronchiolitis 
and less than one-year of age were eligible for enrolment. Infants who had 
congenital heart disease, genetic syndromes or immune dysfunction were 
not eligible. Demographic details including gestational age at birth, time since 
intubation, and weight were recorded. All parents received written 
information about the study (Appendix 1) and gave written informed consent 
prior to collection of data or clinical samples (Appendix 2). 
2.1.2 Cord blood study 
This new study was set up to investigate the immune system in newborn 
babies, in particular the functional capacity of the neutrophil to RSV (REC 
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reference cord blood study 08/H1017/147). Research nurses gave written 
information about the study to pregnant women at elective caesarean section 
pre-assessment clinics at Liverpool Women’s Hospital (Appendix 3). 
Consent was taken to collect up to 60mls of cord blood from the placenta 
after delivery by elective caesarean section. Women were eligible if they 
were having a planned section for maternal reasons from 37/40 gestational 
age (GA). They were not eligible if there were any concerns regarding the 
baby’s health. The control group consisted of healthy adult volunteers who 
gave informed consent for up to 40mls of peripheral blood to be collected. 
Adults were not eligible for inclusion if they had a chronic illness or were 
taking regular medication. 
2.2 Blood neutrophil collection and processing 
Neutrophils were initially isolated from whole blood using polymorphprep™ 
(Axis-Shield). Whole blood, taken directly into tubes containing 3.8% sodium 
citrate, an anti-coagulant, at a ratio of 1:9, was layered at 1:1 ratio over 
polymorphprep™. This was centrifuged at 1800rpm for 40 minutes, with the 
brake set to zero. Neutrophils were analysed by flow cytometry to establish 
the percentage of CD66c positive cells. CD66c is a granulocyte marker, 
which is highly expressed by neutrophils (130). Purity of the enriched 
neutrophil population was 61.3% (Figure 2-1). The majority of the 
contaminating cells were red blood cells but of more concern was the 
potential for monocyte contamination. It has been shown that the presence of 
monocytes, even in small numbers, can alter the behaviour of neutrophils 
(131). To ensure that all responses observed were neutrophil specific, 
magnetic immunoselection was adopted as the neutrophil purification 
technique (Figure 2-2). This method is described below and yielded 99.8% 
CD66c positive cells.   
 
Antibody Concentration Host Supplier 
Anti- human CD66c 
PE (monoclonal) 
0.125μg per sample Mouse ebioscience 
IgG1 isotype PE 
(monoclonal) 
0.125μg per sample Mouse Beckman Coulter  
Table 2-1 Antibodies used for neutrophil identification 
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Figure 2-1 Neutrophil purity using polymorph preparation method 
a) Histogram showing percentage of cells that are CD66c positive measured by flow 
cytometry. Neutrophils were isolated using the polymorph preparation method. Blue line = 
neutrophils labelled with a monoclonal antibody to CD66c conjugated to PE. Red line = 
matched isotype control. In this sample 61.3% of neutrophils expressed CD66c.  b) Flow 
cytometry scatter plot demonstrating the neutrophil population (A) and contaminating cell 
population (B) on the basis of forward and sidelight scatter properties. c) Neutrophils were 
spun onto a slide, then stained using a Romanowsky staining protocol, before being imaged 
using a Leiss microscope. Cells were histologically identified as neutrophils by their multi-
lobed nucleus and stain uptake pattern. 
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2.2.1 Negative immunoselection methodology 
Antibody complexes and dextran-coated magnetic particles were used to 
isolate the neutrophils by removing unwanted cells from the cell suspension. 
The antibody complexes link targeted cell populations to the magnetic 
particles. Labelled cells are pulled to the sides of the tube when the sample 
is placed in the EasySep™ magnet. Magnetically labelled cells (the positive 
fraction) remain in the tube while untouched cells (the negative fraction) can 
be poured into a new tube. For neutrophil isolation, the tetrameric antibody 
complexes recognize CD2, CD3, CD9, CD19, CD36, CD56, glycophorin A 
and dextran coated magnetic particles.  
2.2.2 Neutrophil ultra-purification by magnetic immunoselection 
Neutrophils were isolated from the venous blood of healthy adult volunteers. 
Blood was taken directly into tubes containing 3.8% sodium citrate. Blood 
was centrifuged at 270g for 20 minutes at 18°c before plasma was aspirated 
from the top. Plasma was further centrifuged at 1155g for 10 minutes at 18°C 
to make platelet poor plasma (PPP). To the cell pellet, 6 ml of 6% dextran 
was added and total volume made up to 50ml with warmed 0.9% sodium 
chloride. After 25 minutes, the upper layer, which is red cell depleted 
following dextran sedimentation, was removed and cells pelleted by 
centrifugation at 185g for 6 minutes. Neutrophils were separated by 
discontinuous plasma:Percoll gradient centrifugation, pelleted at 420g for 6 
minutes and resuspended in RoboSep™ buffer (Stemcell™ Technologies).  
 
Ultra-purification of neutrophils was performed using negative 
immunoselection. Resuspended neutrophils were mixed with EasySep™ 
Human Neutrophil Enrichment Cocktail (Stemcell™ Technologies) at 50ul/ml 
cells, mixed well and incubated at room temperature for 10 minutes. 
EasySep™ Nanoparticles (Stemcell™ Technologies) were then vigorously 
pipetted before addition of 100ul/ml cells. After mixing well they were 
incubated at room temperature for 10 minutes. The whole suspension was 
then made up to a total volume of 2.5ml by the addition of RoboSep™ buffer 
before being thoroughly mixed and placed into the EasySep™ magnet for 5 
minutes. The desired fraction was poured off by inverting the magnet and   
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Figure 2-2 Neutrophil purity using negative immunoselection method 
a) Histogram showing percentage of cells that are CD66c positive measured by flow 
cytometry. Blue line = neutrophils labelled with a monoclonal antibody to CD66c conjugated 
to PE. Red line = matched isotype control. Following negative immunoselection where 
antibody complexes link to CD2, CD3, CD9, CD19, CD36, CD56 and glycophorin A and bind 
to magnetic particles leaving a pure preparation of neutrophils, 99.8% of neutrophils 
expressed CD66c. b) Flow cytometry scatter plot demonstrating the one cell population on 
the basis of forward and sidelight scatter properties. c) Neutrophils were spun onto a slide 
then stained using a Romanowsky staining protocol, before being imaged using a Leiss 
microscope. Cells were histologically identified as neutrophils by their multi-lobed nucleus 
and stain uptake pattern. 
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tube into a new tube, which was then placed into the magnet for a further 5 
minutes. This was repeated once, leaving the negatively selected enriched 
cells in the new tube ready for use. 
2.3 Romanowsky staining technique 
Cells were spun onto slides using a cytospin and air-dried. Rapid 
Romanowsky Stain (HD Supplies) was used. 25 mls of each solution (A - 
fixative solution containing thiazine dye in methanol, B - Eosin Y in 
phosphate buffer, and C - Methylene blue in phosphate buffer) were placed 
in sequentially positioned Coplin jars. Slides were placed in solution A for 30 
seconds, then solution B for 30 seconds and finally solution C for 30 
seconds, with no rinsing between each immersion. Slides were washed 
gently in running water before being allowed to air dry for 5 minutes. Slides 
were then examined by Leica microscope (40x/0.5 objective) and images 
recorded using Leica IM50 Image Manager. Leukocytes show excellent 
nuclear and cytoplasmic staining. Immature granulocytes show bright 
azurophilic granules. Erythrocytes are orange-red. 
2.4 Neutrophil culture 
Neutrophils were counted using a manual haemocytometer and suspended 
at 5 million/ml in Dulbecco’s Modified Eagle Medium (DMEM) in 10ml falcons 
for experiments. If serum was required this was either 5% autologous serum, 
or 5% AB serum. Neutrophils were incubated at 37oC/5% CO2. 
2.5 RSV preparation 
30 000 Hep2 Cells/cm2 in a volume of 30ml were seeded into a T175 cm2 
flask and left to grow to approximately 50% confluence overnight at 37oC/5% 
CO2 in DMEM and 10% foetal calf serum (FCS). Medium was removed from 
the flask and cells washed twice with PBS. 1 vial of RSV (MOI 1) and 8mL of 
serum free medium were added to the flask which was left to rock gently at 
37°C for 2hrs. After 2hrs, 22mL of DMEM containing 2% FCS was added 
and cells incubated for 24 hours at 37oC/5% CO2. Media was replaced after 
24 hours with DMEM with 10% FCS. Cells were harvested at the first sign of 
cytopathic effects such as dead cells floating; this usually occurred 48 hours 
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following infection. At this time, all but 4mls of media was removed. The cells 
were scraped from the bottom of the flask using a cell scraper and placed in 
a universal container on ice before being passed through a 25 gauge needle 
10 times. Cells were then spun down at 4oC at 1500rpm for 5 minutes. The 
supernatant was quickly transferred in 500ul aliquots into pre-labelled 
cyrovials before being snap frozen in liquid nitrogen and placed in the -80 oC 
freezer for storage. As RSV is most stable when within cells and unbound 
virus degrades rapidly, work was carried out quickly when thawing and 
freezing down virus containing cryovials. For thawing, the cryovial was 
agitated in a water bath set to 37°C. When the pellet was almost completely 
thawed it was opened in a tissue culture or lamina flow hood and gently 
pipetted up and down to thaw remaining virus and used as quickly as 
possible. The RSV preparation used in the majority of the experiments was a 
gift from Dr. Paul Fitch (University of Edinburgh). This was 50 vials from 1 
batch of propagated RSV A2 strain (PFU 1.79x106).  
2.6 Plaque assay 
A plaque assay was used to quantify the amount of virus propagated. Hep2 
cells were seeded into a 96 well plate in DMEM containing 10% FCS for 24 
hours. A doubling dilution was made of virus stock staring at 1/100 and 
producing 8 dilutions in serum free DMEM. The Hep2 cells were washed with 
PBS and 50ul of virus was added to each well, with each dilution plated in 
triplicate and a virus free control included. After 2 hours at 37oC/5% CO2, 
150ul of DMEM with 10% FCS was added and the cells cultured overnight. 
After this time the cell were washed with PBS (100ul/well) and fixed for 20 
minutes at room temperature with 100% methanol containing 2% hydrogen 
peroxide. The cells were washed with PBS before 100ul of biotinylated anti-
RSV antibody (1/200 dilution with PBS/1%BSA) per well was added for 1 
hour at room temperature. The wells were then washed twice with PBS/1% 
BSA and 100ul of extravidin peroxidase (1/500 dilution in PBS) was added 
for 30 minutes at room temperature. After 2 washes, with PBS/1%BSA, 50ul 
of 3 amino-ethylcarbazole substrate was added per well, for up to 40 
minutes. When plaques appeared the reaction was stopped using a PBS 
wash. The plaques in wells that appeared to have around 100 were counted, 
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as were all replicates of that dilution. The numbers of plaques in the wells in 
the 2 dilutions below were also counted. Plaque forming units (PFU) for each 
virus batch were then calculated using the formula:  
 
Number of plaques x dilution x 20 = PFU/ml 
2.7 Phagocytosis assay 
For this assay pHrodo™ E. coli BioParticles® Phagocytosis Kit for Flow 
Cytometry (Invitrogen) was used. Assays were carried out according to the 
manufacturer’s protocol except that 100ul of neutrophil preparation was used 
rather than whole blood.  Lyophilized pHrodo E. coli BioParticles® Conjugate 
was stored in the freezer. When required, 2ml uptake buffer (HBSS + 20mM 
HEPES, pH 7.4 (NaOH added if necessary)) was placed into the vial 
containing the 2mg lyophilized product and vortexed to resuspend. 
Neutrophils were suspended at 5 million/ml in DMEM. 50ul of pHrodo was 
added to each tube, except the control. When required, 10-20% autologous 
serum was added. Cells were left to incubate at 37oC/5% CO2, except for the 
ice control sample. At 15, 30, 60, 90, 120, 150 and 180 minutes, samples 
from each tube were collected, washed twice and then analysed by flow 
cytometry. Neutrophils that have phagocytosed bacteria emit fluorescence in 
the FL3 channel (Figure 2-3a). Neutrophils that have been incubated with 
pHrodo E. coli on ice were used as a negative control. 
 
This technique was used to quantitatively assess the phagocytic activity of 
the isolated neutrophils and to ascertain the percentage of autologous serum 
needed to enhance phagocytosis.  
2.7.1 Isolated neutrophils are capable of phagocytosis 
The number of neutrophils that had phagocytosed bacteria increased with 
time up to 120 minutes and then plateaued (Figure 2-3c). Neutrophils are 
thought to be able to recognise and internalise targets within minutes of 
exposure. However, the conditions within the phagosome which trigger the 
fluorescence of the E. coli pH sensitive label, takes one to several hours 
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(132). Phagocytosis plateaus at 2 hours as the maximal capacity of the 
neutrophil is reached.  
2.7.2 Autologous serum enhances neutrophil phagocytosis 
Neutrophils incubated with pHrodo E. coli for 2 hours were analysed by flow 
cytometry and percentage phagocytosis measured by percentage of 
neutrophils that were FL3 +ve. Comparison was made between incubations 
carried out with no serum, and in the presence of 10 and 20% autologous 
serum (Figure 2-4). Phagocytosis increased significantly in the presence of 
both 10% serum, from 62.72% (+/- 0.88) to 85.60% (+/- 3.06) p<0.0001 and 
20% serum, to 86.85% (+/- 3.10) p = 0.0001. One-way ANOVA was 
performed with Bonferroni’s post hoc test to allow for multiple testing. 
 
That serum enhances phagocytosis is an anticipated result, as serum 
contains complement and immunoglobulin, capable of opsonising the target 
microorganism and amplifying phagocytosis. Increasing the quantity of 
serum beyond 10% did not further improve uptake, most likely due to all E. 
coli targets being quenched by immunoglobulin and complement with this 
quantity of serum.  
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Figure 2-3 Neutrophil phagocytosis using pHrodo E. coli  
Neutrophils were incubated with pHrodo labelled E. coli particles. Samples were taken at a 
range of time points and analysed by flow cytometry. Using mean fluorescent index FL3 for 
the neutrophil population, a time course was constructed. a) Representative flow cytometry 
histogram plot showing the fluorescence in FL3 channel of neutrophils and E. coli on ice (as 
a control) and neutrophil + E. coli at 37°C. 1. b) Time course of pHrodo E. coli phagocytosis, 
the geometric mean of FL3 is plotted for each time. c) Time course of pHrodo E. coli 
showing increasing phagocytosis until 2 hours when the increase plateaus.   
a.                                                                                    b. 
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Figure 2-4 Autologous serum enhances neutrophil phagocytosis of pHrodo  
Neutrophils incubated with pHrodo E. coli for 2 hours were analysed by flow cytometry. The 
percentage of FL3 +ve neutrophils was used as a surrogate measure for the percentage of 
neutrophils exhibiting phagocytosis. Neutrophil incubation was carried out in the presence of 
no serum, 10% or 20% autologous serum. A statistically significant increase in phagocytosis 
was observed in the presence of 10 and 20% serum. (4 independent experiments/ n=4) 
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2.8 Flow cytometer analysis and set-up 
All flow cytometer analysis was performed using a Beckman Coulter Cytomis 
FC 500MPL flow cytometer equipped with a 488 nm argon-ion laser. To 
analyse samples, two dot plots were set up, one showing forward scatter 
(FSC) vs. side scatter (SSC), and another showing a histogram of cell count 
against fluorescence. A negative control was always applied first. In the 
pHrodo phagocytosis experiment, this consisted of neutrophils with no 
pHrodo™ BioParticles® conjugate that have been through the whole 
methodological procedure.  Linear FSC and SSC voltages were set to locate 
the neutrophil scatter pattern. All flow data was analysed using FlowJo 
9.4.11.  
2.9 Annexin V/PI apoptosis assay 
Annexin V FITC apoptosis detection kit (Sigma) was used to carry out this 
assay. Cells were suspended in 300ul Annexin binding buffer with 3ul of 
Annexin V for 15 minutes in the dark at room temperature. They were then 
flash stained with propidium iodide (PI), 10ul in 900ul of Annexin binding 
buffer and analysed on the flow cytometer. 10,000 events were collected. 
Early apoptosis is identified by Annexin V positivity and cell death by PI 
staining (Figure 2-5). 
2.10 Neutrophil survival 
2.10.1 Neutrophil survival can be extended in vitro by GM-CSF 
Flow cytometry Annexin V/PI analysis was used to assess the percentage of 
viable neutrophils at time points up to 20 hours in the presence or absence of 
5ng/ml human recombinant GM-CSF (Peprotech). In the absence of GM-
CSF, mean (SEM) neutrophil survival was 98.87% (+/- 0.296), 88.97% (+/- 
6.470), 76.27% (+/- 8.03), 42.83% (+/- 15.04) at 0, 2, 4 and 20 hours 
respectively (Figure 2-6). There was a significant decrease in cell viability at 
4 hours (p=0.0216) and 20 hours (<0.0001) when compared to 0 hours. 
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Figure 2-5 Illustration of flow cytometric analysis of Annexin V/PI apoptosis assay  
At appropriate time points, samples were stained with Annexin V (marker of apoptosis (FL1)) 
and propidium iodide (PI - marker of necrosis (FL3)), and analysed by flow cytometry. a) 
Scatter plot shows neutrophils stained for Annexin V/PI. 85.8% of cells are viable (Annexin V 
-ve/PI -ve, Q1), 34.2% are apoptotic (Annexin V +ve/PI -ve Q2), and 0% are apoptotic and 
necrotic (Annexin V +ve/PI +ve, Q3). b) Scatter plot shows neutrophils stained for Annexin V 
and PI, and exposed to GM-CSF. 90.7% cells are viable (Q1), 9.14% cells are apoptotic 
(Q2) and 0% cells are apoptotic and necrotic (Q3). 
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Figure 2-6 Neutrophil survival time course 
Bar chart showing percentage of viable neutrophils at 0, 2, 4 and 20 hours. There was a 
significant decrease in cell viability at 4 hours (p=0.0216) and 20 hours (<0.0001) when 
compared to 0 hours. (3 independent experiments/ n=3)  
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With the addition of GM-CSF cell viability increased to 97.20% (+/- 0.635), 
93.47% (+/- 3.45), 95.00% (+/- 1.44) and 75.47% (+/- 5.28) at 0, 2, 4 and 20 
hours. Cell viability was still significantly decreased at 20 hours (p=0.0059) 
but there was significantly improved cell survival when compared to 
untreated neutrophils (p=0.0458) (Figure 2-7). A two-way ANOVA with 
Bonferroni’s post hoc test was used to allow for multiple testing. 
2.10.2 The effect of RSV on neutrophil survival  
Highly purified neutrophils were incubated with RSV (MOI 0.1) preparation 
for 0, 2, 4 and 20 hours without GM-CSF. At these time points neutrophil 
viability, with and without RSV exposure was measured by flow cytometry. 
Mean (SEM) survival of neutrophils exposed to RSV was 97.10% (+/-2.201), 
96.23% (+/-1.619), 94.67% (+/-1.656) and 78.07% (+/-3.896) at 0, 2, 4 and 
20 hours respectively. The percentage of viable neutrophils was significantly 
higher at 20 hours when compared to RSV unexposed cells (p value =0.007) 
(Figure 2-8).   
2.11 In vitro neutrophil-RSV culture system  
An in vitro Neutrophil-RSV culture system was established by combining the 
various optimised methods and techniques described above in Sections 2.2 
- Section 2.11. This system is illustrated schematically (Figure 2-9).   
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Figure 2-7 Neutrophil survival can be extended in vitro by GM-CSF 
Grouped bar chart showing survival of GM-CSF treated and untreated cells at 0, 2, 4 and 20 
hours. With GM-CSF no significant apoptosis was observed until the neutrophils were 20 
hours old, at which point, survival was significantly better than for untreated cells (p = 
0.0458) (3 independent experiments/ n=3) 
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Figure 2-8 Neutrophil survival is affected in vitro by RSV  
Grouped bar chart showing neutrophil survival +/- RSV at 0, 2, 4, and 20 hours. Neutrophil 
survival was extended in vitro by RSV. There was no significant apoptosis measured until 20 
hours, and survival was statistically better at 20 hours than untreated cells (p value =0.007). 
(3 independent experiments/ n=3)  
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Figure 2-9 In vitro culture system for neutrophil-RSV infection 
Highly purified neutrophils were isolated by negative immunoselection from healthy adult donor blood. Cells were suspended in DMEM at 5x106/ml with the 
addition of 5% autologous serum. If GM-CSF was used this was added at a concentration of 5ng/ml. A2 strain RSV (MOI 0.1) was rapidly thawed and added 
to the neutrophils. If no RSV was added the equivalent volume of DMEM was added to the control tubes. Neutrophils were incubated at 37oC, 5% C02 for up 
to 20 hours. At each time point the neutrophils were washed in PBS twice before either being resuspended for flow cytometric analysis or pelleted for 
Western blot analysis. 
Highly purified 
neutrophils from 
healthy adult 
donor blood, 
suspended at 
5x106/ml in 
DMEM. 
Flow cytometry 
analysis for cell 
viability and purity 
Incubated with A2 
strain RSV +/- 
GMCSF & 5% 
autologous serum. 
Incubated for up to 
20 hours at 37oc, 5% 
C02. 
!
!
Samples taken at 
2, 4  & 20 hours. 
Neutrophils 
washed x 2 with 
PBS and either 
pelleted or 
resuspended. 
Western blot 
analysis  
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2.12 Western blotting  
Western blotting was used to identify RSV proteins, firstly from infected 
epithelial cells and then from RSV exposed neutrophils. The primary and 
secondary antibodies used in western blotting analysis are listed in Table 2-2 
and Table 2-3. 
2.12.1 Principle of western blotting 
Western blotting is a widely used analytical technique for the study of 
proteins. It allows the detection of a single protein within a mixture of proteins 
derived from a biological sample. The sample is broken down by 
homogenisation and then cell lysis, using detergents and buffers in the 
presence of protease inhibitors, to prevent digestion of the sample by its own 
enzyme. The sample is then loaded onto a gel where the proteins are 
separated, by gel electrophoresis, dependant on their molecular weight. A 
ladder containing a mixture of proteins with defined molecular weights is also 
loaded to aid identification of proteins. The proteins migrate along the gel at 
different speeds dependant on their molecular weight, and separate into 
bands. These protein bands are then transferred from the gel onto a 
membrane using electroblotting in order that the protein of interest can be 
detected using an antibody. Following incubation of the blot with the chosen 
primary antibody, a secondary antibody is used. This is linked to a reporter 
enzyme, which by cleaving a chemiluminescent agent produces 
luminescence signal in proportion to the amount of protein. This light output 
can then be detected and imaged using a scanner. Any visible protein bands 
can be identified based on the antibody used and expected size confirmed 
by position in relation to the molecular weight ladder.  
2.12.2 Tissue preparation 
The extracted samples were prepared in 100ul of 89% lysis buffer (10% 
glycerol (Fisher Scientific), 125nM Tris (Fisher Scientific), 3% Sodium 
dodecyl sulfate (SDS) (Bio-Rad), 0.2% bromophenol blue (Sigma), 1% 
protease inhibitor (Thermo Scientific) and 10% 
dichlorodiphenyltrichloroethane (DTT) (Sigma) at pH6.8). Samples were 
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denatured for 3 minutes using a heating block set at 100°C, vortexing every 
60 seconds, before being loaded on to a gel or stored at -20°C for later use. 
2.12.3 Running gel and blotting 
12% Mini-PROTEAN® TGX™ pre-cast gels (Bio-Rad) were used. Precision 
protein plus standard (Bio-Rad) was loaded into the first well followed by the 
samples, 20ul of neutrophil samples, 10ul of epithelial samples, and allowed 
to settle evenly on the bottom of the wells.  Following sample loading with 1x 
electrophoresis running buffer (3.03g Tris Base, 14.4g Glycine, 1g SDS 
made up to 1 litre in H20), the gel was run at 140V for 45 minutes before the 
gel was removed for blotting. The Trans-blot ® Turbo™ Mini Polyvinylidene 
Difluoride (PVDF) transfer packs (Bio-Rad) were used with Trans-Blot ® 
Turbo™ rapid western blotting system for protein transfer.   
2.12.4 Antibody staining 
The PVDF membrane was placed into a small tissue culture flask containing 
blocking buffer for 1 hour. The blocking buffer used was 5% (w/v) non-fat dry 
milk/TBST (100ml 10xTBS, 900ml dH20, 1ml TWEEN 20 (Fisher)). The 
membrane was then incubated overnight at 4°C on an orbital shaker with the 
primary antibody. The primary antibody solution was then removed and the 
blot washed three times for five minutes before addition of the secondary 
antibody. The blot was incubated with the secondary antibody for 1 hour at 
room temperature on a shaker before being washed three times and read.  
Chemiluminescence substrate (Li-Cor) was prepared by adding equal 
volume of the Solution A to an equal volume of the Solution B; approximately 
800µl was needed in total per blot. This was then pipetted on to the protein 
side of the membrane ensuring the mixture covered the membrane evenly 
and incubated for 5 minutes before reading on the C-Digit scanner (Li-Cor). 
Data was analysed using ImageStudioLite (Li-Cor). 
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Antibody Dilution Host Supplier 
Anti-F RSV (monoclonal) 1:500 Mouse Abcam 
Anti-RSV biotin conjugated 
(polyclonal) 
1:2000 Goat Biorad 
Anti-histone H3 1:30 000 Rabbit  Sigma 
Table 2-2 Primary antibodies used for western blot analysis  
 
Antibody Dilution Host Species Against Supplier 
IgG Streptavidin 
HRP 
1:200 Mouse Goat R&D 
Anti-Mouse 1:1000 Goat Mouse R&D 
Anti-Rabbit 1:1000 Goat        Rabbit R&D 
Table 2-3 Secondary antibodies used for western blotting 
2.12.5 RSV proteins measured by Western Blot from infected 
epithelial cells 
Western blot was carried out on pellets harvested at 24 hours from epithelial 
cells infected with RSV (MOI 1). A polyclonal RSV antibody (1/100) was used 
with streptavidin secondary (1/1000). Five bands were clearly seen and 
identified based on their predicted molecular weights as F, G, M, N and P 
proteins. Bands were not detected in non-infected control cells (Figure 
2-10). 
2.12.6 RSV proteins measured by Western blot from neutrophils 
incubated with RSV 
A Western blot was carried out on pellets harvested at 2 hours from 
neutrophils incubated with RSV (MOI 0.1). A polyclonal RSV antibody 
(1/100) was used with streptavidin secondary (1/1000). Four bands were 
clearly seen and identified based on their predicted molecular weights as F, 
G, M, and N proteins. Bands were not detected in neutrophils not incubated 
with RSV (Figure 2-11). A P protein band was not identified, unlike the 
epithelial cell experiment. This may be due to degradation of the RSV 
proteins within the neutrophil, which does not occur in the epithelial cell. 
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Figure 2-10 RSV proteins identified from infected epithelial cells 
Western blot was carried out on pellets harvested at 24 hours from epithelial cells infected 
with RSV (MOI 1). Control pellets consisted of epithelial cells that had not been infected. 
RSV polyclonal antibody with anti-mouse secondary was used. RSV F, G, M, N and P 
proteins were identified from infected cells. Molecular weight of protein ladder is shown in 
kDa. 
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Figure 2-11 RSV proteins identified from neutrophils incubated with RSV 
a) Western blot image of neutrophils incubated for 2 hours with RSV. RSV polyclonal 
antibody with anti-mouse secondary was used. 4 bands are seen at 24, 44, 57 and 120 kDa, 
which correlate with RSV G, F, N and M proteins respectively. Reference protein markers 
are also visualised, which indicate the position of proteins of known molecular weights. b) 
Correlating scatter plot of the protein migration distance (Rf) of the reference protein markers 
against the log of their molecular weight. The calculated equation of the line is shown which 
has then been used to calculate the molecular weight of the RSV proteins. Individual RSV 
proteins were then identified using their expected molecular weights.  
Protein of Interest Calculated MW (Kda) Expected MW (Kda)
G 120 90
F 57 58
N 44 43
M 24 22
y = -0.6114x + 1.4066 
R² = 0.96447 
!0.2%
!0.1%
0%
0.1%
0.2%
0.3%
0.4%
0.5%
0.6%
0.7%
0.8%
0.9%
0% 0.5% 1% 1.5% 2% 2.5% 3%
R
f 
log10 MW (kDa) 
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Quantitative Polymerase Chain Reaction (qPCR) was used in the work 
described in Chapter 3 to establish a time course of RSV N gene expression 
using infected epithelial cells and RSV exposed neutrophils. qPCR was also 
used in the work described in Chapter 6 to validate the findings of a 
microarray analysis.  
2.12.7 Principle of Reverse Transcription qPCR 
 qPCR allows exponential amplification of short deoxyribonucleic acid (DNA) 
sequences (usually 100 to 600 bases) within a longer double stranded DNA 
molecule in order to detect and quantify gene expression. It involves reverse 
transcription of RNA into cDNA followed by PCR to amplify a specific cDNA 
molecule. This can be quantified in real time by the accumulation of 
fluorescence after each amplification cycle (133).  
 
There are two established methods of PCR quantification, relative and 
absolute. Relative quantification determines the mRNA quantity relative to 
the quantity of an internal reference gene. Mathematical algorithms have 
been developed to calculate the corrected relative expression ratio; these 
include the Pfaffl method and the ΔΔCT method (134, 135). Absolute 
quantification can also be used which relies on a standard curve of Ct 
values, generated from a dilution series of a standard with known initial 
target copy number. The reliability of the standard used is paramount for 
accuracy (136, 137). Relative quantification has been used for all qPCR 
analysis in this thesis.  
 
The efficiency of each target assay was calculated by performing a serial 
dilution experiment. The slope of the standard curve was used to measure 
an efficiency value as described in Figure 2-12. 
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Slope = -3.3386 
 
Efficiency = 10(-1/slope) – 1 
                 = 10(0.30) -1  
                 = 0.995 = 99.5%  
 
Figure 2-12 Calculation of PCR efficiency  
PCR efficiency was assessed by plotting the results of serial dilution experiments, and then 
calculating the equation for the slope of the line of best fit. Dilution Log10 was plotted 
against the Ct values. The slope of the standard curve can be translated into an efficiency 
value. The efficiency of the PCR should be between 90–100% (−3.6 ≥ slope ≥ −3.3). If 
efficiency is 100%, the Ct values of the dilution experiment will be 3.3 cycles apart i.e. 2 fold 
change for each change in Ct.  
(Image adapted from applied biosystem PCR manual) 
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The amplification curve for each experiment was inspected to ensure i) that 
the fluorescent threshold was set within the exponential phase of the PCR 
reaction, ii) that the curve continued to rise and was not limited by reagent 
availability, and iii) that the non-template control did not show fluorescence. 
The ΔΔCT method used for quantification relies on absolute PCR efficiency, 
which must be between 90 - 100%. The slope of the curve is directly related 
to the amplification efficiency, so amplification curves were reviewed to 
ensure that R2, the indicator of quality of fit of the curve, was ≥ 0.95. This 
was the case for all but two of target genes analysed (Table 2-4).  
 
Gene R2 Slope Efficiency (%) Threshold 
DICER 1 0.94 -3.59 90 0.2 
DDX58 0.96 -3.49 93 0.2 
DHX58 0.95 -3.30 100 0.2 
IRF7 0.90 -3.30 100 0.1 
MX1 0.98 -3.48 94 0.2 
STAT1 0.98 -3.50 93 0.2 
USP18 0.95 -3.28 95 0.2 
RSV 0.97 -3.61 89 0.2 
GAPDH 
B2M 
0.97 
0.97 
-3.49 
-3.50 
93 
93 
0.015 
0.15 
Table 2-4 Standard curve characteristics of qRT-PCR experiments  
2.12.8 RNA Extraction 
Samples for PCR analysis were stored in TRIzol (life technologies) at -30°C 
for short-term storage and -80°C for long-term storage. Samples were 
thawed on ice when required. 100ul chloroform (Sigma) was added to each 
500ul sample, and the sample vortexed prior to centrifugation at 1300g/10 
minutes. The top aqueous layer was pipetted off into a new Eppendorf to 
which 400ul isopropanol (Sigma) was added and the sample vortexed and 
then cooled at -20°C for 30 minutes. The sample was centrifuged at 
1300g/15 minutes after which the supernatant was removed and 500ul 
RNAse free 70% ethanol (Sigma) added before centrifugation at 1300g for 5 
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minutes. All ethanol was removed and the sample left to dry for 10 minutes 
prior to the addition of 10ul RNAse free water.  
2.12.9 cDNA synthesis 
RNA samples were converted to cDNA using High Capacity cDNA Reverse 
Transcription Kit (applied biosystems). To each tube, 2ul RT buffer, 2ul 
random primers, 1ul dNTP mix, 4ul RNAse free water and 1ul Multiscribe 
Reverse Transcriptase enzyme were added. Samples were then placed at 
37°C in a heating rack for 1 hour. The cDNA was then diluted 1:4 (final 
volume 100ul) with RNAse free H20 and stored at -80°C until use. 
2.12.10 Quantitative Polymerase Chain Reaction 
Probe based Taqman® qPCR detection was used for all qPCR experiments. 
All assays used are detailed in Table 2-5. All target gene expression was 
normalised to an internal standard. The internal reference gene L32 was 
selected for use in all experiments. An RSV Taqman probe (Applied 
biosystems) was used. Primer and probe sequences are described in Table 
2-6, and the methods described in Pachet et al paper on the development of 
quantitative TaqMan RT-PCR for RSV (138). For all reactions 1.25ul of a 
specific gene expression assay probe (Taqman®), 12.5ul Taqman Master 
Mix and 11.25ul cDNA were used and reactions were run in a 96 well PCR 
plate. Plates were sealed with adhesive film and run on Applied Biosystems 
7500 fast Real-Time PCR System. Cycling conditions were – 2 minutes at 
50°C, hold at 95° for 10 minutes, followed by 40-60 cycles of 95°C for 15 
seconds and 60°C for 60 seconds. 
2.12.11 Analysis of qPCR data 
Quantification of gene expression was by comparative quantification method 
(ΔΔCT method). Analysis was performed by: calculation of the mean Ct 
values of target gene and internal reference gene, and calculation of the 
arithmetical mean of the selected internal reference gene to generate the 
mean reference value for each sample.  
ΔCT = Ct (target) – Ct (mean reference) 
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Target gene expression, relative to interval reference gene expression was 
then calculated using the following equation.  
Relative gene expression = 2 – ΔCT 
 
Table 2-5 Pre-designed gene expression assays used for qPCR analysis  
Table 2-6 RSV Primer and probe for qPCR 
2.13 Imaging 
Confocal microscopy was used in Chapters 3, 4 and 5 to identify RSV from 
neutrophils, both from the in vitro system and also from ex vivo neutrophils 
collected from RSV infected infants’ BAL. All antibodies, both primary and 
secondary, used for immunocytochemistry are listed in Table 2-7 and Table 
2-8 respectively. 
2.13.1 Sample preparation for imaging  
Cytospin slides of purified neutrophils (approximately 50,000 cells) were 
prepared from both BAL and blood. Samples were diluted in PBS if required. 
The samples were pipetted on to cyto-chambers secured in slide carries 
containing superfrost® plus slides (Thermo Scientific) and centrifuged at 
400g for 4 minutes in a Rotofix 32A.  Following air-drying slides were fixed 
with either ice cold 100% methanol or paraformaldehyde (PFA) (Sigma).  
Gene Assay ID Supplier 
Mitochondrial ribosomal protein L32 Hs00388301_m1 Life technologies 
DICER 1 Hs00229023_m1 Life technologies 
DDX58 Hs00204833_m1 Life technologies 
DHX58 Hs01597843_m1 Life technologies 
IRF7 Hs00185375_m1 Life technologies 
MX1 Hs00895608_m1 Life technologies 
STAT1 Hs01013996_m1 Life technologies 
USP18 Hs00276441_m1 Life technologies 
Gene Forward Primer Reverse Primer Probe 
RSV N 
gene 
CTCAATTTCCTCACT
CTCCAGTGT 
CTTGATTCCTCGGTGT
ACCTCTGT 
TCCCATTATGCCTAGGC
CAGCAGCA 
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2.13.2 Indirect immunocytochemistry staining  
Cytospin slides were stored at -30°C until required. They were then removed 
and left to thaw before rehydrating them in PBST (PBS plus 0.1% TWEEN) 
for 5 minutes. A circle was drawn around cytospun cells with a hydrophobic 
marker prior to 1 hour of blocking with 5% milk in PBST. Slides were then 
washed with PBST 3 times for 5 minutes. The primary antibody (diluted in 
PBST/5% milk) was added and slides left for 1 hour at room temperature in a 
humid chamber. They were then washed 3 times in PBST before the 
secondary antibody was used, at the required concentration in PBST/5% 
milk, for a further hour. Slides were washed 3 times in PBST before being 
dried and mounted using VECTASHIELD® Mounting Media (vectorlabs) and 
cover slips sealed with clear nail varnish. Co-stains DAPI (1:10,000) (Sigma) 
and Evans Blue (Sigma) were used after application of the secondary 
antibody and prior to mounting. Slides were stored at 4°C until needed.  
Antibody Dilution Host Supplier 
Anti- human CD66c 
PE (monoclonal) 
0.125μg per sample Mouse ebioscience 
IgG1 isotype PE 
(monoclonal) 
0.125ug per sample Mouse Beckman Coulter  
Anti-F RSV 
(monoclonal) 
1:100 Mouse Abcam 
Anti-N RSV 
(monoclonal) 
1:100 Mouse Abcam 
Anti-G RSV 
(monoclonal) 
1:100 Mouse Abcam 
IgG1 isotype 
(monoclonal) 
1:50 Mouse R&D 
Table 2-7 Primary antibodies used for indirect immunocytochemistry staining 
Antibody Dilution Host Species Against Supplier 
IgG Alexa Fluor® 
488 
1:1000 Goat Mouse Life 
technologies 
IgG Alexa Fluor® 
594 
1:1000 Goat Mouse Invitrogen 
Table 2-8 Secondary antibodies used for indirect immunocytochemistry staining 
2.13.3 Confocal microscopy 
Immunofluorescence images were captured with Multiphoton Zeiss Observer 
Z.1 confocal laser microscope. Zeiss Fluor 40x oil and 63x oil immersion 
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objective were used. IgG Alexa Fluor 488 dye was excited at 488nm, using 
an Argon laser (530nm). IgG Alexa fluor 554 dye was excited at 561nm using 
a diode-pumped solid-state laser (575nm). The pinhole was set at 1 airy unit 
(AU) to provide the optimal signal to noise ratio. For Z-stack images the slice 
thickness was between 0.5 – 1μm.   
2.13.4 Image Processing  
Images were exported from Zen 2010 and edited in Fiji (‘Fiji is just Image J’) 
(139). This is an open source, multi-platform software for acquisition, 
visualisation and analysis of biological data. When multidimensional data 
was required, Imaris (Bitplane) software was used. When Z-stacks are 
presented these are seen as single slices, unless specified. Co-localisation 
analysis was carried out in Fiji. Mander’s coefficient was used to measure 
the significance of any observed co-localisation. This significance test 
evaluates the probability that the measured value of fluorescent overlap from 
the two colours is significantly greater than the fluorescent overlap that would 
be expected if there were only random overlap.  
2.14 Statistical Analyses 
The statistical analysis software Graph pad Prism (version 6.0) was used for 
graphical representation of data and statistical analysis (GraphPad software, 
Inc). All data were assessed to ascertain whether they were normally 
distributed using the Shapiro-Wilk test. Normally distributed data were 
compared using a student t-test when there 2 experimental groups. When 
there were more than 2 groups, one-way ANOVA was performed with 
Bonferroni’s post hoc test, to identify for significant differences and to allow 
for correction for multiple testing. In one instance a two-way ANOVA was 
used as there were 2 experimental variables (Section 2.10.1). Non-
parametric data were compared using the Mann-Whitney U test when there 
were 2 experimental groups. When there were more than 2 groups Kruskal-
Wallis test was used for unpaired data or Friedman test when data were 
paired, with Conover Inman post hoc test. Throughout this thesis a 
statistically significant difference was taken as a probability (p) value < 0.05.  
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Chapter 3 Characterisation of RSV-neutrophil 
interactions  
3.1 Introduction 
In Chapter 2, I described an optimised method for the in vitro assessment of 
the interaction between neutrophils and RSV. I showed that RSV could be 
identified within human adult neutrophils, an observation previously only 
made in vivo (129). The logical question to arise from these results is ‘what is 
the nature of this interaction’? A number of studies have explored the role of 
the neutrophil in the pathogenesis of viral disease. Some have shown viral 
components inside the neutrophil and others have purported to show viral 
replication in the neutrophil. Very few have considered mechanisms by which 
virus enters the cell. The word ‘infection’ is frequently used, often rather 
loosely. Sometimes it is used to describe just the entry of virus into the cell, 
whilst at other times, it is used to describe proliferation of the virus with the 
result of viral spread.  
 
A number of groups have reported virus replication inside neutrophils. Some 
have used elegant methods, such as a study into the pathogenesis of West 
Nile virus, in which the authors measured both positive and negative sense 
viral RNA within neutrophils from mice. The presence of negative sense RNA 
was used to indicate active replication, as viral RNA polymerase generates 
negative sense RNA to serve as a template for replication. At 8 hours 
negative-sense RNA was detected. No later time points were used to 
measure production of actual whole virus however, and neutrophil depletion 
resulted in higher viral loads (140). Other studies, on H5N1 influenza, have 
simply used the localization of virus to the neutrophil nucleus as evidence of 
its ability to replicate within. H5N1 viral proteins were found in placental 
neutrophils from virus infected patients. The investigators hypothesised entry 
by phagocytosis and immunohistochemistry localized the virus to the 
cytoplasm that replication was likely to be occurring. No further evidence was 
sought (141, 142). EBV genome has been found in vitro in neutrophil nuclei, 
but no viral transcripts were detected. It was concluded that the cell 
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undergoes apoptosis too rapidly to allow for replication (143). 
Cytomegalovirus replication in neutrophils has been extensively studied. 
Replication has previously been claimed based upon detection of viral 
transcripts within neutrophils (144-146). However, later studies have 
subsequently concluded that the presence of viral proteins and transcripts do 
not represent replication as they lead to only small quantities of viral nucleic 
acids (147).  
 
Other studies have shown virus within neutrophils but with no evidence of 
replication. Nakanishi et al demonstrated in mice that both macrophages and 
neutrophils recruited to the lung during H1N1 influenza infection contained 
influenza infected apoptotic cells (148). Garcia-Sastre et al used whole-organ 
imaging and flow cytometry to track the dynamics of a recombinant influenza 
virus carrying a green fluorescent protein (GFP) reporter gene in mice 
(149).  GFP virus was present not only in epithelial but also hematopoietic 
cells including neutrophils. The authors concluded that intracellular detection 
of virus was due to direct ‘infection’ of the neutrophils, or secondary to 
phagocytosis of infected cell debris. A preceding study looking specifically at 
virus-infected neutrophils with influenza had shown similar uptake but had 
proved, by use of a plaque assay on supernatant fluid, that infectious 
progeny were not produced by neutrophils (150). Recent work on H3N2, a 
highly virulent influenza virus, revealed a small proportion of neutrophils that 
were positive for virus in an in vitro model system. The authors used 
fluorescently labelled influenza virus and used flow cytometry to quantify 
positivity. They found neutrophils did not support active replication, as virus 
titres remained unchanged in the supernatants of the infected neutrophils 
(151).  
 
It is worth noting that the word ‘infection’ is often used indiscriminately in 
these studies. Within this thesis, the term ‘replicative infection’ will be used 
henceforth to describe such an event occurring. ‘Virus positive’ will be used 
to describe the presence of virus in the cell where no evidence of replication 
is presented. Overall, there certainly appears to be evidence of viruses being 
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found within neutrophils in many studies, but evidence that these cells 
actually allow viruses to replicate within them tends to be weak. 
 
There is only one paper that presents evidence of potential RSV replication 
inside the neutrophil.  Our group previously identified RSV F, G and N 
proteins within blood and BAL neutrophils taken from intubated infants with 
severe RSV bronchiolitis. The same neutrophils that were positive for RSV 
proteins, were also found to be RSV mRNA positive raising the possibility 
that active viral transcription was occurring (129). Potentially this could 
happen as part of an abortive replicative process or represent whole viral 
replication. Either scenario could be detrimental to the host, with a build up of 
RSV transcripts and proteins potentially exacerbating inflammation, and 
whole viral replication potentially enabling the neutrophil to contribute to viral 
dissemination.  However, it is also possible that neutrophil take-up of virus is 
a mechanism for enabling viral clearance. Understanding the mode of viral 
entry and the kinetics of virus uptake, in particular whether the neutrophil is a 
site of viral replication, will contribute to our understanding of the role of the 
neutrophil in the airway.  
3.2 Hypothesis 
RSV does not infect and productively replicate within the neutrophil but is 
taken up actively by the neutrophil through endocytosis.  
3.3 Aims 
To answer the above hypothesis the work described in this chapter aimed to: 
 
1. Establish the kinetics of RSV uptake and whether RSV replicates within 
purified healthy adult neutrophils in vitro. 
2. Determine whether neutrophils release RSV progeny into the supernatant 
that are capable of epithelial cell infection  
3. Determine whether autologous serum enhances uptake of RSV 
4. Establish whether the mechanism of viral entry uptake is through 
endocytosis. 
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3.4 Specific methods 
Adult neutrophils and RSV were cultured in vitro using the conditions laid out 
in Chapter 2 (Section 2.12) and illustrated in Figure 2-9. In brief, highly 
purified neutrophils from the whole blood of healthy adults were isolated and 
incubated with A2 strain RSV MOI 0.1 in the presence of 5ng/ml GM-CSF 
and 5% autologous serum for up to 20 hours. From henceforth, all 
experiments on neutrophils were undertaken using these conditions. 
Samples were examined at appropriate time points using a range of analysis 
methods for the presence of RSV using the methods outlined in Chapter 2 
(Sections 2.13 - 2.15). RSV N gene was measured using RT qPCR. 
Productive viral progeny was looked for using a plaque assay. RSV proteins 
were identified across a time course using the Western Blot technique. 
Lastly, indirect immunocytochemistry was used to identify RSV by confocal 
microscopy.  
3.5 Results 
3.5.1 RSV measured by qPCR using a RSV N primer 
To show that RSV could be quantified by RSV N gene qPCR and 
demonstrated to be replicating over time, a positive model of replicative 
infection was used. This model used the epithelial cell line A549. A549 cells 
were infected with RSV (MOI 1) for up to 20 hours and cells harvested, 
washed and pelleted at time points 2 and 20 hours before being stored in 
TRIzol at -30oc. Following reverse transcription, RSV was quantified using 
qPCR and comparative quantification. RSV N quantity significantly increased 
over time (p=0.032) indicating active replication (Figure 3-1).  
3.5.2 No evidence of RSV replication in neutrophils 
To determine whether RSV replication occurred over time in a similar fashion 
to that seen in the epithelial cells RSV N gene qPCR was carried out on RSV 
exposed neutrophils. Highly purified neutrophils at 5x106/ml in DMEM were 
incubated with RSV preparation for 2, 4 and 20 hours, in the presence of 
GM-CSF and with or without 5% autologous serum. At these time points 
neutrophils were pelleted for 5 minutes at 1800rpm. Supernatant was 
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removed and stored at -80oC. Neutrophils were washed in 10 mls PBS twice 
before a dry pellet was resuspended in 500ul TRIzol and stored at -30 oC 
prior to RNA extraction. RNA extraction and reverse transcription was carried 
out as described in Section 2.9. RSV expression was measured at each 
time point and quantified relative to the internal housekeeping gene L32 
(Figure 3-2). RSV expression without serum was not significantly different at 
any time point although there was a trend towards a decrease over time. 
RSV expression with serum showed maximal uptake at 4 hours and a 
decrease by 20 hours, although this trend did not reach statistical 
significance. Uptake was observed to be greater in the presence of 5% 
autologous serum.  
3.5.3 RSV uptake is optimally enhanced by 10% autologous serum 
Given the results described above, I sought to determine the optimum 
concentration of autologous serum to maximize neutrophil uptake of RSV for 
my future studies. Highly purified neutrophils at 5x106/ml in DMEM were 
incubated with RSV preparation for 2 hours, in the presence of GM-CSF and 
either 0%, 0.1%, 1% or 10% serum autologous serum. At these time points 
neutrophils were pelleted for 5 minutes at 1800rpm. Supernatant was 
removed and stored at -80oC. Neutrophils were washed in 10 mls PBS twice 
before a dry pellet was resuspended in 500ul tryzol and stored at -30 oC prior 
to RNA extraction. RNA extraction and reverse transcription was carried out 
as described in Chapter 2. RSV expression was measured at each time 
point and quantified relative to the internal housekeeping gene L32 and 
ΔΔCt method was used to quantify RSV expression compared to expression 
in neutrophils unexposed to serum. There was a significant increase in 
uptake with 10% serum compared to no serum (p value = 0.0231) and 
compared to 0.1% serum (p value = 0.0408) (Figure 3-3) (Friedman test with 
Conover Inman post hoc test was carried out following non parametric 
distribution confirmation by Shapiro-Wilks). 
 
As a result of the above experiment it would have been ideal to carry out 
subsequent experiments using 10% autologous serum, however the usual 
quantity of serum yielded from the blood samples only allowed the use of  
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Figure 3-1 RSV N gene expression relative to L32 in the epithelial cell line A549  
A549 cells were infected with RSV MOI 1. Cells were harvested at 2 and 20 hours and 
stored in TRIzol prior to RNA extraction and reverse transcription. RSV N gene was 
measured by qPCR and is expressed relative to L32 on a log axis. RSV N gene expression 
increases significantly from 2 to 20 hours (p value = 0.032). 
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Figure 3-2 RSV N gene expression relative to L32 in neutrophils incubated with RSV. 
Neutrophils were incubated with RSV in the presence of GM-CSF and in the presence or 
absence of 5% autologous serum. Cells were harvested at 2, 4 and 20 hours and stored in 
TRIzol prior to RNA extraction and reverse transcription. RSV N gene was measured by 
qPCR and is expressed relative to L32 on a log axis. RSV expression without serum was not 
significantly different at any time point although there was a trend towards a decrease over 
time. RSV N gene expression with serum showed maximal uptake at 4 hours and a 
decrease by 20 hours, although this trend did not reach statistical significance. Uptake was 
observed to be greater in the presence of serum. 
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Figure 3-3 RSV uptake is enhanced by the presence of 10% autologous serum 
RSV N gene expression is shown for cells incubated with RSV for 2 hours in the presence of 
0, 0.1%, 1% and 10% autologous serum. There was a significant increase in uptake with 
10% serum compared to no serum (p value = 0.0231) and compared to 0.1% serum (p value 
= 0.0408) 
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5%. For this reason, future experiments were carried out with 5% autologous 
serum.  
 
Of note the stability of housekeeping gene L32 with and without RSV was not 
measured at this point. This is addressed in Section 6.4.3. 
3.5.4 Western blot analysis confirms qPCR time course results 
As RSV N gene was measured from the neutrophils but decreased over 
time, I sought to measure the RSV protein at the same time points. A 
Western blot was carried out on pellets harvested at 2, 4 and 20 hours from 
neutrophils incubated with RSV in DMEM, in the presence of GM-CSF and 
5% autologous serum. A polyclonal RSV antibody (1/100) was used with 
streptavidin secondary (1/1000). 4 bands were clearly seen and identified 
based on their predicted molecular weights as F, G, M and N.  The density of 
the bands reduces clearly at 20 hours suggesting degradation of internalised 
RSV protein (Figure 3-4). The figure shown is representative of 3 identical, 
separate experiments, which revealed the same finding.  
3.5.5 Neutrophils can not disseminate virus to epithelial cells  
In order to confirm the absence of productive RSV infection in the neutrophil, 
the neutrophil supernatant was analysed for infectious progeny. Supernatant 
collected from neutrophils, which had been incubated with RSV for 2 hours, 
using the conditions previously outlined, then washed and cultured for a 
further 22 hours, was added to A549 cells cultured to 80% confluence. At 48 
hours, a plaque assay, measuring the infective capacity of the supernatant, 
was carried out. This revealed that the supernatant from the neutrophils 
exposed to RSV did not cause infection of the epithelial cells. A positive 
control, supernatant from RSV infected epithelial cells, did cause infection as 
evidenced by the level of plaque formation (Figure 3-5).   
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Figure 3-4 Western blot time course for RSV from neutrophils 
A Western blot was carried out on pellets harvested at 2, 4 and 20 hours from neutrophils 
incubated with RSV and 5% autologous serum. The quantity of RSV, as shown by the 
density of the 3 RSV protein bands F, N and M, is markedly reduced by 20 hours.  
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Figure 3-5 Plaque assay of A549s exposed to supernatant from RSV exposed neutrophils 
and A549s 
Neutrophils and A549s were incubated with RSV for 2 hours, after which time they were 
washed and left in culture media for a further 22 hours. Supernatant was then removed and 
added straight to A549 cells cultured to 80% confluence. After 48 hours a plaque assay was 
performed revealing that those cells with neutrophil supernatant (A) had not been infected 
with RSV but the A549s that were cultured in media taken from RSV treated epithelial cells 
(B) had been infected as evidenced by the plaques. 
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3.5.6 Cytochalasin D is an effective phagocytosis inhibitor  
The inhibition of neutrophil uptake of pHrodo E. coli by cytochalasin D, a 
known potent inhibitor of phagocytosis, was tested to check the efficacy and 
concentration of the inhibitor (152). Neutrophils were incubated with pHrodo 
E. coli for 2 hours, as outlined in Chapter 2, following 15 minute pre-
treatment with or without cytochalasin D (concentration = 0.1mg/ml.) 
Neutrophils were analysed by flow cytometry as previously described; 
phagocytosis was quantified by measuring the percentage of neutrophils that 
were FL3 +ve. Comparison was made between those neutrophils exposed 
and unexposed to pHrodo E. Coli both with and without pre-treatment with 
cytochalasin D (Figure 3-6). Cytochalasin D successfully reduced 
phagocytosis to 2.38% from 83.9%.  
3.5.7 RSV uptake is not inhibited by the cytochalasin D 
Following the above optimisation, to determine whether RSV was being 
taken up by the neutrophil using phagocytosis, cytochalasin D was used. 
RSV uptake was measured by RSV N gene qPCR. Highly purified 
neutrophils were incubated with RSV preparation for 2 hours, in the presence 
of GM-CSF and 5% autologous serum +/- 15 minute pre-exposure to 
0.1mg/ml cytochalasin D. At 2 hours neutrophils were washed in 10 mls PBS 
twice before a dry pellet was resuspended in 500ul tryzol and stored at -30 
oC prior to RNA extraction. RNA extraction and reverse transcription was 
carried out as described in Chapter 2. RSV expression was measured at 
each time point and quantified relative to the internal housekeeping gene 
L32 and ΔΔ Ct method was used to quantify RSV expression against 
expression in neutrophils unexposed to cytochalasin D (Figure 3-7a). There 
was no statistically significant difference in RSV expression. Friedman test 
with Conover Inman post hoc test was performed.  
3.5.8 RSV uptake is not enhanced by a RSV monoclonal antibody  
To determine whether RSV uptake could be enhanced by an RSV 
monoclonal antibody, palivizumab was tested in the culture system. Highly  
 
  83 
 
 
 
 
Figure 3-6 Cytochalasin D reduces phagocytosis of pHrodo E. coli  
a) Histogram showing percentage of neutrophils that were FL3 positive following exposure 
to pHrodo E. Coli. Neutrophils were incubated with (blue line) or without pHrodo labeled E. 
coli particles (red line) for 2 hours. Samples were then taken and analysed by flow 
cytometry. b) Histogram showing percentage of neutrophils that were FL3 positive following 
exposure to pHrodo E. Coli following 15-minute treatment with Cytochalasin D (blue line) 
compared to neutrophils not exposed to E. Coli (red line). Phagocytosis was reduced from 
83.9% to 2.38% by exposure to cytochalasin D.  
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A. 
 
 
B. 
 
Figure 3-7 RSV uptake following pre-treatment with cytochalasin D or palivizumab.  
A. Neutrophils were exposed to RSV +/- pre-treatment with the inhibitor cytochalasin D. This 
figure is representative of 3 independent experiments showing RSV N gene expression 
relative to L32, the results of which are summarised in B.  
B. Neutrophils were exposed to RSV +/- pre-treatment with cytochalasin D. Neutrophils were 
exposed to RSV +/- pre-treatment with palivizumab. There was no statistically significant 
difference in RSV N gene expression in either case.  
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purified neutrophils at 5x106/ml in DMEM were incubated with RSV 
preparation for 2 hours, in the presence of GM-CSF, but not the autologous 
serum usually used +/- the monoclonal RSV antibody palivizumab. At 2 
hours, neutrophils were washed in 10 mls PBS twice. The dry pellet was then 
resuspended in 500ul tryzol and stored at -30 oC prior to RNA extraction. 
RNA extraction and reverse transcription was carried out as described in 
Chapter 2. RSV expression was measured at each time point and quantified 
relative to the internal housekeeping gene L32 and ΔΔ Ct method was used 
to quantify RSV expression against expression in neutrophils unexposed to 
palivizumab (Figure 3-7b). There was no statistically significant difference in 
RSV expression. Friedman test with Conover Inman post hoc test was 
performed. 
3.5.9 RSV can be visualised by confocal microscopy   
Using the RSV polyclonal antibody utilised in the previous Western blot, and 
an IgG Alexa Fluor® 594 secondary (Invitrogen), indirect 
immunocytochemistry was carried out on neutrophils that had been in culture 
with RSV preparation for 2 hours, in the presence of GM-CSF and 5% 
autologous serum. Immunocytochemistry was carried out as described in 
Section 2.14. The nucleus was co stained with DAPI. The image presented 
is an overlay of the 3 channels used for DAPI, RSV and a brightfield image 
(Figure 3-8). Neutrophils are shown with positive staining for RSV diffusely 
in the cytoplasmic area, with exclusion of the DAPI stained nucleus.  
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Figure 3-8 Confocal fluorescence microscopy with superimposed brightfield microscopy  
Neutrophils that had been incubated for 2 hours with RSV were spun onto slides and fixed 
with methanol, following which they were stained for RSV and co-stained with DAPI. Images 
were taken using a Multiphoton Zeiss microscope. 3 channels were used for DAPI, RSV and 
a brightfield image. The red indicates RSV and blue the nucleus.   
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3.6 Discussion 
Having established and optimised the in vitro model of RSV and neutrophil 
culture in Chapter 2, I wanted to investigate the nature of the viral-neutrophil 
interaction in more detail. Chapter 2 revealed that the neutrophils had been 
isolated to a high degree of purity and were functionally competent with 
respect to phagocytosis. I also showed that the neutrophil remained viable in 
vitro in short-term culture, up to 20 hours, in the presence of RSV and by 
using the pro-survival factor GM-CSF. Direct interaction of RSV and healthy 
adult neutrophils was demonstrated in vitro. In this chapter, I sought to 
investigate what happens to the quantity of RSV once it is inside the 
neutrophil; does viral replication occur?  
 
Studies referenced in this chapter’s introduction used a variety of 
methodologies to establish whether viral replication occurred within the 
neutrophil. Conventionally, when assessing whether a particular target 
reduces or enhances viral replication of RSV in cell culture, RT-qPCR is 
used to measure the expression of virus either against a control value or 
against an internal housekeeping gene (153, 154). To this end, the approach 
utilised here was similar. Firstly, A549 cells exposed to RSV and then 
analysed for RSV N gene expression over time by qPCR, were used as a 
positive control. Expression at 2 hours represented RSV initially taken up by 
the cell, whilst increased RSV expression at 20 hours represented newly 
formed RSV N, indicating transcription of RSV in the cells.  
 
The same methodology was applied to studies of neutrophils incubated with 
RSV. However, despite an initial robust uptake of RSV at 2 hours, RSV N 
gene expression did not increase over subsequent time points (4 and 20 
hours). In fact there was a trend for RSV N gene expression to decrease 
over this time. Western blot analysis of the RSV protein content of the 
neutrophils over time adds weight to this finding, as there was a marked 
decrease at 20 hours. This suggests that RSV does not replicate inside the 
neutrophil, and that in fact, virus is being degraded over time within these 
cells.  
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In order to ascertain whether viable viral progeny are released from the 
neutrophil after exposure to RSV as occurs with infected epithelial cells, a 
further experiment was carried out. Supernatant, from both RSV exposed 
A549s and neutrophils, was used as media on sterile A549 cells with the 
intention of transmitting any live virus and causing subsequent infection. This 
procedure resulted in infection of the A549s by the supernatant of the RSV 
exposed A549s, but no infection was evident with the supernatant from the 
RSV exposed neutrophils. This supports the conclusion that viable virus is 
not released, and most probably not manufactured by the neutrophil.  
 
Contrary to these results the paper by Halfhide et al, from our group, 
suggested that RSV does replicate inside neutrophils, as evidenced by the 
finding of mRNA in BAL neutrophils from RSV infected infants (129). 
Understanding the RSV replicative process helps us to understand how RSV 
mRNA might be manufactured without viral progeny being produced. Upon 
host infection, viral RNA polymerases synthesise a positive sense mRNA 
strand. These mRNAs then use host-cell machinery to synthesise viral 
proteins. Replication of the genome occurs via the production of a positive 
sense intermediate RNA strand, which is then used for the synthesis of 
further negative strand sense genome. The dynamics of RSV infection have 
been tracked in mice using PCR primers specifically targeting the positive 
sense (replicative intermediate and mRNA) or negative sense (genome) 
strand RSV RNA (154). Mice are not known to be particularly permissive to 
RSV and require high inoculation titres. Positive sense strands were found in 
significantly higher numbers than the negative sense strands, in the whole 
mouse lung, suggesting that viral replication was impaired. Similar findings 
were seen in experiments with cotton rats where increasing expression of 
viral transcripts and genome replication did not lead to the production of 
detectable progeny virus. This phenomenon has been termed abortive 
replication (155). The authors hypothesise that this inability to produce viral 
progeny, despite the presence of transcription, might be due to viral-host cell 
dynamics, with the murine cells not facilitating effective RSV RNA synthesis.  
Primarily, RSV infects and replicates in respiratory epithelial cells (156) 
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(157). However, there are reports of DCs (158), monocytes (159), and 
macrophages (160) being infected. Monocyte-derived DCs were considered 
infected on the basis of positivity for GFP expressing virus, a median of 4.9% 
were positive by flow cytomtery analysis. In monocytes, infection was 
determined on the basis of RSV gene expression in the monocytes, but not 
on the release of virus, suggesting that this transcription is abortive. 
Similarly, in vitro work on macrophages showed initial low-level release of 
infectious progeny, which quickly waned. It would appear that the neutrophil 
is an additional immune cell that is receptive to RSV entry but not permissive 
of productive infection.  
 
Given what is known about the hostile environment inside the neutrophil, and 
its very purpose (i.e. to kill microbes), it is perhaps not surprising that virus, 
once within the cell, is not able to complete its replicative cycle. The first 
stage of replication, the production of the mRNA by viral RNA polymerase, 
could feasibly occur prior to the degradation of RSV. This could explain the 
measurable presence of RSV mRNA in the Halfhide et al study. However, 
when neutrophils come into contact with foreign particles, NADPH production 
and the resultant oxidative burst (161, 162), leads to the generation of 
antimicrobial molecules such as hydroxyl radicals and hydrochlorous acid 
(163), proteases, defensins and antimicrobial peptides (164). Mostly these 
processes occur in the neutrophil endosome. Thus if RSV was to be taken 
up into endosomes, its destruction would be likely. How does RSV gain 
entry, and concomitant to this, where is the internalised RSV located?    
 
As endocytosis was considered a likely mode of viral entry, and serum 
contains antibodies and complement, it seemed likely that serum would 
enhance virus uptake by neutrophils. Phagocytes such as neutrophils 
express receptors that bind opsonin molecules, enhancing phagocytosis and 
eventual intracellular killing (165). This was indeed the case. Furthermore, a 
serum dose response was observed with uptake significantly enhanced with 
the addition of 1 or 10% autologous serum. The serum enhancement of 
uptake suggested that RSV was being taken up into the cell by endocytosis. 
If this were the case then an endocytosis inhibitor should inhibit uptake. 
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Cytochalasin D was chosen as said inhibitor. It disrupts the cytoskeleton by 
disrupting actin filaments, preventing formation of a phagosome. 
Optimisation work using the pHrodo E-coli as the target of phagocytosis 
confirmed successful inhibition and established the concentration needed for 
this. Cytochalasin however, did not inhibit uptake of RSV into neutrophils. 
There is disagreement in the literature over whether all endocytosis 
pathways are inhibited by cytochalasin.  Conventionally it is considered to 
inhibit phagocytosis, an inherently actin dependant process (166). More 
recently the actin cytoskeleton has been implicated in clathrin-dependant 
mechanisms such as macropinocytosis (167), and there is less consensus 
over the ability of cytochalasin to inhibit these mechanisms. 
Macropinocytosis is exploited by many viruses as a way of gaining entry into 
host cells (168). The mechanism involves nonspecific binding to any cell 
surface component. This triggers the plasma membrane to ‘ruffle’, leading to 
the membrane forming macropinocytic protrusions. These protrusions allow 
uptake of fluid along with suspended particles including virus into the cell 
(Figure 3-9). There is no specific test that will define whether virus gains 
entry by macropinocytosis, although some believe that as it is reliant on actin 
dynamics, it should be inhibited by cytochalasin (168). However, it has also 
been shown that actin filament disruption may allow greater ‘ruffling’ of the 
membrane, thus potentially allowing increased entry (169) (Figure 3-10). 
 
If pinocytosis is the mechanism of uptake, which does not rely on 
opsonisation by antibodies or complement, how does serum enhance 
uptake? A possible explanation is that of antibody dependant enhancement 
(ADE), a phenomenon observed in other viral infections such as Dengue 
Fever, Ebola and HIV (170-172). Non-neutralising antiviral proteins, such as 
antibodies, facilitate viral entry through interactions of the complement 
system and receptors. There are several postulated mechanisms. All viruses 
initiate infection by attaching to host cells via viral surface proteins and their 
corresponding receptors. Antibodies specific to the viral surface proteins can 
inhibit or ‘neutralise’ this process. However, these antibodies may also 
potentiate this process via crosslinking of virus-antibody complexes through  
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Figure 3-9 Modes of cellular internalisation by phagocytes 
a) Internalisation of large particles is facilitated by phagocytosis, and enhanced by 
opsonisation. b) Non-specific uptake of small particles can occur through macropinocytosis. 
(Adapted from Petros et al, (2010)) (173) 
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Figure 3-10 Macropinosome ruffling formation 
The membrane protrusions involved in macropinocytosis can take the form of planar 
lamellipodia, circular ruffles or blebs, depending on the cell type. Lamellipodia and circular 
ruffles require polymerisation of actin. Bleb formation is probably the result of local actin 
cortex destabilization. The blue lines represent actin and the red lines the portion of the 
protrusion that will constitute the membrane of the macropinosome. The three different 
forms are shown going through three stages a) membrane protrusion, b) macropinosome 
closure, and c) separation of the macropinosome. The star shows the site of closure. (Taken 
from Mercer & Helenius, (2009)) (174) 
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interaction with cellular Fc receptors (175). In vitro uptake of RSV in the 
presence of RSV specific antibodies has previously been investigated in  
airway epithelial cells. Monoclonal antibodies to RSV surface F and G 
glycoproteins were found to have neutralizing and enhancing properties 
(176). Palivizumab, which is known to neutralize RSV infection of epithelial 
cells, was investigated in our culture system. Palivizumab did not appear to 
neutralise or enhance uptake of the RSV when compared with the usual 
culture conditions. This would suggest that the presence of antibody in the 
culture system might not be a contributing factor to the enhancement of 
uptake. It also shows that neutralisation by an IgG RSV antibody does not 
prevent uptake by the neutrophil.  
 
Pharmacological inhibition of endocytosis is an inherently difficult process to 
investigate because of the nonspecific effects of the available inhibitors used 
to distinguish the major endocytic pathways (177). My lack of success 
elucidating a mechanism of uptake with cytochalasin and the high likelihood 
of similar results with other pharmacological inhibitors of endocytosis, led me 
to attempt using visualisation to gain more insight into the biological 
processes at play. Visualisation has played an important role in our 
understanding of biology since the 17th century when Robert Hooke, a 
natural philosopher, published his book Micrographia with hand drawn 
images of biological objects, termed cells (this term was first coined in this 
book) observed by microscope. The book was a best seller and sparked 
public interest in microscopy. Visualisation in biology has gone on to become 
more complex particularly with the advent of computer technology. 
Visualisation is particularly useful for conveying information, especially where 
data is not easily summarised by equations or algorithms. I therefore used 
indirect immunocytochemistry to fluorescently label RSV in situ. This serves 
two purposes. Firstly, to confirm true internalisation of the virus, as all 
previously used methodologies could have been detecting/measuring 
attached rather than internalised virus. Secondly, if internalised virus was 
confirmed then the location of it could be explored.   
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The confocal image shows diffuse cytoplasmic speckling of fluorescently 
antibody labelled RSV. The size and distribution of RSV within the cells is 
suggestive of an endosomal location. This result confirms that it is possible 
to identify virus using microscopy and further validates the association of the 
neutrophil and virus in vitro. However, this image does not prove 
internalisation - the virus could still be attached to the outside of the cell. This 
is because if the ‘pinhole’ within the confocal microscope is wide open, then 
it is possible for the whole cell to be imaged rather than a slice in the image 
so generated. However, several aspects of the image taken suggest that this 
does indeed represent internalised virus, such as the lack of virus ‘in’ any of 
the nuclei and the lack of virus seen around the edge of the neutrophil. 
Additional confocal work is required to verify this result and this is described 
in the following chapter.  
 
The quantity of RSV used for all the neutrophil experiments in this and 
subsequent chapters should be discussed.  RSV MOI 0.1 was used, initially 
because producing RSV of high enough titre to have a higher MOI was 
difficult.  However, it became apparent that this MOI was adequate to both 
quantify and visualise RSV in conjunction with the neutrophil. MOI relates to 
the number of infective particles per cell and thus only measures the infective 
capability of the virus. It has long been recognised that a large number of 
non-infective particles are produced in the laboratory propagation process 
and as the RSV – neutrophil interaction is not one of replicative infection, the 
measurement of MOI becomes less relevant; both infective and non-infective 
virions may participate in the interaction (178, 179).  
3.7 Summary 
The data presented in this chapter do not suggest that RSV replicatively 
infects neutrophils. Rather, it reveals that RSV is taken up by neutrophils with 
maximal uptake at 4 hours and reduction by 20 hours. RSV uptake is 
improved by serum, which may be as a result of antibody mediated 
enhancement. The mechanism of uptake has not been confirmed but 
macropinocytosis is a possible pathway. This would lead RSV to be localised 
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in endosomes in the cytoplasm as suggested by the initial confocal images, 
whilst not necessarily being inhibited by actin disruption.  
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Chapter 4 Visualisation of RSV within the neutrophil 
by confocal microscopy 
4.1 Introduction      
In Chapter 3, I established that RSV appears to enter neutrophils, in a serum 
dependant manner, before being degraded. Initial confocal microscopy 
showed that the virus was localised to the cytoplasm, in small discrete 
pockets resembling endosomes. Cytochalasin D, an actin cytoskeleton 
disruptor, did not prevent uptake of the virus, from which it can be inferred 
that phagocytosis is not the mechanism of uptake, as this is an actin 
dependant process. In addition, phagocytosis is not a common mechanism 
used by a virus to enter host cells; other forms of endocytosis are more 
commonly exploited due to the particle size of viruses (180).  
 
As obligate intracellular parasites viruses must enter host cells to replicate. 
They can do this in two ways: by a direct mechanism at the plasma 
membrane or by hijacking the host cell’s endocytic pathways (181). 
Internalisation itself is generally not sufficient for productive infection. An 
incoming virus contained within an endosome can be construed as still being 
within the extracellular space. Therefore, endocytosed viruses must 
penetrate or fuse with the endosomal membrane to be released into the 
cytoplasm (182). Viruses not only depend on the machinery of the cell for 
internalisation but also for trafficking within the cytoplasm to the site of 
replication. For nuclear replicating viruses especially, the endosome can 
enable delivery of its viral cargo to the nuclear pore, ready for translocation 
into the nucleus.  
 
Endocytosis is used by cells to internalise extracellular particles, and starts 
with the formation of primary endocytic vesicles (PEVs). It is the formation of 
these PEVs that varies between the different types of endocytosis. PEVs are 
then routed to endosomes, where processes such as recycling, degradation, 
and storage occur. There are six known endocytic pathways used by viruses 
to gain entry into cells. However, there is considerable overlap between 
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pathways and it may be that many of these are actually the same pathway, 
modified by virus or host response (180). Newly discovered and better 
characterised endocytic mechanisms mean that studying virus entry has 
become more complex. Mechanisms of virus entry that were once thought 
understood have come under further scrutiny as more specific and sensitive 
methodologies are employed; paramyxoviruses such as RSV are one such 
family of viruses. 
 
Paramyxovirus entry is conventionally thought to occur through virus-cell 
membrane fusion and is mediated by their attachment proteins and fusion 
protein F (183). The F protein undergoes conformational change upon 
attachment, which results in membrane fusion. The events that occur 
subsequent to receptor binding, that leads to the triggering of the F protein, 
remains largely unknown and appear to be diverse even amongst viruses of 
the same family. The paramyxovirus family contains many common human 
pathogenic viruses, including measles, mumps, the parainfluenza viruses, 
RSV, human metapneumovirus (HMPV), and the zoonotic henipaviruses, 
Hendra and Nipah and avian virus Newcastle disease. Evidence for an 
alternative mechanism of entry by some members of the paramyxovirus 
family has been postulated. Newcastle disease virus, although able to enter 
cells by direct fusion, has been shown, through chemical inhibition studies, to 
also use caveolae-dependant endocytosis (184). Similarly, Schowalter et al 
describe that HMPV entry may require endocytosis, evidenced by up to 90% 
reduction in infectivity following clathrin-mediated endocytosis inhibition (185, 
186).  
 
There is some evidence suggesting that endocytosis could at least be 
partially involved in RSV entry. Entry of RSV into host cells is specifically 
dependent on interactions between its surface glycoproteins G and F 
proteins, which bind to cellular glycosaminoglycans (187). A specific cellular 
receptor had yet to be described until 2011 when Hegele et al showed 
that RSV interacts with host-cell nucleolin via the viral fusion envelope 
glycoprotein and binds specifically to nucleolin at the apical cell surface. 
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Studies on RSV entry have mostly concluded that RSV, similarly to the other 
paramyxoviruses, fuses its membrane directly with the plasma membrane of 
target cells (8). Some more recent studies however contest this. Kolokoltsov 
et al inhibited RSV infection of HeLa cells using targeted siRNA knockdown 
of clathrin light chain, Eps15, and AP-2 surmising that RSV makes use of 
clathrin-mediated endocytosis (10). San-Juan-Vergara et al argue that in 
primary bronchial epithelial cells, RSV entry is a two-step process; RSV 
docks to cholesterol-rich plasma membrane domains facilitating hemifusion 
between the viral envelope and the plasma membrane followed by 
endocytosis (188). In 2013, Helenius et al investigated RSV entry into HeLa 
cells and A549 cells using multiple endocytosis assays, concluding that the 
mechanism of entry had all the hallmarks of macropinocytosis including 
blebbing of the plasma membrane, elevated fluid uptake, and internalisation 
of intact RSV particles into macropinosomes (11, 188).  
 
Macropinocytosis is used by a number of viruses to gain host entry e.g. 
vaccinia virus and herpesvirus (174, 189). Virus particles are capable of 
triggering membrane ‘ruffling’. Vacuole formation occurs at the plasma 
membrane and viruses are internalised in macropinosomes. Penetration by 
the virus can then occur through the macropinosome membrane and virus 
enters the cytosol. Proving macropinocytosis as the mechanism of uptake is 
difficult. Visualization of virus particles at the site of membrane ‘ruffles’ or 
within large irregular vesicles, were used to demonstrate a role for 
macropinocytosis in the entry of human immunodeficiency virus type 1 into 
macrophages (190).  
 
It is not clear if viruses interact differently with immune and non-immune 
cells. It is likely that individual viruses use alternative mechanisms to enter 
different cell types. It may be that mechanisms used by virus to enter 
epithelial cells and replicate, conversely result in degradation in immune 
cells. For example, uptake of RSV and subsequent presentation of viral 
antigen to T lymphocytes by bovine DCs occurs via a caveolae-dependent 
endocytic mechanism. Caveolae, a type of plasma membrane lipid raft, are 
formed and maintained by the protein caveolin. In epithelial cells, caveolae 
  99 
provide a safe route for virus to enter the cell, but in APCs, caveolae target 
the virus for degradation prior to processing and presentation of viral 
antigens (191). Endocytic entry into neutrophils by any virus has not been 
extensively investigated; some work has been done in macrophages (192). 
Macrophages express viral PRRs, the purpose of which is for recognition of 
viruses and triggering of an immune response. However, viruses have been 
known to engage these receptors to attach to and enter immune cells (193). 
Neutrophils express similar PRRs, which may be significant in RSV uptake. 
In this chapter I use confocal microscopy to confirm true internalisation of 
RSV in neutrophils, rather than surface membrane attachment, and to gain 
insight into the mechanism of entry into the cell. Preliminary data presented 
at the end of Chapter 3 showed that RSV could be identified using indirect 
immunocytochemistry. In this chapter further images are presented which 
better identify the exact location of the virus. I also undertook work to find out 
whether RSV can be localised inside endosomes, using dextran as a marker 
of pinocytosis.   
4.2 Hypothesis 
RSV is taken up by macropinocytosis into neutrophils. 
4.3 Aims 
The specific aims of this chapter are: 
1. To identify the location of RSV in the neutrophil.  
2. To determine the mechanism of uptake. 
4.4 Specific methods 
As in the previous chapter, neutrophils were incubated with RSV (MOI 0.1) in 
DMEM in the presence of 5% autologous serum and GM-CSF. After the 
incubation period cytospin slides were made of cells, which were then 
labelled and stained for imaging as detailed in Section 2.15. A full list of the 
antibodies used can be found in Table 2-7. 
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4.4.1 Z stack 
Taking a series of z-stack images is a technique whereby multiple images 
are combined to give a resulting image with a greater depth of field. 
Successive single images were taken at different focal depths, by moving the 
objective lens, and these sets of images, known as z stacks, were 
reconstructed to create either a single 2D stack (the maximal pixel intensity 
was taken), or a 3D image using Imaris software. Orthogonal views have 
been used to display this data. In addition to a XY image, the XZ and YZ 
images for a certain spot are shown to demonstrate internalisation of the 
virus inside the neutrophil.  
4.5 Results 
4.5.1 Validation of RSV F monoclonal antibody by Western blot 
To confirm that the monoclonal antibody that I planned to use in the 
immunocytochemistry experiments was specific for the RSV F protein in 
neutrophils, I used a Western blot technique. Neutrophils that had been 
incubated with RSV for 2 or 4 hours, and epithelial cells that had been 
infected with RSV for 24 hours, were probed with the anti-RSV F antibody 
(Abcam) using the method described in Section 2.13. The Western blot 
confirmed the specificity and sensitivity of the antibody (Figure 4-1). 
4.5.2 Optimisation of RSV antibody using epithelial cells as a 
positive control 
To optimise the antibody for confocal microscopy, RSV infected epithelial 
cells (BEAS-2Bs) were used as a positive control. Confluent BEAS-2B cells 
were infected with RSV (MOI 1) for 24 hours before being spun onto a slide, 
fixed and labelled with RSV F antibody (1/100) for 1 hour. The secondary 
IgG Alexa fluor® 594 antibody was used and the nuclear stain DAPI. Figure 
4-2 shows RSV infection of the epithelial cells with positive staining in the 
nucleus and cytoplasm. The isotype control was negative. 
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Figure 4-1 RSV F antibody validation by Western blot  
Lanes 1-4 show the presence or absence of RSV F protein by Western blot analysis of 
neutrophil pellets (N). Lanes 5-6 show the presence or absence of RSV F protein from 
epithelial cell pellets (E). RSV F protein has a molecular weight of 48kDa, and the protein 
band seen was confirmed to be such using the ladder on the left side of the image. 
Neutrophils were incubated with RSV for 2 or 4 hours before being washed and pelleted. 
Epithelial cells were infected with RSV and cells harvested at 24 hours before being washed 
and pelleted. The RSV F monoclonal antibody is seen be sensitive and specific in epithelial 
cells and in neutrophils.  
 
 
 
 
 
 
 
 
 
 
 
 
 
48kDa 
!!+!!!!!!!#!!!!!!!!!!+!!!!!!!!#!!!!!!!!!+!!!!!!!#! RSV!
cells!!N!!!!!!N!!!!!!!!!N!!!!!!!N!!!!!!!!E!!!!!!!E!
1      2          3         4        5        6     lanes 
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Figure 4-2 RSV antibody optimised to show BEAS2B RSV infection by confocal microscopy  
Fluorescent confocal image of BEAS-2B cells visualised by their blue DAPI stained nucleus. 
RSV is visualised using RSV F antibody and IgG Alexa Fluor® 594 secondary and is 
illustrated in red. The isotype control, matched to primary antibody concentration, reveals no 
nonspecific binding. 
  
!
!
Isotype RSV 
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4.5.3 RSV is internalised within the cytoplasm of the neutrophil 
Neutrophils, incubated with RSV for 2 hours (Chapter 2), and then fixed on 
slides, were labelled using RSV F antibody and IgG Alexa Fluor® 594 
antibody. The nuclei were stained using DAPI (1:10,000). Single images 
were taken as described in Section 2.5.13. These show RSV localised in the 
cytoplasm in discrete pockets (Figure 4-3). Additional slides were labelled 
with the same primary antibody but with an IgG Alexa Fluor® 488 secondary. 
The cytoplasm was stained using Evans Blue, which emits at a similar 
wavelength to the previously used 594 secondary. Z-stacks were taken and 
are presented as orthogonal views. The z-stacks reveal that the RSV is 
indeed internalised within the cytoplasm as evidenced by the green speckles 
entirely surrounded by red stained cytoplasm (Figure 4-4). Surface rendered 
3D projections of the images were generated using Imaris (Bitplane). This 
surface can be given visualisation properties such as transparency. In this 
figure the solid rendered cytoplasm is made 70% transparent revealing the 
internalised RSV (Figure 4-5). In the subsequent images, Imaris ‘Spot 
object’ was used to show localised RSV as small spheres. A representative 
neutrophil is shown in 3D with opaque surface render. When the cytoplasm 
is changed to 70% transparency, RSV can be seen, now represented by 
small green spheres (Figure 4-6). In the next set of images a collection of 
neutrophils are shown, with z stacks processed to produce surface rendered 
3D images which have then been, made partially transparent and then 
rotated 45o to look through the neutrophils revealing the RSV inside (Figure 
4-7).  
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Figure 4-3 Neutrophils visualised by confocal microscopy showing positive staining for RSV 
F protein 
Fluorescent confocal images of neutrophils, visualised with their nuclei stained with DAPI, in 
blue. RSV is visualised by positive staining for RSV F antibody and is shown in red.  
 
! !
Isotype 
RSV 
RSV 
RSV RSV 
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Figure 4-4 Orthogonal view showing RSV within the neutrophil cytoplasm 
(A) Z stack orthogonal view of neutrophils, showing RSV (green) throughout the cytoplasm 
(red) (B) The same image is presented in the second panel but with the red pointer focused 
on an RSV antigen inside the cell, entirely surrounded by red in the ZX and YZ images. In 
this image the nucleus stain channel is shown (blue).  
 
!
!
A 
B 
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Figure 4-5 Surface-rendered neutrophil projection  
Representative neutrophils are shown after image analysis reveals the surface rendered 
fluorescence from Evans Blue cytoplasmic stain (red). The 3D rendered z-stack confocal 
image of the cells is visible in the first image with solid cytoplasm. In the second image the 
cytoplasmic dependent fluorescence intensity is decreased, becoming 70% transparent, the 
internal RSV (green) is readily visible within the cytoplasm (red).  
  
Solid 70% transparency 
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Figure 4-6 Surface rendered neutrophil 
The opaque 3D neutrophil image reveals the surface rendered fluorescence of the Evans 
Blue stained cytoplasm (red). When the render is made 70% transparent, RSV (green) 
becomes readily visible inside the cytoplasm.  
 
  
Solid 70% transparent 
A 
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Figure 4-7 3D reconstruction of neutrophils and internalised RSV 
The top panel (A) shows the 3D rendering of z-stacks taken through the neutrophils. The 
surface has been rendered and the Evans Blue stained cytoplasm (red) is opaque. In the 
middle panel (B) the surface render (cytoplasm) has been made 70% transparent, revealing 
internalised RSV (green) surrounded by cytoplasm. In the bottom panel (C), to better 
analyse the location of the RSV, the image has been rotated 45o along its y-axis. This image 
clearly shows the spatial position of the RSV with respect to the cytoplasm. 
!
A!
B!
C!
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4.5.4 Measurement of discrete RSV labelled areas within 
neutrophils 
Using Fiji calibration and measurement tools, the size of discrete areas of 
RSV staining were measured (139) and were between 0.5 – 1.3μm (Figure 
4-8).  
4.5.5 RSV is not co-localised with dextran in endosomes  
To ascertain whether RSV was localised in endosomes, dextran was used as 
an endosomal marker. Tracing internalisation of extra-cellularly introduced 
fluorescent dextran is a standard technique for analysing fluid-phase 
endocytosis such as macropinocytosis (194-196). Neutrophils were 
incubated with RSV at the usual conditions but with or without the addition of 
a fluorescently labelled dextran. Dextran 10,000MW, alexa fluor® 594 
labelled, anionic fixable (life technologies) was used at 25μg/ml. Preliminary 
experiments optimising this method appeared to show that the location of the 
dextran and RSV were mutually exclusive (Figure 4-9). In view of this, 
multiple images were taken of neutrophils exposed to both dextran and RSV. 
FIJI colocalisation analysis was used to measure the degree of spatial 
overlap between the fluorescently labelled RSV and dextran. Manders 
coefficient, which expresses the fraction of colocalising objects in a dual 
colour image, with 1 being total colocalisation, was used (197). The mean 
Manders coefficient for dextran and RSV colocalisation was 0.03 (+/- 0.02), 
which indicates that they were not colocalised (Figure 4-10). 
4.5.6 RSV uptake is not prevented by inhibitors 
Pharmacological inhibitors were tested to determine if they prevented uptake 
of RSV into the neutrophil. A selection of drugs with differing properties was 
used to narrow down the mechanism of uptake, specifically, amiloride 
(100μM), nystatin (50μM), monodansylcadaverine (MDC) (100μM) and 
cytochalasin D (10ug/ml) (all Sigma). 
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Figure 4-8 Measurement of internalised RSV 
A representative neutrophil is shown with the cytoplasm stained with Evans Blue (red) and 
RSV labelled with IgG Alexa Fluor® 488 (green). In the 2nd image the image has been 
zoomed in and 3 RSV areas are shown with a ruler and associated measurement as 
recorded in FIJI.  
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Figure 4-9 Dextran and RSV visualised by confocal in a neutrophil 
Neutrophils were imaged following incubation with Alexa fluor 594® labelled dextran 
10,000MW. Dextran (red) can be seen in association with the neutrophil and RSV can be 
seen (green), both inside the neutrophil in close proximity but not overlapping. x40 
magnification. 
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Figure 4-10 Dextran and RSV are not colocalised in neutrophils 
Representative fluorescent image of neutrophils showing the 3 channels, dextran, RSV and nucleus and a composite image.  
! Dextran 594 labelled Merge DAPI - nucleus Alexa fluor 488 - RSV 
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Amiloride inhibits macropinocytosis through the blockade of sodium-proton 
exchange (198). Nystatin inhibits caveolae-mediated endocytosis by 
distorting the structure and function of the cholesterol rich membrane domain 
(199). MDC is a specific blocker of clathrin-mediated endocytosis (200) 
(201). Cytochalasin D is an F-actin depolymerizing drug that inhibits 
phagosome formation. It is generally considered to be a global and non-
selective uptake inhibitor (152). Neutrophils were confirmed to be viable in 
the presence of the stated concentration of the inhibitors by Annexin V/PI 
flow cytometry analysis. Images of neutrophils were identical, whether 
exposed to the inhibitors or not, indicating that none of the inhibitors 
prevented RSV uptake. Figure 4-11 shows the absence of nystatin inhibition 
as a representative example of the results of all inhibitors.  
4.6 Discussion 
In Chapter 3, I established that RSV genomic material and protein could be 
measured within neutrophil preparations following a two-hour incubation 
period. That this association was enhanced by the addition of serum and that 
the amount of RSV reduced over time, led to the question addressed in this 
chapter as to the mechanism of uptake. Although evidence suggested that 
the RSV was located intracellularly, rather than being attached to the cell 
surface, and preliminary confocal images appeared to show virus within the 
cytoplasm, conclusive evidence was sought to prove internalisation of the 
virus.  
 
The use of the z stack series and subsequent image analysis revealed that 
the RSV was internalised within the neutrophil. It was consistently found to 
be in the cytoplasm, and never in association with the nucleus. It was located 
at all depths of the cytoplasm and the size of the discrete pockets of RSV 
staining (0.5 - 1.3μm) indicated that it could be within endosomes. RSV 
virions are 0.15 - 0.3μm, suggesting that either single or multiple virions were 
being observed together.  
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Figure 4-11 RSV visualised in neutrophils with and without inhibition 
Representative confocal image of neutrophils incubated with RSV, in the presence or 
absence of the inhibitor nystatin. Neutrophil cytoplasm is seen in red (evans blue stain) and 
the RSV in green (IgG Alexa Fluor® 488).  
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Having established that the virus was intracellular, I investigated its 
mechanism of uptake. My hypothesis that uptake was via endocytosis was 
based on evidence from the literature, discussed in the introduction, 
indicating paramyxoviruses including RSV might use this mechanism to gain 
entry to host cells. The known endocytic pathways used by viruses to gain 
access into host cells is shown in Figure 4-12. This was supported by the 
appearance and size of the RSV ‘pockets’ within the cytoplasm. An 
externally introduced fluorescently labelled dextran to localise endosomes is 
a standard technique to visualise endocytosis (181, 202), as unless taken up 
by endocytosis, dextran is membrane impermeant. In addition, the use of 
florescence microscopy to investigate protein colocalisation is a widely used 
tool for assessing the extent of spatial coincidence between intracellular 
molecule (197, 203). Both of these techniques were exploited to investigate 
whether RSV could be localised within endosomes. The result was 
conclusive – RSV did not colocalise with dextran.  
 
There are a number of possible explanations for this finding. Firstly, RSV 
passes through the endosomal pathway at a different rate to dextran and 
thus is not found in the same place at the same time. Secondly, the 
endosomal pathway classically described in macrophages differs in 
neutrophils, and that RSV and dextran are actually in different types of 
endosomes. Lastly, it is possible that RSV doesn’t enter endosomes and the 
mechanism of uptake is not endocytosis. Each of these explanations will be 
dealt with in turn.  
 
In neutrophils, the formation and maturation of endosomes differs from that 
of other phagocytic cells such as macrophages. Investigating the neutrophil 
endosomal pathway is difficult. Neutrophils are terminally differentiated and 
do not survive in long term culture, as such manipulating them, for example 
with genetic modification, in order to define pathways has not been possible. 
It is common therefore, for endocytic mechanisms characterised in 
macrophages to be extrapolated to neutrophils, despite their inherent 
differences (204). 
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Figure 4-12 Endocytic pathways used by viruses 
 
The six known pathways used by viruses to gain host cell entry are illustrated. 
Macropinocytosis (A) is involved in adenovirus entry and has been implicated in RSV uptake 
by Hep2 cells. Amiloride inhibits macropinocytosis. Clathrin-independent endocytosis (B) 
has been shown for entry of influenza virus. MDC is a specific blocker of this mechanism. 
Clathrin-mediated uptake (C) is the most commonly used pathway by virus. Caveolar 
pathway (D) is one of several cholesterol-dependant mechanisms and can be inhibited by 
nystatin. Cholesterol-dependant endocytosis (E), with no requirement for clathrin or 
caveolin, is used by polyomavirus. Dynamin 2-dependant pathway (F) is similar to D except 
it is dependant on dynamin 2. (Taken from Marsh & Helenius 2006 (180)) 
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In macrophages, the process is well characterised and follows the traditional 
pathway of early and late endosomes (205). After internalisation, the 
contents of the endocytic vesicle are targeted to an early endosome. Those 
contents that are not recycled are then delivered to late endosomes where 
degradation may occur. Lastly the endocytic cargo is delivered to lysosomes 
for terminal degradation (206).  
 
Neutrophils do not possess this classic endosomal pathway. Early and late 
endosomes are not found. Instead, neutrophils have a large number of pre-
formed vesicles and granules that can fuse with the in-coming endosome. 
The timing of fusion of the different granule types has not been established. 
There are also very few studies which show how pathogens are handled 
within the endosomal pathway of the neutrophil (205). This deficit in available 
knowledge means that data derived from a method optimised to study 
macrophage endocytosis, may not mean the same for a neutrophil. For 
example, internalised particles in neutrophils might move through the 
cytoplasm in endosomes at different rates depending on their content. This 
would result in dextran and RSV being at different stages of endocytosis 
when visualised, unlike in macrophages where anything taken up by 
pinocytosis would pass through from early to late endosomes at a similar 
speed. Stopping the experiment at multiple time points to look at particle 
progression, and whether they ever colocalise would be a method to 
investigate this further. 
 
Not enough is known about the endocytic mechanism of the neutrophil to 
know whether dextran and virus would end up in the same compartment 
together, even if they were both taken up by macropinocytosis. The 
neutrophil contains a variety of granules that fuse with incoming endosomes, 
delivering antimicrobial and cytotoxic substances to aid pathogen destruction 
(207). It may be that internalised virus is handled differently by the neutrophil 
to internalised dextran. Neutrophils also contain viral PRRs so could 
recognise virus as a threat and consequently handle it differently to inert 
dextran. However, the use of endocytosis by virus as a mechanism of entry 
into neutrophils suggests that it might confer some evolutionary advantage. 
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Endosomal conditions, such as low pH, can trigger un-coating of virus or 
enable release from the hostile endosome (208, 209). This could enable the 
virus to avoid degradation. If this were to be the case for RSV, then it might 
allow the virus to escape the endosome into the cytoplasm, hence the spatial 
separation from dextran, which might still be contained within the endosome.  
 
Paramyxovirus entry to host cells is usually by means of plasma membrane 
fusion. However, some paramyxoviruses have also recently been shown to 
use endocytosis to gain entry into some cell types. The type of endocytosis 
used by a cell or pathogen seeking entry is determined by particle size, 
receptor availability, and cell tropism. I hypothesised that macropinocytosis 
would be the specific endocytic mechanism of uptake for RSV because this 
is the mechanism used by multiple other viruses including vaccinia, 
coxsackievirus, herpes simplex virus 1 and HIV (174, 210-212). Interestingly, 
HIV can also enter host cells by plasma membrane fusion, with its surface 
glycoproteins activated by binding to two surface receptors triggering 
conformational change, resulting in fusion of the virus envelope with the 
plasma membrane (213). Macropinosomes are irregular in size and shape, 
with a diameter of 0.5–10 μm, which would fit with the size and irregularity of 
the pockets seen in the neutrophil images. In addition, this mechanism has 
recently been demonstrated for RSV entry into HEP2 cells. That the virus 
does not appear to be within endosomes would suggest endocytosis, of any 
type, is not the mechanism involved in RSV uptake in neutrophils. Virus entry 
mechanisms into neutrophils have not been extensively investigated. It is 
evident however, that individual viruses can use different methods of entry 
depending on the host cell type. Although useful to gain knowledge about 
RSV entry into other cells, it does not necessarily extrapolate to the 
neutrophil.  
 
As the colocalisation experiments were not able to provide an answer 
regarding the mechanism of uptake, I revisited the use of endocytosis 
inhibitors, using visualisation of internalised virus as the outcome measure. 
Quantifying virus uptake would have been ideal, to see if there was a 
measurable reduction in uptake with the use of inhibitors, as multiple 
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mechanisms of entry is a possibility. However, no method of quantification in 
previous optimisation experiments had proved reproducible. As none of the 
inhibitors appeared to prevent uptake, with the visual quantity of RSV 
identical with or without inhibitors, further quantification was not pursued.  
 
Cytochalasin D has consistently failed to inhibit RSV uptake measured by 
PCR and now confocal microscopy. As discussed previously (Chapter 3), 
the role of actin in macropinocytosis is accepted. However, whether the actin 
disruption effected by cytochalasin D disrupts macropinocytosis, inhibiting 
uptake, has been disputed. This is because the effect of cytochalasin D may 
vary depending on cell type (214). Keller et al also found that cytochalasin D 
could stimulate, rather than prevent, fluid pinocytosis and increase actin 
polymerization in neutrophils and that neutrophil pinosome formation differed 
depending on the stimulus. Thus cytochalasin D inhibited dextran uptake 
when used to inhibit phagocytosis of one strain of S. Pyogenes bacteria. 
However, pinocytic uptake occurred when it was similarly used to inhibit 
phagocytosis of a different strain (215). The authors concluded that the 
neutrophil actin filament network behaved differently dependant on different 
conditions. For these reasons I trialled a number of endocytosis inhibitors, all 
identified in a recent review of pharmacological inhibition of endocytosis 
(177). All these inhibitors had limitations and there is considerable overlap in 
their inhibitory effects on different endocytic processes. That they did not 
inhibit RSV uptake at all into neutrophils is likely because the mechanism of 
uptake was not endocytosis. However, it must also be considered that the 
inhibitors may not be, at the concentrations used, successful inhibitors in 
neutrophils. Testing them further using a variety of endocytic targets would 
be an appropriate next step to consider.    
 
Given that all tested endocytosis inhibitors failed to stop uptake and that no 
evidence has been gained to show endosomal location of RSV, it would 
seem likely that viral endocytosis is not occurring and that direct plasma 
membrane fusion is the mechanism of entry. Additionally, it may be that RSV 
makes use of multiple internalisation pathways and therefore uptake might 
not be prevented by one inhibition method alone. It has been reported that 
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several tests and approaches are needed to define a macropinocytic 
pathway (174). As endocytosis involves multiple mechanisms that are not 
fully defined or understood, investigating this process in the neutrophil has 
proved problematic.  
 
In this chapter, definitive evidence of RSV internalisation has been 
established, but not the mechanism of uptake. That there is far more to 
discover about both neutrophil endocytic pathways and methods of studying 
the neutrophil is evident. Several potential strategies to take this work further 
have been proposed. However, arguably more important than elucidating the 
precise mechanism of RSV entry into the neutrophil is the response of the 
cell to virus internalisation; this will be studied in the next chapters. Given the 
multitude of neutrophils within the RSV infected airway, this response may 
be critical to disease progression or recovery/resolution.  
4.7 Summary 
Data presented in this chapter reveal that RSV is internalised within the 
neutrophil cytoplasm but is not found within endosomes. The mechanism of 
uptake is unlikely to be macropinocytosis. That RSV enters at the plasma 
membrane by direct fusion has neither been ruled out nor confirmed but 
seems the probable mechanism of entry.  
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Chapter 5 Interaction of cord blood derived 
neutrophils with RSV 
5.1 Introduction 
Previous work in this thesis used adult neutrophils to study RSV-neutrophil 
interaction. However, bronchiolitis is a disease of infants and so I would have 
ideally liked to study infant neutrophils. This is not possible because of the 
ethics of taking a sufficient volume of blood, at least 10mls, from infants of 
the age affected by bronchiolitis, typically six weeks to six months. Many 
studies show that neutrophils from newborns differ from adult neutrophils in 
their response to pathogens. The literature is predominantly focused on 
bacterial and fungal microbes, presumably as these pathogens can cause 
severe disease in newborn infants (216-219). An alternative approach, used 
in this chapter, is to study cord blood neutrophils. This allows the study of 
neutrophil responses in a patient group approaching the age of the target 
demographic, and provides some evidence to validate my model based on 
adult neutrophils. The advantages are that cord blood is easily accessible, 
available in an adequate quantity compared to infant blood and can be 
acquired non-invasively through venepuncture of the placenta after delivery. I 
have repeated experiments on adult neutrophils presented in Chapters 3 
and 4, to discover whether similar RSV uptake is seen by cord blood 
neutrophils.  
  
In vitro studies on cord blood neutrophils may not accurately reflect the 
interaction of airway neutrophils in infants with RSV. The limitations of single 
cell in vitro cultures are covered in the discussion. For this reason I have 
extended the work further to investigate whether my results are simply an in 
vitro phenomenon or one that occurs in vivo. Thus, I have isolated 
neutrophils from BAL of RSV infected infants and used confocal imaging to 
visualise the RSV-neutrophil interaction.  
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5.2 Overall aim 
To study the interaction between RSV and neutrophils from patient groups 
which reflect the demographic of those affected by RSV bronchiolitis, in order 
to validate the adult neutrophil model.  
5.3 Specific aims 
The specific aims of this chapter are: 
3. To isolate highly purified neutrophils from cord blood of healthy term 
infants. 
4. To establish the kinetics of RSV uptake in cord blood neutrophils and 
whether it is degraded similarly to that seen in adult neutrophils. 
5. To visualise virus within the cord blood neutrophil by confocal 
microscopy.  
6. To image ex vivo BAL neutrophils to establish whether the in vitro 
results are physiologically relevant. 
5.4 Specific Methods 
5.4.1 Cord blood collection  
Liverpool Women’s Hospital research midwives recruited mothers to the cord 
blood study (described in Section 2.1.2) at preoperative assessment clinic. 
Whole blood was collected from the placenta immediately after delivery. The 
cord was clamped and a needle inserted into one of the veins to withdraw 
blood.  Blood was collected only when there were intact membranes, clear 
amniotic fluid, no signs of neonatal distress or infection during pregnancy 
and no concerns regarding baby’s health, and if the gestational age was 
equal to or more than 37/40.  
5.4.2 Cord blood neutrophil isolation 
Cord blood neutrophils were isolated (outlined in Section 2.2.1) as for adult 
blood neutrophils. When using adult neutrophils, autologous serum was 
used. Due to the smaller volume of blood and hence serum from cord blood, 
AB serum (Sigma) has been used in its place for the experiments in this 
chapter. 
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5.4.3 BAL sample collection and processing  
Infants were recruited to the mucin study (described in Section 2.1.1) by 
medical doctors on the respiratory team at Alder Hey Hospital. Members of 
the physiotherapy team collected non-bronchoscopic bronchoalveolar lavage 
(BAL) samples from children ventilated and muscle relaxed on PICU. 
European Respiratory Society (ERS) guidelines on collection of BAL in 
children were followed (220). A suction catheter was passed down the endo-
tracheal tube until resistance was felt. 1ml/kg aliquot of 0.9% NaCl was 
instilled. BAL fluid was recovered with suction pressure and collected into a 
mucus trap.  
5.4.4 BAL neutrophil isolation 
All BAL samples were stored at 4oC and used within an hour of collection. 
The total volume of sample obtained was first recorded. Each sample was 
pipetted vigorously and if the volume was less than 1 ml, the sample was 
diluted by a known amount using PBS. Samples were then centrifuged at 
2000rpm for 10 minutes and the BAL supernatant was aliquoted into 1ml 
Eppendorf tubes, labelled with recruit number and stored at -80oC. The cell 
pellet was resuspended in 1ml RoboSep™ buffer, and 25ul neutrophil 
enrichment cocktail added prior to 10 minutes incubation at room 
temperature. 50ul of RoboSep™ magnetic particles were added prior to 
another 10 minute incubation. The whole suspension was then made up to a 
total volume of 2.5ml by the addition of RoboSep™ buffer before being 
thoroughly mixed and placed into the EasySep™ magnet for 5 minutes. The 
desired fraction was poured off by inverting the magnet and tube into a new 
tube, which was then placed into the magnet for a further 5 minutes. This 
was repeated once, leaving the negatively selected enriched cells in the new 
tube ready for use.  
5.5 Results 
5.5.1 Maternal characteristics 
In total 17 mothers consented to participate in the study, of which ten had 
cord blood collected. The reason for non-collection of other samples was 
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earlier delivery date than expected or complications subsequently making 
them ineligible. The mean maternal age was 32 years and all infants were 
between 38+2 and 39+2 weeks gestation. The mean infant weight was 3.48kg, 
(range 2.69 – 4.11kg). The mean volume of blood collected was 10mls 
(range 5mls – 16mls). A mean of 1.32 x106 neutrophils/ml of blood collected 
were isolated. 
5.5.2 Cord blood neutrophils can be isolated to 98.7% purity as 
determined by CD66c positivity 
To confirm that pure neutrophils could be isolated from cord blood in 
adequate volumes, purity was assessed using flow cytometry analysed 
CD66c positivity. Briefly, neutrophils were isolated using dextran 
sedimentation, percoll gradient and then highly purified using negative 
immunoselection. 98.7% of isolated cells were identified as neutrophils 
based on their expression of CD66c. Additionally, neutrophils were assessed 
by Romanowsky staining and were identified morphologically (Figure 5-1).  
5.5.3 Cord blood neutrophil survival can be extended in vitro by GM-
CSF 
As for the adult neutrophils, to ensure that cord blood neutrophils remained 
viable throughout the course of the experiments, GM-CSF was used. 
Annexin V/PI analysis by flow cytometry of apoptosis and cell death was 
used to assess the percentage of viable neutrophils at time points up to 20 
hours in the presence or absence of 5ng/ml human recombinant GM-CSF 
(Peprotech). Early apoptosis was identified by Annexin V positivity and cell 
death was identified by PI staining. In the absence of GM-CSF, mean (SEM) 
neutrophil survival was 97.20% (+/- 0.914), and 63.78% (+/- 7.717) at 4 and 
20 hours respectively. There was a significant decrease in cell viability at 20 
hours (p=0.0033) when compared to 4 hours. With the addition of GM-CSF 
cell viability increased to 97.33% (+/- 0.333), and 81.067% (+/- 6.583) at 4 
and 20 hours. Cell viability was not significantly decreased at 20 hours in the 
presence of GM-CSF. 2-way ANOVA with Bonferroni’s post hoc test 
incorporating correction for multiple testing was used (Figure 5-2). 
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Figure 5-1 Cord blood neutrophil purity  
a) Histogram showing percentage of cells that are CD66c positive measured by flow 
cytometry. Blue line = neutrophils labelled with a monoclonal antibody to CD66c conjugated 
to PE. Red line = matched isotype control. Following negative immunoselection where 
antibody complexes link to CD2, CD3, CD9, CD19, CD36, CD56 and glycophorin A and bind 
to magnetic particles leaving a pure preparation of neutrophils, 98.7% of neutrophils 
expressed CD66c. b) Flow cytometry scatter plot demonstrating the one cell population on 
the basis of forward and sidelight scatter properties. c) Neutrophils were spun onto a slide 
then stained using a Romanowsky staining protocol, before being imaged using a Leiss 
microscope. Cells were histologically identified as neutrophils by their multi-lobed nucleus 
and stain uptake pattern. 
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Figure 5-2 GM-CSF prevents significant neutrophil apoptosis  
Grouped bar chart showing survival of GM-CSF treated and untreated cells at 4 and 20 
hours. Control cells showed significant reduction in viability at 20 hours (p value = 0.0033). 
With GM-CSF treatment no significant neutrophil apoptosis was observed at 20 hours.  
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5.5.4 RSV uptake time course measured by western blot  
RSV protein was measured from the neutrophils to ascertain whether RSV 
interacted with neutrophils, as seen with adult cells, and whether it was 
degraded over time. A Western blot was carried out on pellets harvested at  
2, 4 and 20 hours from neutrophils incubated with RSV in DMEM, in the 
presence of GM-CSF and 5% AB serum. The polyclonal RSV antibody 
(1/100) was used with streptavidin secondary (1/1000). 4 bands were clearly 
seen and identified based on their predicted molecular weights as F, G, M 
and N.  The density of the bands reduces at 20 hours (Figure 5-3) 
suggesting degradation of internalised RSV protein. The figure shown is 
representative of 3 identical, separate experiments, which revealed the same 
finding.  
5.5.5 RSV is internalised within the cytoplasm of cord blood 
neutrophils 
Neutrophils that had been in culture in the usual conditions with RSV 
preparation for 2 hours, in the presence of GM-CSF and 5% AB serum, were 
spun onto slides. Using the RSV monoclonal antibody to F protein (Abcam) 
used in the previous chapter, and an IgG Alexa Fluor® 488 secondary 
(Invitrogen), indirect immunocytochemistry was carried out, (as described in 
Section 2.14). The cytoplasm was co-stained with Evans Blue. The image 
presented shows positive staining for RSV diffusely in the cytoplasmic area, 
with exclusion of the nucleus (Figure 5-4). In addition to the single images, 
z-stacks were taken, (as described in Section 4.4.1). These z-stacks are 
presented as orthogonal views and reveal that, identical to the adult 
neutrophil images, RSV is internalised throughout the cytoplasm, as 
indicated by the green speckles surrounded by red stained cytoplasm 
(Figure 5-5).   
5.5.6 RSV uptake not inhibited by phagocytosis inhibitor 
Pharmacological inhibition of RSV uptake was tested using cytochalasin D 
(Sigma). Neutrophils were pre-incubated with cytochalasin D (10μg/ml) for 
15 minutes prior to addition of RSV, and then cultured at the usual conditions  
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Figure 5-3 Western blot time course of RSV proteins from cord blood neutrophils 
A Western blot was carried out on pellets harvested at 2, 4 and 20 hours from neutrophils 
incubated with RSV and 5% AB serum. The quantity of RSV, as shown by the density of the 
4 RSV protein bands G, F, N and M, is reduced by 20 hours. The most distant band has not 
been identified and is of lower molecular mass than the full-length protein and may therefore 
represent fragments of proteolytic cleavage.  
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Figure 5-4 Cord blood neutrophils visualised by confocal microscopy showing RSV 
Neutrophils that had been incubated for 2 hours with RSV were spun onto slides and fixed 
with methanol, following which they were stained for RSV (green) and co-stained with Evans 
Blue (red). Images were taken with a multiphoton Zeiss microscope.  
 
 
 
 
 
 
 
 
 
 
 
!
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Figure 5-5 Orthogonal view showing RSV within the cord blood neutrophil cytoplasm  
A z-stack orthogonal view of cord blood neutrophils showing RSV (green) throughout the 
cytoplasm (red).  
 
 
 
 
 
 
 
 
 
 
!
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for 2 hours prior to cytospin and immunocytochemistry analysis. Similarly to 
the adult neutrophils RSV uptake was not inhibited (figure not shown). 
5.5.7 Bronchiolitis patients’ characteristics 
5 infants with RSV bronchiolitis were recruited and had a BAL sample 
collected for neutrophil isolation and cytospin. The characteristics of these 
patients are shown in Table 5-1. The mean GA at birth was 36 weeks (range 
34 - 40 weeks). A mean of 9.7x105 neutrophils/BAL sample collected were 
isolated. 
 
GA at birth 
(weeks) 
Corrected age at 
admission (weeks) 
Time sample taken 
after intubation (hours) 
Number of 
neutrophils isolated 
40 3  18  2,300,000 
34 15  24  400,000 
35 27  23 150,000 
37 3  24  1,500,000 
35 1  7  500,000 
Table 5-1 Table of RSV patient recruit characteristics  
The gestational age (GA), corrected age on admission and the time the BAL was taken after 
intubation are shown for the 5 recruits. In addition, the number of neutrophils isolated from 
each BAL sample is shown. 
 
5.5.8 RSV identified by confocal in ex vivo BAL neutrophils 
Neutrophils were isolated from BAL (as described in Section 5.4.2). Ex vivo 
neutrophil cytospins were stained to identify RSV using the same method 
used for the in vitro neutrophils. Images were taken and are presented, firstly 
as single images revealing RSV positivity, and a negative isotype control 
(Figure 5-6). Secondly, a different recruit’s BAL neutrophils are shown as an 
orthogonal image. In this image RSV can be seen throughout the cytoplasm, 
and in addition RSV can be seen attached to the neutrophil (Figure 5-7).  
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Figure 5-6 Ex vivo neutrophils showing RSV by immunocytochemistry 
Neutrophils isolated from RSV infected infant’s BAL fluid were fixed on slides and stained for 
RSV F protein, using an IgG Alexa Fluor® 488 secondary antibody. The cytoplasm is stained 
with Evans Blue (red), the RSV is seen in green and the nuclei are co-stained with DAPI 
(blue). The isotype (seen in the 2nd panel) was negative.  
  
!
!
RSV Isotype 
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Figure 5-7 Orthogonal view of ex vivo neutrophils 
Z-stack orthogonal views of ex vivo BAL neutrophils showing RSV (green) and cytoplasm, 
co-stained with Evans Blue (red). Neutrophils were isolated from RSV infected infant’s BAL 
fluid and stained for RSV F protein, using an IgG Alexa Fluor® 488 secondary antibody. 
 
  
!
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5.6 Discussion 
Data presented in this chapter show that cord blood neutrophils interact with 
RSV in a similar way to adult neutrophils. Thus, western blot revealed that 
RSV protein, seen at 2 and 4 hours, is reduced by 20 hours, suggesting that 
RSV is degraded once internalised. Confocal microscopy showed that the 
RSV is internalised within the cytoplasm in discrete pockets and that uptake 
is not prevented by cytochalasin D. That there appears to be no apparent 
difference between RSV and cord neutrophils, and RSV and adult 
neutrophils is perhaps unexpected, given the documented literature, 
discussed below, on cord blood impaired responses to pathogens.  
 
Term newborns have blood neutrophil counts very similar to adults and older 
children (221), but some reports suggest they differ with respect to migration, 
phagocytosis, and oxidative burst. A recent study employed proteomic 
analysis to compare newborn cord blood neutrophils with peripheral adult 
neutrophils. This analysis indicated impaired function of newborn neutrophils, 
specifically relating to the proteasome, lysosome, phagosome and migration 
(222). In the literature the commonest observed functional difference is that 
of reduced chemotaxis, with newborn neutrophils migrating at about half the 
speed of adult neutrophils in in vitro studies (216, 223). Term newborns tend 
to establish normal chemotactic function by ten days to two weeks postnatal 
age (224, 225). Interpretations differ as to the phagocytic capacity of the 
newborn neutrophil with differences probably attributable to variation in 
experimental conditions, as some studies use cord blood neutrophils with 
serum from the newborn donor while some use adult serum. Specifically 
these differences in phagocytic ability appear to be dependant on adequate 
opsonisation. Thus phagocytosis of bacteria normalises in term infants’ 
neutrophils when using infant blood and adult immunoglobulin and 
complement (216, 226). Respiratory burst activity of neutrophils harvested 
from cord blood of term infants does not differ significantly from adult 
neutrophils (227, 228). Intriguingly however, superoxide generation, the initial 
phase of respiratory burst, is increased in newborn neutrophils compared to 
those from adults (229).  
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It is a common approach to use cord blood as a source of immune cells 
when studying infant responses to a pathogen (230-232), although few 
studies have explored its suitability as a surrogate for infant blood. However, 
it would appear that cord blood neutrophils are markedly more immature than 
neutrophils from infants, even of a few weeks of age. One study showed that 
the impaired ability of the cord neutrophil to phagocytose was transient and 
that by day three, activity was similar to that seen in adult neutrophils (233). 
Similarly studies investigating neutrophil chemotaxis showed that adult-like 
chemotactic ability is achieved by two weeks of age (224, 225).  
 
If cord blood neutrophil responses lack maturity when compared to those 
from a 2-week-old infant, why in this study do they appear to have responded 
similarly to adult neutrophils? It could be that the use of GM-CSF has 
activated and thus matured them. GM-CSF has been used as a pro-survival 
factor throughout this research. It is a haematopoietic growth factor that 
regulates proliferation and differentiation of precursor cells and has also 
been found to exert functional effects on neonatal and adult neutrophils (234, 
235). The presence of GM-CSF can prolong neutrophil longevity in vivo and 
in vitro (236-239). Part of my justification for using GM-CSF was that it is 
produced by airway epithelial cells and is found in high concentrations in the 
airways of infants with severe RSV infection (240, 241). I found that GM-CSF 
prevented significant neutrophil apoptosis at 20 hours for the cord blood but 
not adult neutrophils. In Chapter 2 GM-CSF exposed adult neutrophils 
showed improved survival compared to untreated neutrophils, but still 
significant apoptosis at 20 hours (Figure 2.6).  Most studies using GM-CSF 
have looked at its action on adult neutrophil function, but work carried out 
investigating the response of the neonatal neutrophil to GM-CSF revealed 
that it enhanced chemotaxis, and improved the respiratory oxidative burst to 
a greater degree than in adult neutrophils (242). That the cord blood 
neutrophil is more sensitive to the effects of GM-CSF may explain the 
similarity in response to the adult neutrophil. 
 
A challenge of any in vitro study occurs when extrapolating back to the 
biology of the intact organism (243). Immunocytochemistry of the ex vivo 
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neutrophil has revealed RSV, internalised within the neutrophil and 
distributed throughout the cytoplasm, in a pattern corresponding to that seen 
in the in vitro experiments, which confirms the biological relevance of the 
work to this point. There are a number of limitations to the in vitro model that 
could result in the interaction observed not accurately reflecting human RSV 
infection and disease. Firstly, the interaction of just one immune cell with 
RSV is modelled. Neutrophils have been removed from their natural 
environment, eliminating interaction with other cell types, and simplifying the 
events that would occur in the airways of infants infected with RSV. Even 
though neutrophil influx occurs early in infection, epithelial cells and alveolar 
macrophages would also be present within the airway and would interact 
with the neutrophil. However, the main advantage of single cell type in vitro 
models is their ability to provide information on that cell’s particular reaction 
to an infectious microbe. Secondly, it is not possible to know the correct ratio 
of virus to neutrophil and imitate that in a physiologically relevant space. 
Nonetheless, that the neutrophil does encounter RSV and that an interaction 
occurs has been confirmed in multiple patients’ BAL samples. The 
magnitude of RSV seen in individual samples did vary, presumably reflecting 
the personal viral load of the different recruits. The ex vivo neutrophil results 
lend support to the RSV neutrophil interaction being a genuine disease 
phenomenon.  
5.7 Summary 
Data presented here shows that the cord blood neutrophil-RSV interaction is 
very similar to the adult blood neutrophil-RSV interaction. In addition, BAL 
from infants with bronchiolitis shows a similar distribution of RSV within the 
neutrophils, lending support for the use of the in vitro model to examine RSV-
neutrophil interactions.  
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Chapter 6 Innate antiviral response to RSV  
6.1 Introduction 
RSV infection triggers a robust innate immune response characterised by 
high levels of airway cellularity. Neutrophils make up a large proportion of the 
cells, and throughout this study evidence of RSV entry into the neutrophil has 
been presented. This has been examined in an in vitro model system, 
showing that viral replication is not supported within the neutrophil, and in ex 
vivo neutrophils in which RSV was visualised. A 2015 review by Pickles and 
DeVincenzo highlights the lack of knowledge regarding the interaction of the 
neutrophil with RSV, in particular, how RSV affects neutrophil function and 
consequently impacts disease severity (244). This thesis attempts to fill that 
gap in understanding, but thus far, the response of the neutrophil to RSV has 
not been examined. 
 
Neutrophils can express and produce a wide range of cytokines, either 
constitutively or upon activation, which influence antiviral defence. Activation 
of the neutrophil, can be effected through an array of receptors including 
colony stimulating, and cytokine receptors, G protein coupled-, Fcy- and 
complement receptors and many PRRs (105). The PRRs, RIG-I and MDA-5 
are present in the neutrophil, enabling the cell to recognise intracellular viral 
components, as discussed in Chapter 1. Once stimulated, neutrophils can 
control cytokine production through regulation at the transcriptional level 
(102, 245). The RSV infected airway contains a melange of pro-inflammatory 
and anti-viral cytokines. The neutrophil’s contribution to this environment is 
not known with any certainty but the expanding list of neutrophil derived 
cytokines means they probably contribute considerably, either directly or 
indirectly. Our group has previously shown large amounts of TNF-α in the 
RSV infected airway (246). Neutrophils produce low-levels of TNF-α (105, 
247, 248), and through the expression of TRAIL, which is expressed on and 
secreted by neutrophils, are thought to play an active role in the early 
defence against viral infection. Neutrophil antiviral activities, specifically in a 
murine model of CMV infection were shown to act through the 
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TRAIL/TRAILR pathway (248). RSV specific studies in humans have shown 
increased levels of MIP-1 α (CCL3) and CXCL8, cytokines that neutrophils 
are known to produce (118). IL-9 was found in abundance in the BAL of term 
infants with RSV, immunostaining showed that neutrophils were the main 
source of this type 2 cytokine (249).  
  
The neutrophil’s contribution to immune modulation is far more than cytokine 
production alone. Since the 2000s, a number of high-throughput studies, 
using proteomic analysis, oligonucleotide array and microarray, have 
examined the scope of neutrophil gene expression during an inflammatory 
response (250-252). Microarray allows analysis of the regulation of gene 
expression at the transcriptional level for thousands of genes at one time. 
Microarrays have enhanced our knowledge of the number of transcripts 
involved in neutrophil biology and has revealed pathways not traditionally 
associated with the neutrophil such as cell to cell signalling, and regulation of 
T cell activation (253). In vivo work has then proceeded to confirm these 
functions. In influenza A, neutrophils have been shown to be capable of 
acting as APCs for CD8+T cells in the lungs, expressing MHCI, CD80 and 
CD86 (254).  
 
Although transcriptional studies of neutrophils are becoming more 
commonplace, I have only been able to identify one study that has 
investigated the transcriptional response to a virus, specifically influenza 
H3N2 and none have specifically investigated the response to RSV (151). 
One study did undertake whole blood gene expression in infants with RSV. 
There were 2,317 differentially regulated transcripts in total. Two of the top 
ten overexpressed genes related to neutrophil function, and neutrophil 
related genes were significantly overexpressed in patients with RSV 
compared to other respiratory viral infections (255). That the neutrophil may 
contribute to the anti-viral response to RSV seems likely, and investigating 
their transcriptional profile by microarray, would appear to be a suitable 
method of elucidating this contribution.  
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6.2 Hypothesis 
RSV uptake by neutrophils induces change in transcription in these cells, 
characterised by an antiviral response.  
6.3 Aims 
To answer the above hypothesis the work described in this chapter aimed to: 
1. Utilise gene microarray technology to identify differentially expressed 
genes from RSV exposed neutrophils. 
2. Use pathway analysis to determine the pattern of differentially expressed 
genes. 
3. Validate the microarray analysis by measuring select, pertinent genes by 
RT qPCR.  
6.4 Specific methods 
6.4.1 Microarray 
The aim of this experiment was to identify differentially expressed genes in 
RSV exposed and control human neutrophils. Blood was collected from 4 
healthy adult volunteers (2 male, 2 female; mean (range) age 25 (20 – 33) 
years). Neutrophils were isolated and ultrapurified as described in Section 
2.2. They were incubated at 37oC/5% C02 for up to 20 hours, in DMEM 
containing 5% AB serum, either in the presence or absence of RSV (MOI 
0.1). Samples were collected at 4 and 20 hours.  
 
16 RNA samples were prepared from neutrophils using the method 
described in Section 2.10.2. However, an additional step of DNA digestion 
was incorporated into the protocol after RNA extraction, to remove 
contaminating DNA. RNase-Free DNase Set (Quiagen) was used. RNA 
solution was mixed with 10ul Buffer RDD and 2.5ul DNAse I stock solution, 
and made up to 100ul with RNase-free water. This was incubated for 10 
minutes at room temperature, after which Quiagen RNA cleanup protocol 
was followed. The samples were assessed using Agilent 2100 Bioanalyser 
RNA 6000 Nano chips. 100ng of total RNA, dried by speed-vac, was used for 
one-colour target labelling and amplification using an Agilent Low-Input 
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Amplification Kit (LIQA) according to the manufacturer’s instructions (sample 
IDs and information can be found in Appendix 4). 600ng of Cy3 labelled 
RNA was fragmented and loaded onto the arrays, which were then 
hybridised for 17 hours at 65oC and 10rpm in an Agilent hybridisation oven. 
Following this, the arrays were washed and scanned by the Agilent Scanner, 
using the G3_GX_1 colour protocol and 3uM resolution. The data were 
extracted with Agilent Feature Extraction software v11.01.1.1, using Design 
ID 039494 and Protocol GE1_1100_Jul11. Dr Lucille Rainbow (Centre for 
Genomic Research (CGR), University of Liverpool) carried out both the RNA 
sample quality assessment and the microarray.  
6.4.2 qPCR validation of microarray findings  
In order to validate the findings of the microarray analysis, qPCR was 
utilised. Analysis was carried out on the 4 original microarray RNA samples 
and in addition 2 further samples, which were produced using the same 
method, described in Section 2.10.2.  
6.4.2.1 cDNA synthesis 
RNA samples were converted to cDNA using Moloney Murine Leukaemia 
Virus reverse transcriptase (Bioline). RNA samples were incubated at 60oC 
for 5 minutes to denature RNA. RT mastermix, made up as shown in Table 
6-1, was added immediately (20μl per 30μl RNA sample). Samples were 
incubated at 42oC for 1 hour, then at 80oC for 10 minutes to inactivate the RT 
enzyme. cDNA samples were diluted with 450μl sterile dH20 and stored at -
20oC prior to use. 
For 1 reaction 30μl RNA 
sample (μl) 
Deoxynucleotide triphosphosphates dNTPs 40mM (Bioline) 
Random Hexamer (AB) 
1.5 
1.0 
UBioscript 5x RT Bufer (Bioline) 5.0 
Bioscript RT Enzyme (Bioline) 
Sterile distilled H20 
0.5 
12.0 
Table 6-1 Reverse transcription mastermix used in cDNA synthesis Table stating the 
quantities of components used for the reverse transcription mastermix for cDNA synthesis.  
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6.4.2.2 Quantitative Polymerase Chain Reaction 
For all reactions, 0.5μl gene expression assay (Taqman®) probe, 5.0μl 
Taqman® mastermix, 2.5μl sterile dH20 and 2μl cDNA were used. Plates 
were sealed with adhesive film and run on Applied Biosystems 7500 fast 
Real-Time PCR System. Cycling conditions were: 2 minutes at 50°C, hold at 
95° for 10 minutes, followed by 40-60 cycles of 95°C for 15 seconds and 
60°C for 60 seconds. 
6.4.3 Housekeeping gene selection 
In Chapter 3, when qPCR was previously used, it was found that L32, the 
housekeeping gene utilised was not efficient in the neutrophil system. In 
order for relative quantification to take place, the efficiency of a probe must 
be 90 – 100%, which was not the case for L32. For this reason 
housekeeping gene selection was carried out using the GeNorm™ reference 
gene selection kit and software package (Primerdesign). This enabled the 
choice of a housekeeping gene combination, which had been shown to be 
stable within the human neutrophil cell type and across the different 
experimental conditions.  
  
6 housekeeping genes were selected for testing, B2M, ACTB, GAPDH, 
YWHAZ, UBC and SDAH. 6 cDNA samples were probed for each of these 
genes in duplicate using a standard qPCR technique. The results were 
analysed in qbasePLUS (Biogazelle). 2 parameters are used in this package in 
order to assess the suitability of the genes; the M value which measures the 
expression stability of each of the genes and the V value which determines 
the combination and number of housekeeping genes required for an 
experimental condition.  
 
M value: This indicates the average expression stability value (M) of 
reference genes during a stepwise exclusion of the least stably expressed 
reference gene. Starting from the least stable gene on the left, the genes are 
ranked according to increasing expression stability, ending with the most 
stable gene on the right, which were B2M and GAPDH (Figure 6-1). 
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V value: This determines the optimum number of reference genes required 
by showing the variation in average stability. The chart shows sequential 
addition of each reference gene starting with the two most stably expressed 
genes on the left with the inclusion of a 3rd, 4th… etc moving to the right. A 
proposed value of 0.15 is given, as guidance for the determination of optimal 
number of reference genes, which was 2 in this system (Figure 6-2).  
 
From these results B2M and GAPDH were chosen as housekeeping genes 
and amplification curves were produced as described in Section 2.14.1 
(Table 6-2).  All subsequent ΔΔCT quantification analysis was carried out 
using the average of these two housekeeping genes. 
 
Gene R2 Slope Efficiency (%) Threshold 
GAPDH 
B2M 
0.97 
0.97 
-3.49 
-3.50 
93 
93 
0.015 
0.15 
Table 6-2 Standard curve characteristics of qRT-PCR experiments 
Table showing the efficiency of the housekeeping genes B2M and GAPDH and the 
threshold used for each gene. 
 
Gene Assay ID Supplier 
GAPDH Hs99999905_m1 Life technologies 
B2M Hs00984230_m1 Life technologies 
Table 6-3 Pre-designed gene expression assays used for qPCR analysis 
Table detailing the assay IDs and supplier for the housekeeping genes 
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Figure 6-1 Average expression stability of reference targets 
Line graph showing the geNorm M value (expression stability) for each of the 6 housekeeping genes tested. The genes start with the least stable 
gene at the left side of the x-axis and move towards the right side to the most stable gene.  
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Figure 6-2 Determination of the optimal number of reference targets 
Bar chart showing the V value as an additional gene is added sequentially. The optimal number of reference genes required for normalisation was 
determined by pairwise variation (geNorm V value of n/n+1). A value below 0.15 indicates consistent normalisation gene expression and indicates 
the minimum number (n) of genes required. In this experiment a combination of two reference genes was sufficient for normalisation since V2/3 was 
0.105. 
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6.5 Results 
6.5.1 RNA Pico chip traces 
RNA samples were assessed to see whether they were of good enough 
quality to be analysed by microarray. 1μl of each RNA sample to be used for 
microarray was diluted to 5ng/μl and run on a Pico chip (Figure 6-3). The 
RNA integrity number (RIN) (256), a mathematical interpretation of sample 
quality, was above 6.50 for all samples, indicating that although a small 
amount of RNA degradation was present the samples were of good enough 
quality to be used for microarray analysis (Figure 6-4).  
6.5.2 Data quality assessment  
Once the data had been extracted, a general data quality assessment was 
performed by analysing the processed signal for each array feature. Firstly, 
normalisation was carried out. When running experiments that involve 
multiple high-density oligonucleotide arrays, it is important to remove sources 
of variation between the arrays that are not of biological origin. Figure 6-5 
shows the density distribution curve of the expression values before and 
after normalisation. This shows that the expression curves for different 
samples become almost identical after applying a quantile normalisation 
method to the expression data (257).   
 
Variation assessment was carried out using Principal Component Analysis 
(PCA) (258). Figure 6-6 is a PCA plot of the log expression of all the arrays. 
The plot reveals that samples from the two time points can be well 
discriminated based on the 2nd principal component. However, the RSV 
exposed (RSV) and control (CON) samples cannot be separated clearly. 
This suggests that there might not be a large percentage of genes that are 
differentially expressed.  
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Figure 6-3 Electrophoresis run summary of total RNA on Pico chip 
This is the image of a digital gel, produced on a bioanlayzer, for all 16 samples and a water 
control. The top band represents the 28S ribosomal band and the lower band the 18S 
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Figure 6-4 Electropherogram graphs and calculated RIN 
The electropherograms show the analysis of each total RNA analysis. The first (left) 
peak is 18S ribosomal peak and the second (right) peak is 28S ribosomal peak.  The 
sample integrity is determined mathematically, by the software, using the entire 
electrophoretic trace of the RNA sample. This includes the presence or absence of 
degradation products. The presence of a mildly wavy baseline indicates a small amount 
of RNA degradation. However, all RIN was > 6.50, which was adequate for continuing 
with the microarray analysis. These graphs show the same result as the electrophoresis 
blots just visualised in an alternate way to illustrate the 18S:28S ratio.  
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Figure 6-5 Distribution of log expression signal before and after normalisation 
The upper panel presents the density distribution of the expression values. Different 
line style and colour combinations represent different samples. Expression distribution 
for different samples are very similar when expression level >5 (2.3 on the log2 scale). 
The lower panel shows that the expression density curves for different samples become 
almost identical after normalisation of the data.   
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Figure 6-6 PCA plot of log2 gene expression for all samples  
The plot reveals that the samples from two time points can be well discriminated based 
on the 2nd principal component. However the RSV and CON samples cannot be 
separated as clearly. This suggests that there may not be a large percentage of genes 
identified as differentially expressed.   
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6.5.3 Differential gene expression analysis  
The differential expression analysis was performed in R using the package 
limma (259). The Agilent human genome v2 microarray used contained 62 
976 reportable features, which belong to 50 739 unique probes. These 
probes are annotated to 36 344 uniquely named genes. The feature level 
expression data was de-replicated to probe and then gene level, in order to 
have only one value for each gene, despite multiple features/probes 
measuring for that particular gene. The mean expression of multi-features 
was taken as the de-replicated expression value for the gene. The log2 gene 
expression data was modelled using a linear model with 4 model parameters 
representing the expression for grouped samples. The model parameters 
were estimated using the maximum likelihood approach. This process 
generated log2 fold change (logFC) values for both RSV 4 hour/CON 4 hour 
and RSV 20 hour/CON 20 hour. These fold changes were tested using a t-
test. P-values, associated with the logFC were adjusted for multiple testing 
using the False Discovery Rate (FDR) approach (260). Significant differential 
expression was defined as those with an FDR-adjusted P-value < 0.05. The 
results of this analysis are summarised in Table 6-4. Dr Yonxiang Fang 
(CGR, University of Liverpool) carried out data normalisation and differential 
gene expression analysis.  
 
Regulation Direction RSV 4/CON 4 RSV 20/CON 20 
Probes 
Total Number 
 
1197 
 
217 
Up 692 149 
Down 
Genes 
505 68 
Total Number 911 180 
Up 518 122 
Down 393 58 
Table 6-4 Number of differentially expressed probes and genes and regulation direction 
Table detailing the number of differentially expressed probes and genes at each time point. 
The data is then divided to show the total number of probes and genes that have gone up 
and down at each time point.  
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6.5.4 Ingenuity Pathway Analysis  
Data were analysed through the use of QIAGEN’s Ingenuity® Pathway 
Analysis (IPA) (261). IPA initially maps the genes to an IPA Knowledge Base 
and produces an annotated data set. Of the 1091 genes that were 
differentially expressed over the two time points, 128 were unmapped. In 
total, there were 794 mapped genes at the early time point of 4 hours and 
157 at the late time point of 20 hours (Full list of genes in Appendix 5). The 
q-value (FDR corrected p-value) was set at < 0.05, which incorporated all of 
the genes inputted, as this had previously been used in the analysis to 
identify differentially expressed genes. I used IPA to: 
1. Determine over-represented signalling and metabolic canonical 
pathways. 
2. Divide data into diseases and functions that are over-represented in 
the dataset.  
3. Create molecular networks (algorithmically generated pathways).  
6.5.5 IPA statistics 
Fisher’s exact test p-value is calculated to answer the null hypothesis: Is the 
proportion of genes mapping to a function or pathways in my samples similar 
to the proportion that map in the entire population? P values quoted in the 
results are p-values of Fisher’s exact test. P value < 0.05 was taken as 
indicative of a statistically significant, non-random association. 
6.5.6 Canonical pathways  
IPA maps the differentially expressed genes against known canonical 
pathways, generated prior to data input based on known literature. Two 
measures of association are calculated, firstly a ratio of the number of genes 
from the list that map to the pathways, divided by the total number of genes 
that map to the same pathway, secondly, a p-value of the Fisher’s exact test 
(Table 6-5) (Table 6-6). 
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Name p-value Ratio 
Activation of IRF by cytosolic PRRs 
Death receptor signalling 
5.19E-04 
1.15E-03 
9/58 (0.155) 
11/91 (0.121) 
Retinoic acid mediated apoptosis signalling 1.83E-03 8/56 (0.143) 
Salvage pathways of pyrimidine ribonucleotides 
p53 signalling 
3.56E-03 
6.08E-03 
10/90 (0.11) 
10/97 (0.103) 
Table 6-5 Top canonical pathways of early response 
Table of the top 5 canonical pathways at the early time point of 4 hours with associated 
ratio and p-value. 
 
 
Name p-value Ratio 
Agranulocyte adhesion and diapedesis 
Granulocyte adhesion and diapedesis 
3.92E-05 
1.89E-04 
8/167 (0.048) 
7/157 (0.045) 
Pyrimidine deoxyribonucleotides de novo biosynthesis 4.38E-04 3/20 (0.15) 
Salvage pathways of pyrimidine ribonucleotides 
Communication between innate & adaptive immune cells 
5.98E-04 
1.94E-03 
5/90 (0.056) 
4/70 (0.057) 
Table 6-6 Top canonical pathways of late response  
Table of the top 5 canonical pathways at the late time point of 20 hours with the 
associated ratio and p-value. 
6.5.7 Disease and function analysis 
IPA divides the data into diseases and biological functions that are over 
represented in the data. IPA provides these categories based on high quality 
gene ontology information and manually curated IPA content. For each 
potential disease/function two statistical measurements are made. Firstly the 
overlap p-value, which assesses the significance of the overlap between 
dataset genes and known targets. Secondly, the activation z-score, which is 
used to infer the activation state of the regulators (Table 6-7) (Table 6-8). 
6.5.8 Upstream regulator analysis 
IPA identifies the upstream transcriptional regulators that could explain the 
observed gene expression in the dataset. This can help identify the biological 
activities occurring in the neutrophil. This analysis is achieved by using prior 
knowledge of expected effects between transcriptional regulators and their 
target genes. The analysis examines how many known targets of each 
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transcription regulator are present in the dataset and considers the direction 
of change to what might be expected from the literature. A prediction can 
thus be made with regards to the activation state of the regulator; activated 
or inhibited. For each potential regulator two statistical measurements are 
made. A p-value assesses the significance of the overlap between dataset 
genes and known targets and the activation z-score, which is used to infer 
the activation state of the process (Table 6-9). 
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Categories Diseases/Functions 
Annotation 
p-Value Predicted 
Activation State 
Activation 
z-score 
No. of 
Molecules 
Molecules 
Inflammatory Response innate immune response 1.35E-07 Increased 2.538 25 APOBEC3A, APOBEC3F, APOBEC3G, 
BST2, DDX58, FFAR2, FFAR3, IFIH1, 
IFIT2, IRF7, ISG15, MX1, OTULIN, PML, 
PPARG, STAT1, TNFRSF10A, TRIM11, 
TRIM14, TRIM21, TRIM26, TRIM5, 
TRIM56, TRIM8, ZBP1 
Antimicrobial Response, 
Inflammatory Response 
antiviral response 1.22E-05 Increased 2.931 20 APOBEC3F, APOBEC3G, BST2, 
DDX58, DHX58, FOSL1, HYAL2, IFIH1, 
IFIT1, IFIT1B, IFIT2, IFIT3, IRF7, ISG20, 
MB21D1, MX1, PML, STAT1, TRIM5, 
USP21 
Antimicrobial Response inhibition of virus 2.10E-04 Increased 2.271 9 APOBEC3B, APOBEC3F, APOBEC3G, 
BST2, GSK3B, IL27, MX1, SP100, 
TRIM5 
Antimicrobial Response, 
Inflammatory Response 
antimicrobial response 3.50E-04 Increased 2.931 24 APOBEC3F, APOBEC3G, BST2, 
DDX58, DHX58, FOSL1, HYAL2, IFIH1, 
IFIT1, IFIT1B, IFIT2, IFIT3, IRF7, ISG15, 
ISG20, MB21D1, MICA, MX1, PML, 
PPM1D, STAT1, TLR6, TRIM5, USP21 
 
Cell Signalling replication of viral replicon 1.34E-06 Decreased -3.148 12 APOBEC3A, APOBEC3B, APOBEC3C, 
APOBEC3F, APOBEC3G, BST2, 
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Table 6-7 Disease and function table of early response  
Table showing the top and most relevant disease and functions the dataset has mapped to, including a p-value, z-score, predicted activation 
direction, the number of genes involved in any given function and the specific genes involved. 
DICER1, IFIT1, ISG15, ISG20, MX1, 
PARP10 
Infectious Disease replication of Herpesviridae 8.82E-06 Decreased -2.556 12 CXCL10, DDX58, IFIH1, ISG20, 
PARP12, PML, SAMHD1, SP100, 
STAT1, TGFBR2, ZBP1, ZEB2 
Cell Signalling viral life cycle 9.26E-06 Decreased -2.377 14 APOBEC3A, APOBEC3B, APOBEC3C, 
APOBEC3F, APOBEC3G, BST2, 
DICER1, IFIT1, ISG15, ISG20, MX1, 
NUP62, PARP10, PSIP1 
Infectious Disease replication of virus 8.90E-05 Decreased -3.326 49 AGO4, APOBEC3B, APOBEC3C, 
APOBEC3F, APOBEC3G, ATP6V1A, 
BST2, CCR1, CD58, CNOT7, CXCL10, 
DDX58, DICER1, FSCN1, GSK3B, 
HERC5, IFIH1, IFIT1, IL27, IRF2, IRF7, 
ISG15, ISG20, MID1IP1, MX1, NUP62, 
PARP12, PIKFYVE, PML, PRKAG2, 
PSIP1, RAB11FIP1, RACGAP1, RAF1, 
RHOH, SAMHD1, SGPL1, SP100, 
SPHK1, STAT1, TGFBR2, TNK2, 
TRADD, TRIM14, TRIM21, TRIM5, 
USP21, ZBP1, ZEB2 
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Categories Disease/Functions 
Annotation 
p-value Predicted 
Activation State 
Activation 
Z-score 
No. of 
molecules 
Molecules 
Cellular Movement, Haematological 
System Development and Function, 
Immune Cell Trafficking 
cell movement of 
myeloid cells 
1.57E-06 Increased 2.386 18 CCL4, CD69, CXCL2, CXCR1, CXCR2, 
CYBB, EGLN1, HIF1A, IL1A, IL1RN, 
ITGAM, MADCAM1, PPBP, SEMA4A, 
SERPINB1, TICAM1, 
TMSB10/TMSB4X, TXN 
Cellular Movement, Immune Cell 
Trafficking 
leukocyte migration 4.51E-06 Increased 2.491 23 CCL4, CD22, CD69, CD80, CXCL2, 
CXCR1, CXCR2, CYBB, EGLN1, GGT5, 
HIF1A, IL1A, IL1RN, ITGAM, 
MADCAM1, PPBP, PRMT2, RARA, 
SEMA4A, SERPINB1, TICAM1, 
TMSB10/TMSB4X, TXN 
Haematological System Development 
and Function, Tissue Morphology 
quantity of 
leukocytes 
5.34E-06 Increased 2.902 23 AFF1, CCL4, CD22, CD69, CD80, 
CISH, CXCL2, CXCR2, CYBB, HIF1A, 
IL1A, IL1RN, ITGAM, KLF10, MPZL2, 
PIM1, PIM2, RARA, SERPINB1, 
SIGIRR, SIGLEC1, THRA, TICAM1 
Cellular Movement, Haematological 
System Development and Function,  
Immune Cell Trafficking 
cell movement of 
leukocytes 
6.05E-06 Increased 2.213 21 CCL4, CD22, CD69, CD80, CXCL2, 
CXCR1, CXCR2, CYBB, EGLN1, 
HIF1A, IL1A, IL1RN, ITGAM, 
MADCAM1, PPBP, RARA, SEMA4A,  
SERPINB1, TICAM1, 
TMSB10/TMSB4X, TXN 
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Table 6-8 Disease and function table of late response 
Table showing the top and most relevant disease and functions the data has been mapped to, including a p-value, z-score, predicted 
activation direction, the number of genes involved in any given function and the specific genes involved.   
Cell Death and Survival cell viability 9.82E-06 Increased 2.106 28 AGRN, CAMK1G, CCL4, CD22, CD80, 
CISH, CXCL2, CYBB, DAB2, HIF1A, 
IGFBP7, IL1A, IL1RN, ITGAM, NME1, 
PIM1, PIM2, PPBP, PPFIA4, 
PPP1R12B, RARA, RRM1, SERPINB5, 
SHFM1, TICAM1, TNK2, TPK1, TXN 
       
Cell Death and Survival apoptosis of blood 
cells 
2.46E-05 Decreased -2.458 15 AGRN, CCL4, CD22, CD69, CD80, 
CXCL2, CYBB, HIF1A, IL1RN, ITGAM, 
PIM1, PIM2, RARA, THRA, TICAM1 
Cell Death and Survival apoptosis of 
hematopoietic cells 
1.41E-03 Decreased -2.621 7 AGRN, CCL4, HIF1A, PIM1, PIM2, 
RARA, THRA 
Cellular Compromise degeneration of cells 8.61E-03 Decreased -2.236 8 AFF1, HIF1A, IL1RN, LRPAP1, MME, 
SEMA4A, THRA, TXN 
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Upstream regulator Activation Z 
score 
p-value Predicted activation 
state 
IFNA2 
IFNL1 
5.565 
4.727 
1.16E-16 
1.00E-15 
activated 
activated 
IRF7 (log ratio +2.556) 
IRF3 
TLR4 
MAVS 
DDX58 (log ratio +3.373) 
STAT1 (log ratio +2.793) 
5.146 
4.277 
2.680 
3.536 
2.651 
3.697 
2.71E-15 
6.15E-11 
7.44E-10 
1.83E-09 
4.08E-08 
5.89E-07 
activated 
activated 
activated 
activated 
activated 
activated 
MAPK1 
TRIM24 
IL1RN (log ratio +2.745) 
-5.773 
-4.122 
-3.207 
1.92E-13 
3.45E-12 
1.11E-04 
inhibited 
inhibited 
inhibited 
Table 6-9 Upstream regulators of early response  
Table of selected upstream regulators, including an associated activation Z score, p-
value and the predicted activation state at the 4-hour time point. Those upstream 
regulators that were found differentially expressed in the dataset have their log ratio 
included also. 
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6.5.9 Validation of microarray results by qPCR 
12 RNA samples (6 control and 6 RSV exposed) for the 4 hour time point 
were analysed using qPCR. RNA was converted to cDNA and qPCR 
undertaken as described in Section 6.1.4 to look for the expression of 7 
differentially expressed genes purposively selected from the microarray data 
on the basis of their high expression value (2.5 - 7.9), and involvement at 
different steps of the pathways of relevance. These genes were DDX58, 
DHX58, IRF7, MX1, STAT1, and USP18, which were all up-regulated. One 
down regulated gene was chosen, DICER. The microarray results were 
confirmed with a statistically significant change in the expected direction for 
all genes (Figure 6-7). A 12.87 fold increase was found for IRF7 following 
RSV exposure (p=0.026) A 41.08 fold increase was found for MX1 
(p=0.0022).  A 129.64 fold increase was found for USP18 (p=0.0022). A 9.15 
fold increase was found for STAT1 (p=0.0022). A 21.55 fold increase was 
found for DDX58 (p=0.0022). A 90.42 fold increase was found for DHX58 
(p=0.0095). Expression of DICER was significantly decreased in response to 
RSV (p=0.0022).  Statistical analysis was performed using Mann Whitney U 
tests and confirmed on two statistical programmes (PRISM, StatsDirect).  
6.5.10 RSV uptake with reduction over time confirmed  
All of the 8 RSV exposed neutrophil cDNA samples were analysed to 
quantify the amount of RSV in each sample compared to the mean of the 
internal housekeeping genes B2M and GAPDH. RSV N gene was quantified 
at 4 hours and 20 hours and a statistically significant decrease at 20 hours 
was observed (p value = 0.0152) (Figure 6-8). Mann Whitney U test was 
used.  
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Figure 6-7 Target genes from microarray validated by qPCR 
Expression of IRF7, MX1, USP18, DXD58, STAT1, DHX58 and DICER 1 were 
measured by qPCR. All were significantly upregulated in RSV exposed neutrophils 
compared to control except for DICER 1, which was significantly downregulated. IRF7 p 
value = 0.026, MX1, USP18, STAT1, DICER1, DDX58 p values = 0.0022 and DHX58 p 
value= 0.0095.   
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Figure 6-8 Relative RSV gene expression 
RSV N gene expression was measured by qPCR at 4 and 20 hours, and is expressed 
relative to the internal housekeeping genes B2M and GAPDH on a log axis. RSV N 
gene was found in the neutrophil at both time points and there was a significant 
decrease in RSV N gene at 20 hours compared to 4 hours. 
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6.6 Discussion  
There are two possible sources of experimental variation when analysing 
samples using microarray; the biological samples and the performance of the 
technology. By using the CGR facility and staff with their established and 
standardised laboratory protocols, the latter was minimised.  The data quality 
assessment carried out, to ensure data suitability to address the hypothesis, 
included analysis of the expression density curves for all samples. The 
results implied that there was no flaw in the data with respect to cross-
chip/cross-array normalisation.  
 
The two data sets, from the early time point of 4 hours and the later time 
point of 20 hours, were markedly different, as shown by the principal 
component analysis (Figure 6-6). Neutrophils are short-lived cells, and it is 
thus not that surprising that their transcriptional profiles would change over 
this relatively short period of time. Therefore, I will discuss the results of their 
RSV induced transcriptional changes in two separate sections and finish with 
a section relating to the persistent changes across both time points, of which 
there were 87 shared differentially expressed genes.  
 
As described in Chapter 3, RSV does not replicate inside neutrophils. This 
was confirmed in this study and the reduction in RSV at 20 hours from 4 
hours was found to be statistically significant. This significance, compared to 
the non-significant trend in Chapter 3, is likely due to a more robust RT-PCR 
method, using an optimised pair of housekeeping genes as the internal 
reference to RSV expression. The microarray data and subsequent PCR 
validation sheds light on the mechanisms at play in the neutrophil that allow 
inhibition of viral replication.   
6.6.1 Early response  
Ingenuity pathway analysis revealed activation of IFN regulatory factor (IRF) 
and IFN signalling pathways as the most significantly over-represented 
pathways at 4 hours. In addition, the majority of the disease/function groups 
identified were related to anti-viral function. The predicted upstream 
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regulators also reflect this antiviral response. To validate the microarray data, 
RT-PCR was performed for several of the IFN-related genes, including 
DDX58 (RIG-I), DHX58, IRF7, USP18, MX1, and STAT1. Correlating with 
the microarray data, there was upregulation of these genes at the early time 
point of 4 hours providing evidence for an early anti-viral response to RSV by 
the neutrophil. In the sections below, I will detail the known pathways and 
antiviral mechanisms using relevant literature relating to the anti-viral genes 
identified at work in the neutrophil.  
6.6.2 Pattern recognition receptors 
Interferon responses are essential for the immune response to virus and are 
triggered through the actions of cytoplasmic helicases RIG-I (DDX58) and 
MDA5 (IFIHI) (40, 262, 263). Intracellular viral products such as RNA initiate 
the signalling. Transcription of both these PRR genes was upregulated in my 
data set at 4 hours. Signalling through both RIG-I and MDA5 involves 
interaction with interferon promoter-stimulating factor 1 (IPS-1) adaptor 
protein, also known as MAVS (mitochondrial antiviral signalling protein). 
MAVS was identified as an activated upstream regulator. This interaction 
results in activation of two parallel signalling pathways leading to nuclear 
translocation of NF-κB and IFN regulatory factors (IRFs), and the consequent 
production of IFN and chemokines. The rapid production of IFN-α/β leads to 
the expression of hundreds of Interferon Stimulated Genes (ISGs), which 
have antiviral and immunomodulatory properties directed at limiting infection 
(264). RIG-I has specifically been shown to be triggered by RSV, playing a 
role in inhibiting viral replication and spread (45, 262, 265). MDA5 induction 
has more recently been found to be required to prevent early degradation of 
IRF3, a key transcriptional regulator of type I IFN responses (266). LGP2, 
encoded by DHX58 (DEXH (Asp-Glu-X-His) box polypeptide 58), or RIG-I 
like receptor, is a regulator of both RIG-I and MDA5 mediated signalling, 
which can bind both ssRNA and dsRNA.  
 
TLR4 was also identified as a potential upstream regulator in this data set. A 
study, which examined the response of TLR4 deficient mice to RSV, found 
an impaired ability of the mice to respond to RSV with delayed viral 
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clearance. The authors suggested that the innate immune response to RSV 
may be mediated by signalling through TLR4 (267). More recently Blanco et 
al have shown the interaction is between RSV F protein and TLR4 co-
receptor MD-2 (268). TLR4 activation leads to signal transduction and gene 
expression via the NF-κB pathway. The upregulation in the PRRs RIG-1 and 
MDA5, and the apparent involvement of the upstream regulators TLR4 and 
MAVS indicate that the neutrophil is recognising and responding to the 
presence of RSV. In addition a number of molecules involved in key antiviral 
pathway were also differentially expressed, such as LGP2 and IRF7. The two 
key pathways identified, interferon regulatory (IRF) pathway and the JAK-
STAT pathway, are discussed and illustrated below. 
6.6.3 The interferon regulatory factor pathway  
Recognition of RSV by the PRRs RIG-1 and MDA5 activates the IRF 
pathway (Figure 6-9). In the early phase of infection signalling through these 
PRRs is by LGP2 and effected by MAVS. This results in upregulation of 
interferon stimulated genes (ISGs) and induction of cytokines, in particular 
interferons. Type I IFNs then upregulate IRF7 leading to further induction of 
IFNs through phosphorylation of STAT, enhancing the antiviral state of the 
cell. 
 
IRFs are a family of transcription factors, which control type I IFN expression. 
Nine human IRFs have been identified. Of these, IRF1, 3 and 7 are the key 
regulators of the type I IFN response to viral infection (269, 270). IRF7 is 
usually expressed at low levels until viral contact, when it is induced, 
phosphorylated, undergoes dimerization and nuclear translocation. It was 
one of the key upstream regulators found within my microarray dataset. The 
IRF7 gene was also differentially transcribed, and this was confirmed by 
PCR. RSV induced IRF1 and -7 activation has been described in alveolar 
epithelial cells in a time dependant manner, with expression peaking at 6 
hours post infection (271).  
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Figure 6-9 Regulation of the innate immune response by RNA sensing molecules 
Two pathways are shown which are involved in the regulation of the innate immune 
response by RNA sensing molecules. Firstly, on the left, is the response to the early phase 
of infection. RIG-1 detects RSV; single stranded RNA virions and potentially any dsRNA 
made by attempts to replicate. MDA5, another PRR also detects virus. LGP2 regulates 
signalling of both these PRRs. Signalling by MDA5 and RIG-1 is effected through MAVS, 
identified as an activated upstream regulator, leading to upregulation of interferon stimulated 
genes (ISGs) and induction of cytokines including IFNs. The second pathway, on the right, is 
the response to the late phase of RNA virus. Upregulation of IRF7 is triggered by type I IFNs 
that then leads to further induction of IFNs through the phosphorylation of STAT. These 
pathways drive the cell into an antiviral state.  
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6.6.4 Jak-STAT Pathways  
STAT 1 (Signal transducer and activator of transcription 1) is involved in 
mediating cellular responses to IFNs. Following type I IFN binding to cell 
surface receptors, signalling via protein kinases leads to activation of Jak 
kinases and phosphorylation of STAT1. This is illustrated in Figure 6-10. 
STAT1, which is shown transcriptionally upregulated by RSV, becomes 
phosphorylated and then associates with ISGF3G/IRF-9 to form ISGF3 
transcription factor. This enters the nucleus where it acts as a transcription 
activator of IFN stimulated genes (ISGs), which drive the cell into an antiviral 
state. Figure 6-10 shows the well-characterised downstream effect of this 
interferon-signalling pathway, i.e. the production of IFI35, IFIT1, MX1 and 
IFIT 3, all transcriptionally upregulated in my dataset. 
6.6.5 IFN stimulated genes (ISGs) 
Interferon-stimulated genes modulate biologic effects of IFNs. There are 
>300 ISGs which can be assigned to functional categories. The specific 
function of a large proportion of these is unclear, but some are known to play 
key roles in host defence (272). Below I outline some of the highly 
differentially transcribed ISGs within my dataset and highlight those that are 
particularly pertinent to RSV infection. 
6.6.5.1 Ubiquitin Specific Peptidase 18 
Ubiquitin Specific Peptidase 18 (USP18), also known as ISG43, was the 
highest upregulated mRNA at the early time point (FC 7.95). This protein 
cleaves ubiquitin from ubiquitinylated substrates, specifically ISG15 fusions. 
ISG15 is a ubiquitin-like protein that is conjugated to intracellular target 
proteins (ISGylation) upon activation by IFN. ISGylation may modulate the 
JAK-STAT pathway. The secreted form of ISG15 has a number of roles; it 
can induce natural killer cell proliferation, act as a chemotactic factor for 
neutrophils and as an IFN-γ-inducing cytokine. The ISG15/USP18 pathway 
has been found highly expressed in response to a number of viruses, 
including hepatitis C and vesicular stomatitis virus (273, 274). 
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Figure 6-10 Interferon signalling pathway through Jak-STAT pathway 
The cell response to IFN can be mediated through the Jak-Stat pathway. Activation of 
Jak kinases and phosphorylation of STAT1 allows association with IRF-9 to form ISGF3 
transcription factor, which enters the nucleus and drives the cell into an antiviral state. 
Downstream IFI35, IFIT1, MX1 and IFIT 3 were all transcriptionally upregulated in the 
microarray data. 
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6.6.5.2 Myxovirus resistance 1 
Myxovirus Resistance 1 (MX1) gene encodes a GTP-metabolising protein 
that participates in the cellular antiviral response. It is activated through the 
Jak-STAT pathway, induced by type I and II IFNs and antagonises the 
replication process of RNA (particularly negative stranded) and DNA viruses. 
It achieves this by binding and inactivating their ribonucleocapsid. MX genes 
were discovered around 50 years ago by Lindenmann et al (275). The 
protein encoded by MX1, called MXA, has a broad antiviral activity, which 
has been studied in the context of infection with a large number of different 
RNA viruses (276). In measles, a member of the paramyxoviridae family, 
MX1 has been shown to inhibit virus in a human mononuclear cell line (277). 
In contrast RSV infection of Vero cells was resistant to the antiviral effects of 
MxA (278).  In a study using RSV infected cotton rats MX1 and 2 were highly 
expressed in the lungs early in infection and in a dose dependant fashion, 
which the authors concluded, was evidence of a robust type 1 IFN response 
(279).  
6.6.5.3 Tetherin 
Tetherin, encoded by the BST2 gene, is expressed as part of the IFN 
dependant antiviral response pathway and is a viral ‘restriction’ factor. This 
was significantly upregulated at the early time point.  A mechanism whereby 
tetherin inhibits enveloped virus release by tethering the budding virus like 
particles has been proposed (280). Tetherin has been associated with all 
tested retroviruses, and some filoviruses. It has been recently reported that 
tetherin can act as a PRR inducing NF-kB dependant pro-inflammatory gene 
expression in virus infected cells (281).   
6.6.5.4 Double stranded RNA-specific endoribonuclease 
Double stranded RNA-specific endoribonuclease (DICER) gene encodes a 
protein that possesses an RNA helicase motif containing a DEXH box. This 
ISG was down-regulated by RSV exposure, a finding confirmed by PCR. It 
functions as a ribonuclease and plays a central role in short dsRNA-
mediated post-transcriptional gene silencing. Gene silencing, mediated by 
RNA inference, controls the elimination of transcripts from mobile and 
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repetitive DNA elements of the genome, and the degradation of exogenous 
RNA of viral origin. Reduced DICER expression in the cord blood of infants 
subsequently admitted with severe RSV disease has recently been reported. 
The authors hypothesized that this reduction might have led to diminished 
anti-viral activity and impairment of innate cellular function (282). They did 
not measure the level of DICER in the patients at the time of illness. It is 
possible that those children who are already predisposed by low DICER 
levels and thus a reduced ability to interfere with viral replication are made 
more so by RSV mediated down regulation of DICER.  
 
A number of groups of genes, whose antiviral functions have previously been 
recognised, were well represented in the data, including the APOBEC3, 
TRIM and IFIT families. The mechanism by which many of these genes 
inhibit viral replication is not fully known, but it is possible that they interfere 
with one or more of the following: viral entry, viral DNA synthesis, 
intracellular movement of viral nucleic acids and viral gene expression (283-
285).  
6.6.5.5 APOBEC3 enzymes 
APOBEC3 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-
like) is a superfamily of enzymes encoded by the APOBEC3 gene.  They are 
capable of deaminating cytidines in single stranded DNA replication 
intermediates, leading to cytidine being changed to uridine and guanine to 
adenine, a phenomenon termed DNA editing. APOBEC3G is the most widely 
studied member of the family. In my dataset, APOBEC3 -A, -B, -C, -F and -G 
were upregulated, with APOBEC3-F and –G being the most highly 
expressed. RNA virus replication of measles, mumps and RSV, has been 
found to be sensitive to A3G (APOBEC3G) inhibition in in vitro study (284).  
6.6.5.6 TRIM Proteins 
A number of genes encoding proteins of the TRIM (tripartite motif-containing 
proteins) family were differentially expressed within my dataset. Thus TRIM 
5, 14, 21, 26, 34 and 56 were up-regulated and TRIM 8 and 11, down-
regulated.  The TRIM family is a diverse family of RING finger domain-
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containing protein that are classified into 11 subgroups. They are involved in 
the regulation of innate immune responses through modulation of PRR 
signalling pathways including TLRs and RIG-I. Many TRIM proteins are 
induced by type I IFN stimulation (286, 287). TRIM 21 has previously been 
shown to be induced by RNA viral infection, and is an essential modulator of 
IRF3 stability (288). TRIM proteins can exert antiviral activity through 
modulation of viral proteins as well as interacting with the innate immune 
signalling pathways (289). TRIM 56 was recently identified to associate with 
the N-terminal protease of bovine diarrhoea virus and inhibit its replication 
(285). TRIM 5, 11, 26 and 31 have been demonstrated to inhibit HIV entry. 
TRIM 11, which was down-regulated in the analysis, inhibits RIG-1 mediated 
IFN beta production by targeting the TBK1 complex (290).  
6.6.5.7 IFIT protein encoding genes 
IFIT (interferon-induced protein with tetratricopeptide repeats) protein 
encoding genes were over-represented at 4 hours, all by a >3 fold change, 
specifically –1, -1B, -2, -3, -5. Their transcription can be induced by viral 
infection. IFIT proteins show antiviral activity in two ways. They bind to both 
viral nucleic acids and to eIF3 (eukaryotic initiation factor 3) thereby inhibiting 
the translation process (283). IFIT1-5 genes were expressed in the whole 
blood analysis of infants with RSV (255).  
6.6.6 Late response  
The number of differentially expressed genes at the later time point was less 
than I expected. This may relate to variability in the quality of the data, with 
less genes reaching acceptable levels of significance, rather than less genes 
actually being differentially expressed. There are limitations to carrying out 
pathway analysis based on a small number of differentiated genes. A large 
number of pathways may be highlighted showing one or two differentially 
expressed genes rather than identification of a small number of significantly 
overrepresented pathways. In addition, the limitations of my model become 
apparent at this timepoint. Neutrophils present in the airways of an infant with 
RSV bronchiolitis for 20 hours would have been exposed to 
cytokines/chemokines and had direct contact to many other immune cells, 
  171 
rather than just RSV, and their responses may change accordingly. In this in 
vitro system however, the top function networks relate to the movement and 
activation of lymphocytes and leukocytes. Genes for molecules that are 
chemoattractants such as CCL4, CYBB, EGLN1, HIF1A, IL1RN, TICAM, 
IL1A were all upregulated. Neutrophils, as they age and potentially become 
apoptotic, appear to be stimulating the influx of other immune cells to the site 
of inflammation. This would seem to include strong signals for further 
neutrophil migration. PPBP encodes a protein CXCL7, which is a potent 
chemoattractant and activator of neutrophils, and was the second highest 
upregulated molecule (LogFC 5.2). In contrast, there also appears to be an 
attempt at modulating/down-regulating neutrophil activation. Both CXCR1 
and CXCR2, receptors for the neutrophil activating and migration factor 
CXCL8, are down-regulated at 20 hours. A picture of inflammatory balance is 
emerging at both time points, between inflammatory anti-viral processes and 
an attempt to keep the inflammation in check by the use of regulators. CISH 
(cytokine inducible SH2-containing protein) a cytokine signalling suppressor 
that works through a negative feedback system of the STAT pathway was 
upregulated at 20 hours. This was also found at 4 hours, although less 
pronounced, suggesting that this regulation of inflammation and anti-viral 
response is constant during neutrophil exposure to RSV.  
 
Microarray data indicating an ability for neutrophils to interact with cells of the 
innate and adaptive immune systems occurred at both time points, so will be 
discussed in combination. 
6.6.7 Immune crosstalk 
Some evidence that the neutrophil is capable of modulating the function of 
other immune cells in response to RSV can be found in the microarray data. 
Further work would need to be done to confirm the interactions, but intriguing 
hypotheses can be built. The gene for IL-27, a novel IL-12 cytokine family 
member was upregulated. This is an immunoregulatory cytokine, which has 
been found in mice to have a dominant role in the suppression of immune 
hyperactivity, with IL-27 receptor deficient mice succumbing to CD4+ T cell 
mediated inflammatory disease (291). IL-27 appears to have inhibitory 
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effects on Th1, Th2 and Th17 responses. Interestingly IL-27 has been shown 
to inhibit vaccine enhanced pulmonary disease following RSV infection (292). 
In addition, IL-27 receptor deficient mice experience severe RSV-induced 
disease, characterised by mucus secretion, enhanced expression of the 
Th17-related cytokine IL-17a and Th2-related cytokines IL-5 and IL-13, and 
inhibition of the Th1-associated cytokine IFNγ (293). Effective, efficient 
clearance of RSV from the airways relies on a balanced Th cell response, 
and IL-27 appears to play a regulatory role within this process (294). The 
neutrophil may contribute to airway levels of this cytokine. 
 
A number of investigators have recently speculated that the neutrophil may 
play a role as antigen-presenting cells (APCs) particularly to T cells (295, 
296). Antigen presentation involves the appearance of antigens, such as 
virus or bacteria, on major histocompatibility complex (MHC) molecules on 
the cell surface in order to be recognised by other immune cells. Intracellular 
antigens, such as internalised virus, can be presented on MHC class I or II 
molecules, in order that CD4+T cells recognise the antigen and kill the target 
cell. DCs, macrophages and B cells are the three main professional APCs. 
Only MHC II expressing APCs, such as DCs, are able to both present 
antigen to the T cell and to prime them.  
 
Neutrophils have been found to have resting, cytoplasmic stores of 
molecules required for antigen presentation and T cell stimulation i.e. major 
histocompatibility complex class II (DR) antigen, CD80 and CD86 (297, 298).  
CD80, a protein that provides a co-stimulatory signal needed for T cell 
activation and survival, was upregulated at 20 hours in my dataset. This 
suggests a maturation process by the neutrophil, following RSV entry, similar 
to that seen by DCs. Support for this concept is the concurrent upregulation 
of CD11c (ITGAX). Recent reports have described the existence of 
neutrophil-dendritic cell hybrids during inflammation, characterised by co-
expression of DC surface markers (including CD11c and CD80), and 
neutrophil markers (including Ly6G). It has been hypothesized that these 
may be important for bacterial clearance and antigen presentation (299, 
300). The differential expression of these genes does not necessarily mean 
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that the respective proteins are expressed on the cell surface membrane but 
it does lend some weight to the concept that the neutrophils may act as 
APCs in RSV infection.  
 
The microarray approach taken in this chapter begins to explore the antiviral 
response of the neutrophil to RSV, but is only able to provide data on 
transcriptional change. Genes can be regulated in a number of ways and 
mRNA upregulation might not necessarily equate with protein production as 
mRNA can be transcribed yet not translated. Advancing this work further 
would need to involve measurement of proteins translated from the 
differentially expressed mRNA, in order to give a more complete picture of 
the neutrophil antiviral response. A further limitation of this study is that the 
RSV lysate used is not pure. The RSV has been propagated, as described in 
Section 2.4, in Hep2 cells and this process is likely to have resulted in the 
RSV lysate containing other activators, which may also contribute to the 
differential expression measured. This limitation of the in vitro model and its 
implications is discussed in more detail in Chapter 7. 
6.7 Summary  
In this chapter, I have shown that the neutrophil is a transcriptionally active 
cell, which alters its gene expression profile in response to virus exposure. 
The microarray data reveals potential contributions by the neutrophil to both 
innate and adaptive arms of the host immunity. 
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Chapter 7 General discussion 
RSV bronchiolitis is characterised by airway neutrophilia and inflammation 
(39, 55). Compared to other cells within the airway, the immune response of 
neutrophils to RSV has been somewhat neglected. This is in part due to the 
traditionally held view of the neutrophil as a short lived, phagocytic cell with 
limited capacity to interact with and affect the environment and cells around 
it. However, the neutrophil has an armoury of pro- and anti-inflammatory 
capabilities and is increasingly being recognised as a cell with immune-
regulatory potential (102). In this thesis, the interaction and transcriptional 
response of the neutrophil to RSV has been examined in detail for the first 
time.    
 
The overall aim of work described in this thesis was to investigate the nature 
of the interaction between neutrophils and RSV. The first specific aim was to 
establish an in vitro model of neutrophil-RSV interaction. In Chapter 2 this 
model was established and optimised using ultra-purified adult neutrophils 
and laboratory propagated RSV. Previously, the majority of in vitro virus 
work, including RSV, has been carried out on immortalised cell lines such as 
A549 cells, which are not good physiological models of the human airway 
epithelium. The increasing use of primary epithelial cells better models 
clinical disease. However, the epithelium is not the only cell type 
encountered by the virus, and therefore immune cells, particularly the highly 
abundant phagocytic cells, should be considered. Neutrophils are difficult to 
work with, due to their short lifespan in vitro; they are not amenable to long 
term culture or storage and revival. This has resulted in the extrapolation of 
results from other similar, but not identical phagocytic cells, such as 
macrophages, the limitations of which were discussed in Section 4.6. In this 
thesis, the examination of human neutrophils, not an immortalised neutrophil-
like cell line such as HL-60, or a ‘similar’ phagocytic cell, has been 
undertaken. In doing so the virus interaction is better modelled and results 
are more readily translated back to the disease and patient.  
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Any in vitro model is an imperfect representation of the in vivo situation. 
Acknowledgement of the model’s limitations is important and where possible 
confirmation of the findings in vivo should be sought. The RSV preparation 
used throughout this study was produced by propagation in Hep2 cells. 
Although Hep2 cell debris was spun out of the RSV containing supernatant, 
Hep2 derived cytokines may have been present in the supernatant. The 
implication of this is that the neutrophil responses observed cannot be seen 
solely as a consequence of RSV, but of RSV plus epithelial cell line derived 
factors, which potentially include cytokines and chemokines. In this work I 
have not attempted to identify or quantify these proteins. Although Hep2 cells 
are a transformed epithelial cell line, originating from laryngeal carcinoma, 
their cytokine response to RSV infection is not dissimilar to that seen by 
primary epithelial cells. They have been shown to produce CCL2, CCL3, 
CCL5, IL-8, and IL-6 in response to RSV (301). The limitation of single cell 
models has been discussed in Section 5.6 and it could be argued that 
exposing the neutrophils not only to RSV but also to epithelial cell derived 
cytokines represents an enhanced physiological model, more closely 
resembling the in vivo environment found in the airway of an infant with 
bronchiolitis.  
 
In order to identify neutrophil transcriptional changes due to RSV alone, 
lengthy RSV purification techniques would be needed. I did trial a sucrose 
density gradient ultra-purification method for RSV isolation. However, 
ultracentrifugation in sucrose has previously been found to damage virus and 
result in low yields on culture (302, 303). I also found this to be the case with 
RSV. In addition, sucrose, which has high viscosity and hyper-osmotic 
properties, can be toxic to cells used with the RSV preparation, whether 
neutrophils or epithelial cells, affecting downstream work.  
 
The second and third aims of the study were to determine whether RSV is 
taken up into the neutrophil and whether it productively replicates inside the 
neutrophil. The results presented in Chapters 3 and 4 reveal that RSV 
becomes internalised inside the neutrophil. Although RSV was localised to 
endosomal-sized pockets, the mechanism of uptake was not been confirmed 
  176 
to be any form of endocytosis. Rather, my supposition was that uptake was 
by fusion at the plasma membrane.  
 
My data did not support the suggestion that neutrophils are a host for 
productive replication, nor that they were capable of transmitting RSV 
infection to epithelial cells. On the contrary, both RSV genomic material and 
protein measured from neutrophils exposed to virus decreased over time, 
suggesting virus degradation by the neutrophil. This novel discovery 
suggests a role for neutrophils in viral clearance. In RSV-infected mice 
depleted of neutrophils, a reduction in early viral load was observed but then 
a subsequent delay in viral clearance (304). This perhaps suggests that the 
neutrophils, through interaction with other cells, are indirectly concerned with 
viral clearance. The same study did show a reduction in lung DCs, and virus 
specific CD4 and CD8 cells in neutrophil depleted mice, suggesting that 
neutrophils are key to bringing about viral clearance in a timely fashion (304).  
 
It is conceivable that virus could be spread by neutrophils, as they have the 
capacity to move around the lung, and to reverse migrate out of the lung. In 
vitro work on the interaction between CMV and neutrophils sets a precedent 
for this. A study by Saez-Lopez et al showed that neutrophils could transmit 
CMV to naïve fibroblasts after co-culture with virus suggesting a role for 
neutrophils in virus dissemination (235). The study by Halfhide et al, 
examining neutrophils from RSV infected infants, did show infant blood 
neutrophils to be positive for viral proteins and genes, in addition to the BAL 
neutrophils (129). If viable infective RSV was present within these neutrophil, 
dissemination out of the lung could be a possibility.  However, neutrophils in 
my study were not shown to be capable of producing infective RSV progeny 
making this scenario unlikely. In addition, neither RSV viraemia nor satellite 
RSV infection outside the lung is a common occurrence in the immune-
competent patient so the disease relevance of this finding is uncertain.  
 
The findings in Chapters 3 and 4 highlight the importance of using multiple 
techniques to dissect neutrophil and viral interaction. Microscopic or 
biochemical methods used alone to follow virus do not distinguish productive 
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and non-replicative virus. As discussed more fully in Chapter 3, a number of 
studies have claimed infection of immune cells, including neutrophils, without 
evidence of replication (142, 305). A combination of approaches is needed, 
which incorporates visual, biochemical and functional method. In so doing, 
my work has built up a picture of non-productive viral entry. 
 
The fourth aim of this work was to compare neutrophil-RSV interaction in 
adult and infant neutrophils. In Chapter 5, cord blood neutrophils, modelling 
infant neutrophils, were shown to interact with RSV in the same way as adult 
neutrophils, confirming their applicability to neutrophils from young infants, 
the age group most at risk of severe RSV disease. The validity of my findings 
was confirmed through visualisation of RSV inside BAL neutrophils of infants 
with bronchiolitis. The similar distribution lent support to the RSV neutrophil 
interaction being a genuine disease phenomenon. 
 
The fifth and final aim was to investigate the response of the neutrophil to 
RSV. The microarray data in Chapter 6 revealed an RNA virus specific 
transcriptional response to RSV within the adult neutrophil. RSV replication 
and transcription involves the formation of RNA replication intermediates, 
which can then act as viral molecular patterns recognized by PRRs. These 
have been shown previously to modulate the activation state of a variety of 
cells, such as macrophages, dendritic cells, and natural killer cells. The same 
is likely to be true for the neutrophil. Previous studies have shown RNA 
receptors RIG-1, MDA5, and TLR8 mRNA and protein in neutrophils (115). 
My data revealed upregulation of both RIG-1 and MDA5 in response to RSV. 
Whether these PRRs are detecting whole virus or replication intermediates 
was not determined, but our previous finding of RSV mRNA transcripts in 
BAL neutrophils, raises the possibility of abortive transcription of RSV inside 
the neutrophil (129). Differentially expressed genes identified in these 
experiments need to be investigated in patient samples, something 
discussed in more detail below. 
 
What impact, both good and bad, might the neutrophil be having, based on 
the findings of this in vitro work, on RSV disease? It is possible that the 
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regulation, activation state and/or number of neutrophils determine whether 
an immune response to RSV is ‘appropriate’ leading to viral clearance, 
activation of the adaptive response and resolution of the infection or ‘overly 
robust’ leading to lung inflammation and damage, and consequent severe 
disease. Neutrophils could undoubtedly result in immune mediated damage 
through the pro-inflammatory release of chemokines and granular enzymes 
(119, 126). In addition, pathological findings from RSV patients include signs 
of airway obstruction due to sloughing of epithelial cells, mucus secretion, 
and accumulated immune cells (39). Airway obstruction and oedema 
contribute to reduced lung function. Although in the minority compared to 
mononuclear cells, neutrophils contribute to the debris found in the airway 
lumen. (39) Microarray data in Chapter 6 reveal the potential for the 
neutrophil to produce a number of chemoattractants in response to RSV, 
driving not only their own but also other immune cell’s pulmonary 
recruitment. The RSV stimulated upregulation of ISGs has the potential to 
drive the neutrophil into an antiviral state, potentiating the pre-existing 
surrounding inflammatory environment resulting from infection, leading to 
further recruitment of immune cells, and pro-inflammatory chemokine 
production. However, the neutrophil also has a role to play in the resolution 
of the inflammation. The late response microarray data revealed 
downregulation of neutrophil activation receptors including CXCR1 and 
CXCR2. Neutrophils have previously been shown to have anti-inflammatory 
capabilities through their ability to block and scavenge chemokines such as 
CCL3 and CCL5, and produce anti-inflammatory cytokines such as IL-1RA 
and TGFβ1&2 (101, 102). The in vitro work in Chapter 3 suggested that the 
neutrophil has a role in viral clearance. This combined with its ability to 
upregulate an antiviral response, provides strong evidence of a vital immune 
role against RSV infection. The balance between these different roles of the 
neutrophil may be important to RSV disease pathogenesis and hence 
severity. Neutrophils are required for an adequate immune response, but it 
may be that an excess of activated neutrophils results in unregulated, 
excessive inflammation.  
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Neutrophils are now considered to have a key role in the pathogenesis of 
inflammatory, infectious, autoimmune and neoplastic disease (102). Future 
work may involve translating recent insights in neutrophil biology into 
neutrophil-targeted therapies for treatment of inflammatory conditions. The 
challenge will be doing this without compromising immunity. One potential 
therapeutic area is that of apoptosis manipulation. Knowledge of the 
molecular mechanisms of apoptosis have allowed development of apoptosis 
modulators, which target different points of the pathway. For example, 
chemical mimetics of Smac have been developed which increase caspase 
activity and thus neutrophil apoptosis (306, 307). Inhibition of NFkB can be 
achieved by a number of drugs and there is in vivo evidence of inflammation 
resolution enhancement in a rat model of pleurisy using one of these 
molecules, PGD2 (308). As a number of apoptosis mechanisms are unique to 
the neutrophil, it is possible that pharmacological intervention could be used 
to target this cell to control inflammation (309). It does require however, a 
clearer understanding of the importance of airway neutrophilia on disease 
resolution. It could be that in certain situations increased neutrophil survival 
is the goal.  
7.1 Future directions 
There are a number of aspects of the study, which on reflection I may have 
done differently. In future work, it might be possible to use a novel method 
now available to overcome the impurity of the virus, in order to confirm the 
contribution RSV alone is making to the neutrophil response. This method 
involves the use of magnetic particles to capture and concentrate virus (a 
similar technique to that used for the neutrophil ultra-purification). The viral 
particles are captured by magnetic nanoparticles on the basis of electrostatic 
and hydrophobic interaction and a magnetic field concentrates the magnetic 
beads (Ozbiosciences) (310). The viral particles can then be suspended in a 
smaller volume to concentrate them. This technology might either allow the 
use of a purer preparation of RSV or potentially the use of the supernatant 
minus RSV so that a true control, identical except for the presence of RSV 
could be used.  
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It would have been useful to perform the microarray analysis earlier in the 
study, as data on new areas and pathways that I would have liked to 
investigate further was generated. There are a number of avenues for future 
work. Firstly, I need to confirm that the genes found differentially regulated in 
the microarray results translate to the protein level and produce the expected 
up- or down-expression of the individual proteins. This is best done using the 
RSV exposed in vitro neutrophils, as measuring target cytokines in BAL may 
confirm their presence but identifying the source as being the neutrophil 
would be less easy. BAL neutrophils could however be used to look for the 
transcriptional responses observed in vitro. Future work will need to consider 
the interaction between the neutrophil and the other important immune cells 
in RSV disease. The microarray data have revealed the potential for the RSV 
exposed neutrophil to prime and/or activate T cells. Mechanistic work, 
exposing T cells to RSV primed neutrophils, could confirm this and further 
our understanding of T cell responses in RSV disease.  
 
A major limitation is that we can only study cells from the lower airways in 
BAL from severely infected patients. Ideally, we need to be able to compare 
the neutrophils across the spectrum of RSV disease to understand their 
impact on disease. It is possible that studying circulating neutrophils from 
patients could shed some light on the different functions of the neutrophils 
dependant on disease severity. Halfhide et al studied activation of matched 
BAL and blood neutrophil samples from infants intubated with RSV infection 
and showed that neutrophils become partially activated in the peripheral 
circulation (48). This might be ethically acceptable, as it would involve a 
minimum of 5mls of peripheral blood, and the advantage would be that it 
could be collected from any RSV infected patient regardless of severity. This 
may allow a better understanding of how the under- or over-activation of the 
neutrophil affects the severity of disease. The caveat being that the severity 
of disease could be the driving force to the neutrophil and not vice versa.  
7.2 Final conclusions 
Evidence presented in this thesis supports a novel role for neutrophils as 
innate cells at the frontline of antiviral immunity in RSV disease. For the first 
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time the degradation of internalised RSV has been shown in the neutrophil 
suggesting a role for this cell in viral clearance. In addition, a robust 
transcriptional response to RSV preparation has been revealed, specifically 
highlighting a number of interferon regulatory pathways. That severe RSV 
bronchiolitis is characterised by immunopathogenesis driven to a large 
degree by neutrophils is acknowledged in the literature. However, this thesis 
describes for the first time, the function of the neutrophil as a cell of 
importance in the immune response to RSV infection.  
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 Information sheet (Patient) 
The immune response of the newborn to 
inflammation and infection 
 
 
Name of Researchers:    
Dr Paul McNamara Dr Gemma Saint 
Dr Brian Flanagan Dr Mark Turner 
  
You are being invited to take part in the above research project.  Before you 
decide, it is important for you to understand why the research is being done and 
what it will involve.  Please take time to read the following information carefully 
and discuss it with friends, or relatives. Ask us if there is anything you do not 
understand or if you would like more information.  Take time to decide whether 
or not you wish to take part.  Thank you for reading this. 
 
What is the purpose of the study? 
The purpose of the study is to look at the immune system of newborn babies. 
We have found that babies who get a severe infection when they are a few 
months old fight infections differently from adults. We now want to do some 
laboratory tests on blood cells from newborn babies in order to see whether 
the differences are present when babies are born.   
 
Why have I been chosen? 
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You have been chosen because you are about to deliver a newborn who we 
believe is healthy and has not been exposed to infections in the womb.  
 
Do I have to take part? 
Entering the trial is completely voluntary.  If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent 
form. If you decide to take part you are still free to withdraw without giving a 
reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
If you decide to take part in this study, we will ask you to sign a consent form. 
Taking part in this study will mean that we will take about 10 -30 mls of blood 
from the umbilical cord after the baby is born and the cord has been cut. The 
placenta and umbilical cord, once cut and removed from the baby in the first 
few minutes after birth, is normally disposed of in a respectful manner. 
However it still contains some of your baby’s blood and this can be used to 
study the immune system of the newborn. 
 
What are the possible benefits of taking part? 
There will be no direct benefits to you from taking part in this study.  
However, the information we get from this study may be of benefit to other 
babies in the future. It will help us to determine how newborn babies fight 
infections and this may lead to the development of new treatments. We will 
not be able to predict if your baby is more, or less, likely to get an infection 
than other babies. 
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What if something goes wrong? 
It is very unlikely that you or your baby will be harmed by this study.  The 
blood samples are collected only after the baby is born and from the large 
umbilical vein of the cord after it is no longer attached to the baby.  This 
study does not involve blood tests for you or your baby.  If you are harmed 
by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you 
may have grounds for a legal action but you may have to pay for it.  
Regardless of this, if you wish to complain about any aspect of the way you 
have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you. 
 
Will my taking part in this study be kept confidential? 
All information collected about you or your baby during the course of the 
research will be kept strictly confidential. Any information about you or your 
baby, which leaves the hospital, will have all personal details removed so 
that you cannot be recognised from it. Your medical notes as well as the 
baby’s medical notes may be looked at to obtain information relevant to this 
study but this will only involve the checking that you and the baby do not 
have any illnesses and the baby’s sex and gestational age.   
 
What will happen to the results of the research study? 
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The results will be published in scientific journals and presented at 
conferences to further our understanding of the immune response to 
infection. 
 
Who is organising the research? 
The research is being organised by the University Of Liverpool. 
 
Who has reviewed the study? 
The Liverpool Research Ethics Committee. 
 
How can I know the results of this study? 
If you wish to obtain a summary of the investigation that is easy to read once 
data collection and analysis are complete please contact the research team. 
 
Contact for Further Information 
Dr Mark Turner 
Liverpool Women’s NHS Foundation Trust 
Crown Street 
Liverpool L8 7SS 
Tel: 0151 708 9988 
Thank you for reading this. 
  192 
 
 
 
CONSENT FORM 
The immune response of the newborn to 
inflammation and infection 
 
Name of Researchers:   
 
 
Dr Paul McNamara Dr Mark Turner 
Dr Brian Flanagan Dr Gemma Saint  
 
                                                                                                           Please initial box 
 
1. I confirm that I have read and understand the information sheet for the  
            above study. 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
            at any time without my medical care or legal rights being affected. 
 
3.  I understand that sections of any of my medical notes may be looked at by  
           responsible individuals from Liverpool Women’s NHS Foundation Trust, 
           or from regulatory authorities where it is relevant to my taking part in research. 
           I give permission for these individuals to have access to my records and my  
           baby records. 
 
4. I agree to take part in the above study. 
 
_________________________  ___________         _____________________ 
Name of Patient    Date     Signature 
 
_______________________   ___________        _____________________ 
Researcher     Date    Signature 
 
_________________________  ____________       _____________________ 
Name of Person taking consent  Date    Signature 
(If different from researcher) 
   
If you wish to obtain a summary of the investigation that is easy to read once data 
collection and analysis are complete please contact the research team. 
 
1 copy for patient, 1 copy for research, 1 copy to be kept with hospital notes 
The immune response of the newborn to inflammation and infection 
consent form Version 4 15/12/2013 
  193 
Appendix 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  194 
 
 
RNA sample information  
Sample IDs, description, concentration, volume, and nanodrop measurements are 
shown. The volume used for labelling in order to use 100ng of RNA is shown, as is 
the volume of water needed to equalise the volumes across all the samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tube ID Sample name Description
Concentration 
(ng/ul)
Sample 
volume 
(ul) 260/280 260/230
amount-for-
100ng-
input
volume-of-
H2O-to-
11.4-ul-for-
SV
6072_1 1 RSV 1 4hrs 11.59 30 1.97 0.46 8.63 2.77
6072_2 2 RSV 1 20hrs 12.25 30 1.83 0.8 8.16 3.24
6072_3 3 Con 1 4hrs 8.77 30 1.63 0.1 11.40 0.00
6072_4 4 Con 1 20hrs 14.25 30 1.93 0.08 7.02 4.38
6072_5 13 RSV 4 4hrs 35.99 30 2.01 0.87 2.78 8.62
6072_6 14 RSV 4 20hrs 9.89 30 1.78 1.38 10.11 1.29
6072_7 15 Con 4 4hrs 51.08 30 2.16 0.14 1.96 9.44
6072_8 16 Con 4 20hrs 52.77 30 2.14 2.49 1.90 9.50
6072_9 17 RSV 5 4hrs 30.41 30 1.97 0.35 3.29 8.11
6072_10 18 RSV 5 20hrs 33.42 30 2.07 1.04 2.99 8.41
6072_11 19 Con 5 4hrs 38.05 30 2.08 0.97 2.63 8.77
6072_12 20 Con 5 20hrs 28.22 30 2.01 0.83 3.54 7.86
6072_13 21 RSV 6 4hrs 60.91 30 2.06 1.49 1.64 9.76
6072_14 22 RSV 6 20hrs 53.01 30 2.07 1.8 1.89 9.51
6072_15 23 Con 6 4hrs 47.04 30 2.13 1.7 2.13 9.27
6072_16 24 Con 6 20hrs 62.87 30 2.01 0.48 1.59 9.81
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Gene	 Description	 Location	 Action	
39142	 N(alpha)-acetyltransferase	60,	NatF	catalytic	subunit	 Cytoplasm	 enzyme	
ABTB1	 ankyrin	repeat	and	BTB	(POZ)	domain	containing	1	 Cytoplasm	 translation	
regulator	
ACN9	 ACN9	homolog	(S.	cerevisiae)	 Cytoplasm	 other	
ACOT9	 acyl-CoA	thioesterase	9	 Cytoplasm	 enzyme	
ACSS2	 acyl-CoA	synthetase	short-chain	family	member	2	 Cytoplasm	 enzyme	
ACTL10	 actin-like	10	 Extracellular	
Space	
other	
ACTN3	 actinin,	alpha	3	 Plasma	
Membrane	
other	
ADCK3	 aarF	domain	containing	kinase	3	 Cytoplasm	 kinase	
ADCY7	 adenylate	cyclase	7	 Plasma	
Membrane	
enzyme	
ADNP	 activity-dependent	neuroprotector	homeobox	 Nucleus	 transcription	
regulator	
ADPGK	 ADP-dependent	glucokinase	 Other	 kinase	
ADPRHL2	 ADP-ribosylhydrolase	like	2	 Cytoplasm	 enzyme	
ADRBK1	 adrenergic,	beta,	receptor	kinase	1	 Cytoplasm	 kinase	
ADRBK2	 adrenergic,	beta,	receptor	kinase	2	 Cytoplasm	 kinase	
AEN	 apoptosis	enhancing	nuclease	 Nucleus	 enzyme	
AFF1	 AF4/FMR2	family,	member	1	 Nucleus	 transcription	
regulator	
AGO4	 argonaute	RISC	catalytic	component	4	 Cytoplasm	 translation	
regulator	
AGRN	 agrin	 Plasma	
Membrane	
other	
AK091028	 GMDS	antisense	RNA	1	(head	to	head)	 Other	 other	
AKAP10	 A	kinase	(PRKA)	anchor	protein	10	 Cytoplasm	 other	
AKIRIN1	 akirin	1	 Cytoplasm	 enzyme	
ALKBH7	 alkB,	alkylation	repair	homolog	7	(E.	coli)	 Cytoplasm	 other	
AMPD2	 adenosine	monophosphate	deaminase	2	 Cytoplasm	 enzyme	
ANKFY1	 ankyrin	repeat	and	FYVE	domain	containing	1	 Cytoplasm	 transcription	
regulator	
ANKMY1	 ankyrin	repeat	and	MYND	domain	containing	1	 Other	 other	
ANKRD34B	 ankyrin	repeat	domain	34B	 Nucleus	 transcription	
regulator	
ANXA2R	 annexin	A2	receptor	 Plasma	
Membrane	
other	
ANXA9	 annexin	A9	 Plasma	
Membrane	
transmembrane	
receptor	
AP1S3	 adaptor-related	protein	complex	1,	sigma	3	subunit	 Cytoplasm	 transporter	
  197 
AP4B1	 adaptor-related	protein	complex	4,	beta	1	subunit	 Cytoplasm	 transporter	
APAF1	 apoptotic	peptidase	activating	factor	1	 Cytoplasm	 other	
APOBEC3A	 apolipoprotein	B	mRNA	editing	enzyme,	catalytic	
polypeptide-like	3A	
Cytoplasm	 enzyme	
APOBEC3B	 apolipoprotein	B	mRNA	editing	enzyme,	catalytic	
polypeptide-like	3B	
Cytoplasm	 enzyme	
APOBEC3C	 apolipoprotein	B	mRNA	editing	enzyme,	catalytic	
polypeptide-like	3C	
Other	 enzyme	
APOBEC3F	 apolipoprotein	B	mRNA	editing	enzyme,	catalytic	
polypeptide-like	3F	
Cytoplasm	 enzyme	
APOBEC3G	 apolipoprotein	B	mRNA	editing	enzyme,	catalytic	
polypeptide-like	3G	
Nucleus	 enzyme	
APTR	 Alu-mediated	CDKN1A/p21	transcriptional	regulator	
(non-protein	coding)	
Other	 other	
ARID4B	 AT	rich	interactive	domain	4B	(RBP1-like)	 Nucleus	 other	
ARL8B	 ADP-ribosylation	factor-like	8B	 Plasma	
Membrane	
enzyme	
ARSB	 arylsulfatase	B	 Cytoplasm	 enzyme	
ASNSD1	 asparagine	synthetase	domain	containing	1	 Other	 enzyme	
ATF7IP	 activating	transcription	factor	7	interacting	protein	 Nucleus	 transcription	
regulator	
ATG2B	 autophagy	related	2B	 Other	 other	
ATP1B1	 ATPase,	Na+/K+	transporting,	beta	1	polypeptide	 Plasma	
Membrane	
transporter	
ATP6V1A	 ATPase,	H+	transporting,	lysosomal	70kDa,	V1	subunit	
A	
Plasma	
Membrane	
transporter	
ATP6V1E2	 ATPase,	H+	transporting,	lysosomal	31kDa,	V1	subunit	
E2	
Cytoplasm	 transporter	
ATP6V1F	 ATPase,	H+	transporting,	lysosomal	14kDa,	V1	subunit	F	 Cytoplasm	 enzyme	
ATXN2	 ataxin	2	 Nucleus	 other	
ATXN7L1	 ataxin	7-like	1	 Other	 other	
AZI2	 5-azacytidine	induced	2	 Cytoplasm	 other	
B3GALNT1	 beta-1,3-N-acetylgalactosaminyltransferase	1	
(globoside	blood	group)	
Cytoplasm	 enzyme	
B4GALT3	 UDP-Gal:betaGlcNAc	beta	1,4-	galactosyltransferase,	
polypeptide	3	
Cytoplasm	 enzyme	
BAALC	 brain	and	acute	leukemia,	cytoplasmic	 Cytoplasm	 other	
BAG1	 BCL2-associated	athanogene	 Cytoplasm	 other	
BARD1	 BRCA1	associated	RING	domain	1	 Nucleus	 transcription	
regulator	
BATF2	 basic	leucine	zipper	transcription	factor,	ATF-like	2	 Other	 other	
BC013229	 UDP-GlcNAc:betaGal	beta-1,3-N- Cytoplasm	 enzyme	
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acetylglucosaminyltransferase	5	
BHLHE40	 basic	helix-loop-helix	family,	member	e40	 Nucleus	 transcription	
regulator	
BICD2	 bicaudal	D	homolog	2	(Drosophila)	 Cytoplasm	 other	
BLZF1	 basic	leucine	zipper	nuclear	factor	1	 Cytoplasm	 transcription	
regulator	
BMI1	 BMI1	proto-oncogene,	polycomb	ring	finger	 Nucleus	 transcription	
regulator	
BNIPL	 BCL2/adenovirus	E1B	19kD	interacting	protein	like	 Cytoplasm	 other	
BOD1L1	 biorientation	of	chromosomes	in	cell	division	1-like	1	 Nucleus	 other	
BRCA2	 breast	cancer	2,	early	onset	 Nucleus	 transcription	
regulator	
BREA2	 breast	cancer	estrogen-induced	apoptosis	2	 Other	 other	
BRF2	 BRF2,	RNA	polymerase	III	transcription	initiation	factor	
50	kDa	subunit	
Nucleus	 transcription	
regulator	
BRICD5	 BRICHOS	domain	containing	5	 Other	 enzyme	
BST2	 bone	marrow	stromal	cell	antigen	2	 Plasma	
Membrane	
other	
BTG1	 B-cell	translocation	gene	1,	anti-proliferative	 Nucleus	 transcription	
regulator	
C10orf105	 chromosome	10	open	reading	frame	105	 Other	 other	
C10orf120	 chromosome	10	open	reading	frame	120	 Other	 other	
C10orf131	 chromosome	10	open	reading	frame	131	 Other	 other	
C11orf68	 chromosome	11	open	reading	frame	68	 Other	 other	
C12orf75	 chromosome	12	open	reading	frame	75	 Other	 other	
C15orf48	 chromosome	15	open	reading	frame	48	 Nucleus	 other	
C17orf62	 chromosome	17	open	reading	frame	62	 Other	 other	
C17orf67	 chromosome	17	open	reading	frame	67	 Other	 other	
C17orf75	 chromosome	17	open	reading	frame	75	 Extracellular	
Space	
other	
C17orf96	 chromosome	17	open	reading	frame	96	 Other	 other	
C19orf12	 chromosome	19	open	reading	frame	12	 Other	 other	
C19orf33	 chromosome	19	open	reading	frame	33	 Nucleus	 other	
C19orf66	 chromosome	19	open	reading	frame	66	 Other	 other	
C1GALT1	 core	1	synthase,	glycoprotein-N-acetylgalactosamine	3-
beta-galactosyltransferase	1	
Plasma	
Membrane	
enzyme	
C1GALT1C1	 C1GALT1-specific	chaperone	1	 Cytoplasm	 enzyme	
C21orf91	 chromosome	21	open	reading	frame	91	 Other	 other	
C2orf44	 chromosome	2	open	reading	frame	44	 Other	 other	
C2orf80	 chromosome	2	open	reading	frame	80	 Other	 other	
C3orf18	 chromosome	3	open	reading	frame	18	 Other	 other	
C4orf45	 chromosome	4	open	reading	frame	45	 Other	 other	
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C5orf24	 chromosome	5	open	reading	frame	24	 Other	 other	
C5orf30	 chromosome	5	open	reading	frame	30	 Cytoplasm	 other	
C5orf56	 chromosome	5	open	reading	frame	56	 Other	 other	
C5orf58	 chromosome	5	open	reading	frame	58	 Other	 other	
C6orf1	 chromosome	6	open	reading	frame	1	 Other	 other	
C7orf60	 chromosome	7	open	reading	frame	60	 Other	 other	
C8orf88	 chromosome	8	open	reading	frame	88	 Other	 other	
C9orf139	 chromosome	9	open	reading	frame	139	 Other	 other	
C9orf24	 chromosome	9	open	reading	frame	24	 Cytoplasm	 other	
CAB39L	 calcium	binding	protein	39-like	 Cytoplasm	 kinase	
CACNA1A	 calcium	channel,	voltage-dependent,	P/Q	type,	alpha	
1A	subunit	
Plasma	
Membrane	
ion	channel	
CACUL1	 CDK2-associated,	cullin	domain	1	 Other	 other	
CAMK1G	 calcium/calmodulin-dependent	protein	kinase	IG	 Cytoplasm	 kinase	
CAMK2G	 calcium/calmodulin-dependent	protein	kinase	II	
gamma	
Cytoplasm	 kinase	
CARHSP1	 calcium	regulated	heat	stable	protein	1,	24kDa	 Cytoplasm	 other	
CARKD	 carbohydrate	kinase	domain	containing	 Cytoplasm	 enzyme	
CASP9	 caspase	9,	apoptosis-related	cysteine	peptidase	 Cytoplasm	 peptidase	
CBWD5	 COBW	domain	containing	5	 Other	 other	
CBX7	 chromobox	homolog	7	 Nucleus	 other	
CBX8	 chromobox	homolog	8	 Nucleus	 other	
CC2D1B	 coiled-coil	and	C2	domain	containing	1B	 Nucleus	 other	
CCDC112	 coiled-coil	domain	containing	112	 Extracellular	
Space	
other	
CCDC167	 coiled-coil	domain	containing	167	 Other	 other	
CCDC170	 coiled-coil	domain	containing	170	 Extracellular	
Space	
other	
CCDC28A	 coiled-coil	domain	containing	28A	 Other	 other	
CCDC85B	 coiled-coil	domain	containing	85B	 Cytoplasm	 other	
CCL4	 chemokine	(C-C	motif)	ligand	4	 Extracellular	
Space	
cytokine	
CCL4L2	 chemokine	(C-C	motif)	ligand	4-like	1	 Plasma	
Membrane	
other	
CCND2	 cyclin	D2	 Nucleus	 other	
CCR1	 chemokine	(C-C	motif)	receptor	1	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
CCT6B	 chaperonin	containing	TCP1,	subunit	6B	(zeta	2)	 Cytoplasm	 transporter	
CD164	 CD164	molecule,	sialomucin	 Plasma	
Membrane	
other	
CD22	 CD22	molecule	 Plasma	 transmembrane	
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Membrane	 receptor	
CD274	 CD274	molecule	 Plasma	
Membrane	
enzyme	
CD58	 CD58	molecule	 Plasma	
Membrane	
transmembrane	
receptor	
CD68	 CD68	molecule	 Plasma	
Membrane	
other	
CD69	 CD69	molecule	 Plasma	
Membrane	
transmembrane	
receptor	
CD80	 CD80	molecule	 Plasma	
Membrane	
transmembrane	
receptor	
CDC123	 cell	division	cycle	123	 Cytoplasm	 other	
CDC14C	 cell	division	cycle	14C	 Nucleus	 other	
CDC40	 cell	division	cycle	40	 Nucleus	 other	
CDC42SE2	 CDC42	small	effector	2	 Plasma	
Membrane	
other	
CDC73	 cell	division	cycle	73	 Nucleus	 other	
CDK19	 cyclin-dependent	kinase	19	 Nucleus	 kinase	
CDK5R1	 cyclin-dependent	kinase	5,	regulatory	subunit	1	(p35)	 Nucleus	 kinase	
CDK7	 cyclin-dependent	kinase	7	 Nucleus	 kinase	
CEBPA	 CCAAT/enhancer	binding	protein	(C/EBP),	alpha	 Nucleus	 transcription	
regulator	
CEBPD	 CCAAT/enhancer	binding	protein	(C/EBP),	delta	 Nucleus	 transcription	
regulator	
CENPF	 centromere	protein	F,	350/400kDa	 Nucleus	 other	
CEP44	 centrosomal	protein	44kDa	 Cytoplasm	 other	
CEP85L	 centrosomal	protein	85kDa-like	 Cytoplasm	 other	
CEP97	 centrosomal	protein	97kDa	 Cytoplasm	 other	
CERS4	 ceramide	synthase	4	 Cytoplasm	 transcription	
regulator	
CHMP5	 charged	multivesicular	body	protein	5	 Cytoplasm	 other	
CHRM4	 cholinergic	receptor,	muscarinic	4	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
CHRNB1	 cholinergic	receptor,	nicotinic,	beta	1	(muscle)	 Plasma	
Membrane	
transmembrane	
receptor	
CIDEC	 cell	death-inducing	DFFA-like	effector	c	 Cytoplasm	 other	
CIDECP	 cell	death-inducing	DFFA-like	effector	c	pseudogene	 Other	 other	
CISH	 cytokine	inducible	SH2-containing	protein	 Cytoplasm	 other	
CLCF1	 cardiotrophin-like	cytokine	factor	1	 Extracellular	
Space	
cytokine	
CLEC4A	 C-type	lectin	domain	family	4,	member	A	 Plasma	 transmembrane	
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Membrane	 receptor	
CLINT1	 clathrin	interactor	1	 Cytoplasm	 other	
CLPX	 caseinolytic	mitochondrial	matrix	peptidase	chaperone	
subunit	
Cytoplasm	 enzyme	
CLU	 clusterin	 Cytoplasm	 other	
CMAHP	 cytidine	monophospho-N-acetylneuraminic	acid	
hydroxylase,	pseudogene	
Cytoplasm	 other	
CMTM1	 CKLF-like	MARVEL	transmembrane	domain	containing	1	 Other	 other	
CMTR1	 cap	methyltransferase	1	 Nucleus	 enzyme	
CNEP1R1	 CTD	nuclear	envelope	phosphatase	1	regulatory	
subunit	1	
Other	 other	
CNOT2	 CCR4-NOT	transcription	complex,	subunit	2	 Nucleus	 transcription	
regulator	
CNOT7	 CCR4-NOT	transcription	complex,	subunit	7	 Nucleus	 transcription	
regulator	
CNP	 2',3'-cyclic	nucleotide	3'	phosphodiesterase	 Cytoplasm	 enzyme	
CNPY3	 canopy	FGF	signaling	regulator	3	 Cytoplasm	 other	
CNTF	 ciliary	neurotrophic	factor	 Extracellular	
Space	
cytokine	
COL12A1	 collagen,	type	XII,	alpha	1	 Extracellular	
Space	
other	
CORO1A	 coronin,	actin	binding	protein,	1A	 Cytoplasm	 other	
CPS1	 carbamoyl-phosphate	synthase	1,	mitochondrial	 Cytoplasm	 enzyme	
CT83	 cancer/testis	antigen	83	 Nucleus	 other	
CTAGE1	 cutaneous	T-cell	lymphoma-associated	antigen	1	 Other	 other	
CTC-338M12.4	 uncharacterized	LOC101928649	 Other	 other	
CTSLP8	 cathepsin	L	pseudogene	8	 Other	 other	
CUEDC1	 CUE	domain	containing	1	 Other	 other	
CXCL10	 chemokine	(C-X-C	motif)	ligand	10	 Extracellular	
Space	
cytokine	
CXCL2	 chemokine	(C-X-C	motif)	ligand	2	 Extracellular	
Space	
cytokine	
CXCL6	 chemokine	(C-X-C	motif)	ligand	6	 Extracellular	
Space	
cytokine	
CXCR1	 chemokine	(C-X-C	motif)	receptor	1	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
CXCR2	 chemokine	(C-X-C	motif)	receptor	2	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
CXorf21	 chromosome	X	open	reading	frame	21	 Other	 enzyme	
CXorf38	 chromosome	X	open	reading	frame	38	 Other	 other	
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CYBB	 cytochrome	b-245,	beta	polypeptide	 Cytoplasm	 enzyme	
CYR61	 cysteine-rich,	angiogenic	inducer,	61	 Extracellular	
Space	
other	
CYTH3	 cytohesin	3	 Cytoplasm	 other	
DAB2	 Dab,	mitogen-responsive	phosphoprotein,	homolog	2	
(Drosophila)	
Plasma	
Membrane	
other	
DAGLB	 diacylglycerol	lipase,	beta	 Plasma	
Membrane	
enzyme	
DAPL1	 death	associated	protein-like	1	 Other	 other	
DAPP1	 dual	adaptor	of	phosphotyrosine	and	3-
phosphoinositides	
Cytoplasm	 other	
DBF4B	 DBF4	zinc	finger	B	 Nucleus	 other	
DBP	 D	site	of	albumin	promoter	(albumin	D-box)	binding	
protein	
Nucleus	 transcription	
regulator	
DCAF4L1	 DDB1	and	CUL4	associated	factor	4-like	1	 Other	 other	
DCAF4L2	 DDB1	and	CUL4	associated	factor	4-like	2	 Other	 other	
DCLRE1C	 DNA	cross-link	repair	1C	 Nucleus	 enzyme	
DCP2	 decapping	mRNA	2	 Nucleus	 enzyme	
DCTN6	 dynactin	6	 Cytoplasm	 enzyme	
DCUN1D3	 DCN1,	defective	in	cullin	neddylation	1,	domain	
containing	3	
Cytoplasm	 other	
DDX28	 DEAD	(Asp-Glu-Ala-Asp)	box	polypeptide	28	 Nucleus	 enzyme	
DDX58	 DEAD	(Asp-Glu-Ala-Asp)	box	polypeptide	58	 Cytoplasm	 enzyme	
DDX60L	 DEAD	(Asp-Glu-Ala-Asp)	box	polypeptide	60-like	 Other	 other	
DESI2	 desumoylating	isopeptidase	2	 Cytoplasm	 other	
DHTKD1	 dehydrogenase	E1	and	transketolase	domain	
containing	1	
Cytoplasm	 enzyme	
DHX58	 DEXH	(Asp-Glu-X-His)	box	polypeptide	58	 Cytoplasm	 enzyme	
DICER1	 dicer	1,	ribonuclease	type	III	 Cytoplasm	 enzyme	
DICER1-AS1	 DICER1	antisense	RNA	1	 Other	 other	
DIP2B	 DIP2	disco-interacting	protein	2	homolog	B	
(Drosophila)	
Cytoplasm	 other	
DKC1	 dyskeratosis	congenita	1,	dyskerin	 Nucleus	 enzyme	
DNAJC13	 DnaJ	(Hsp40)	homolog,	subfamily	C,	member	13	 Cytoplasm	 other	
DOCK11	 dedicator	of	cytokinesis	11	 Cytoplasm	 other	
DPF2	 D4,	zinc	and	double	PHD	fingers	family	2	 Nucleus	 other	
DRAP1	 DR1-associated	protein	1	(negative	cofactor	2	alpha)	 Nucleus	 transcription	
regulator	
DSTYK	 dual	serine/threonine	and	tyrosine	protein	kinase	 Cytoplasm	 kinase	
DUS2	 dihydrouridine	synthase	2	 Cytoplasm	 other	
DUSP11	 dual	specificity	phosphatase	11	(RNA/RNP	complex	1-
interacting)	
Nucleus	 phosphatase	
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DUSP5	 dual	specificity	phosphatase	5	 Nucleus	 phosphatase	
DYNLT1	 dynein,	light	chain,	Tctex-type	1	 Cytoplasm	 other	
EDEM1	 ER	degradation	enhancer,	mannosidase	alpha-like	1	 Cytoplasm	 enzyme	
EDN1	 endothelin	1	 Extracellular	
Space	
cytokine	
EFNA1	 ephrin-A1	 Plasma	
Membrane	
other	
EFNA4	 ephrin-A4	 Plasma	
Membrane	
kinase	
EGLN1	 egl-9	family	hypoxia-inducible	factor	1	 Cytoplasm	 enzyme	
EIF4A1	 eukaryotic	translation	initiation	factor	4A1	 Cytoplasm	 translation	
regulator	
EIF4E	 eukaryotic	translation	initiation	factor	4E	 Cytoplasm	 translation	
regulator	
ELMSAN1	 ELM2	and	Myb/SANT-like	domain	containing	1	 Nucleus	 other	
EML4	 echinoderm	microtubule	associated	protein	like	4	 Cytoplasm	 other	
EMP1	 epithelial	membrane	protein	1	 Plasma	
Membrane	
other	
ENST00000287667	 NODAL	modulator	1	 Plasma	
Membrane	
other	
ENST00000316517	 olfactory	receptor,	family	56,	subfamily	B,	member	3	
pseudogene	
Other	 other	
ENST00000390300	 immunoglobulin	lambda	variable	5-37	 Other	 other	
ENST00000390465	 T	cell	receptor	alpha	variable	38-2/delta	variable	8	 Other	 other	
ENST00000391437	 uncharacterized	protein	DKFZp667F0711	 Other	 other	
ENST00000525262	 unc-93	homolog	B6	(C.	elegans)	 Other	 other	
ENST00000582047	 keratin	17	pseudogene	1	 Other	 other	
EPB41	 erythrocyte	membrane	protein	band	4.1	 Plasma	
Membrane	
other	
EPHB6	 EPH	receptor	B6	 Plasma	
Membrane	
kinase	
EPS15L1	 epidermal	growth	factor	receptor	pathway	substrate	
15-like	1	
Plasma	
Membrane	
other	
ERP27	 endoplasmic	reticulum	protein	27	 Other	 other	
ERP29	 endoplasmic	reticulum	protein	29	 Cytoplasm	 transporter	
EVI5	 ecotropic	viral	integration	site	5	 Cytoplasm	 other	
EXOC3L1	 exocyst	complex	component	3-like	1	 Cytoplasm	 other	
EXTL3	 exostosin-like	glycosyltransferase	3	 Cytoplasm	 enzyme	
EYA3	 EYA	transcriptional	coactivator	and	phosphatase	3	 Nucleus	 phosphatase	
F8A1	 coagulation	factor	VIII-associated	1	 Nucleus	 other	
F8A2	 coagulation	factor	VIII-associated	1	 Nucleus	 other	
FAM101B	 family	with	sequence	similarity	101,	member	B	 Other	 other	
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FAM106CP	 family	with	sequence	similarity	106,	member	C,	
pseudogene	
Other	 other	
FAM117A	 family	with	sequence	similarity	117,	member	A	 Other	 transporter	
FAM122C	 family	with	sequence	similarity	122C	 Other	 other	
FAM174A	 family	with	sequence	similarity	174,	member	A	 Extracellular	
Space	
other	
FAM184B	 family	with	sequence	similarity	184,	member	B	 Other	 other	
FAM212B	 family	with	sequence	similarity	212,	member	B	 Other	 other	
FAM214A	 family	with	sequence	similarity	214,	member	A	 Other	 other	
FAM217B	 family	with	sequence	similarity	217,	member	B	 Other	 other	
FAM222A	 family	with	sequence	similarity	222,	member	A	 Other	 other	
FAM27E2	 family	with	sequence	similarity	27,	member	E2	 Other	 other	
FAM27E3	 family	with	sequence	similarity	27,	member	E3	 Other	 other	
FAM46A	 family	with	sequence	similarity	46,	member	A	 Other	 other	
FAM53B	 family	with	sequence	similarity	53,	member	B	 Other	 other	
FAM63A	 family	with	sequence	similarity	63,	member	A	 Cytoplasm	 other	
FAM72A	 family	with	sequence	similarity	72,	member	A	 Cytoplasm	 other	
FAM72D	 family	with	sequence	similarity	72,	member	D	 Nucleus	 other	
FAM83H-AS1	 FAM83H	antisense	RNA	1	(head	to	head)	 Other	 other	
FANCA	 Fanconi	anemia,	complementation	group	A	 Nucleus	 other	
FAR1	 fatty	acyl	CoA	reductase	1	 Cytoplasm	 enzyme	
FBRS	 fibrosin	 Extracellular	
Space	
cytokine	
FBXL20	 F-box	and	leucine-rich	repeat	protein	20	 Cytoplasm	 other	
FBXO6	 F-box	protein	6	 Cytoplasm	 enzyme	
FBXW4	 F-box	and	WD	repeat	domain	containing	4	 Other	 other	
FCHO1	 FCH	domain	only	1	 Plasma	
Membrane	
other	
FDFT1	 farnesyl-diphosphate	farnesyltransferase	1	 Cytoplasm	 enzyme	
FFAR2	 free	fatty	acid	receptor	2	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
FFAR3	 free	fatty	acid	receptor	3	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
FHL2	 four	and	a	half	LIM	domains	2	 Nucleus	 transcription	
regulator	
FIBP	 fibroblast	growth	factor	(acidic)	intracellular	binding	
protein	
Nucleus	 other	
FKBP15	 FK506	binding	protein	15,	133kDa	 Plasma	
Membrane	
enzyme	
FLJ32255	 uncharacterized	LOC643977	 Other	 other	
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FLJ40194	 uncharacterized	FLJ40194	 Other	 other	
FLJ42393	 uncharacterized	LOC401105	 Other	 other	
FLOT1	 flotillin	1	 Plasma	
Membrane	
other	
FMR1	 fragile	X	mental	retardation	1	 Nucleus	 other	
FNTB	 farnesyltransferase,	CAAX	box,	beta	 Cytoplasm	 enzyme	
FOSL1	 FOS-like	antigen	1	 Nucleus	 transcription	
regulator	
FOXO3	 forkhead	box	O3	 Nucleus	 transcription	
regulator	
FOXO4	 forkhead	box	O4	 Nucleus	 transcription	
regulator	
FSCN1	 fascin	actin-bundling	protein	1	 Cytoplasm	 other	
FUT11	 fucosyltransferase	11	(alpha	(1,3)	fucosyltransferase)	 Cytoplasm	 enzyme	
FUT7	 fucosyltransferase	7	(alpha	(1,3)	fucosyltransferase)	 Cytoplasm	 enzyme	
FYCO1	 FYVE	and	coiled-coil	domain	containing	1	 Cytoplasm	 other	
GAB3	 GRB2-associated	binding	protein	3	 Other	 other	
GALK1	 galactokinase	1	 Cytoplasm	 kinase	
GCC1	 GRIP	and	coiled-coil	domain	containing	1	 Cytoplasm	 other	
GDE1	 glycerophosphodiester	phosphodiesterase	1	 Plasma	
Membrane	
enzyme	
GDPD3	 glycerophosphodiester	phosphodiesterase	domain	
containing	3	
Cytoplasm	 enzyme	
GGT5	 gamma-glutamyltransferase	5	 Plasma	
Membrane	
enzyme	
GIT2	 G	protein-coupled	receptor	kinase	interacting	ArfGAP	2	 Nucleus	 other	
GLRX2	 glutaredoxin	2	 Cytoplasm	 enzyme	
GLUL	 glutamate-ammonia	ligase	 Cytoplasm	 enzyme	
GMNN	 geminin,	DNA	replication	inhibitor	 Nucleus	 transcription	
regulator	
GNG11	 guanine	nucleotide	binding	protein	(G	protein),	gamma	
11	
Plasma	
Membrane	
enzyme	
GNG12	 guanine	nucleotide	binding	protein	(G	protein),	gamma	
12	
Plasma	
Membrane	
enzyme	
GNPAT	 glyceronephosphate	O-acyltransferase	 Cytoplasm	 enzyme	
GNPDA1	 glucosamine-6-phosphate	deaminase	1	 Cytoplasm	 enzyme	
GPR27	 G	protein-coupled	receptor	27	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
GPX3	 glutathione	peroxidase	3	(plasma)	 Extracellular	
Space	
enzyme	
GRINA	 glutamate	receptor,	ionotropic,	N-methyl	D-aspartate- Other	 ion	channel	
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associated	protein	1	(glutamate	binding)	
GRM1	 glutamate	receptor,	metabotropic	1	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
GSDMD	 gasdermin	D	 Extracellular	
Space	
other	
GSK3B	 glycogen	synthase	kinase	3	beta	 Nucleus	 kinase	
GSTO1	 glutathione	S-transferase	omega	1	 Cytoplasm	 enzyme	
GTF2B	 general	transcription	factor	IIB	 Nucleus	 transcription	
regulator	
GTPBP2	 GTP	binding	protein	2	 Extracellular	
Space	
enzyme	
H19	 H19,	imprinted	maternally	expressed	transcript	(non-
protein	coding)	
Cytoplasm	 other	
H2AFX	 H2A	histone	family,	member	X	 Nucleus	 transcription	
regulator	
HAS1	 hyaluronan	synthase	1	 Plasma	
Membrane	
enzyme	
HAVCR1	 hepatitis	A	virus	cellular	receptor	1	 Plasma	
Membrane	
other	
HAX1	 HCLS1	associated	protein	X-1	 Cytoplasm	 other	
HBEGF	 heparin-binding	EGF-like	growth	factor	 Extracellular	
Space	
growth	factor	
HEATR5B	 HEAT	repeat	containing	5B	 Cytoplasm	 other	
HELZ2	 helicase	with	zinc	finger	2,	transcriptional	coactivator	 Nucleus	 transcription	
regulator	
HERC5	 HECT	and	RLD	domain	containing	E3	ubiquitin	protein	
ligase	5	
Cytoplasm	 enzyme	
HERPUD1	 homocysteine-inducible,	endoplasmic	reticulum	stress-
inducible,	ubiquitin-like	domain	member	1	
Cytoplasm	 other	
HES4	 hes	family	bHLH	transcription	factor	4	 Other	 other	
HEXIM1	 hexamethylene	bis-acetamide	inducible	1	 Nucleus	 transcription	
regulator	
HIF1A	 hypoxia	inducible	factor	1,	alpha	subunit	(basic	helix-
loop-helix	transcription	factor)	
Nucleus	 transcription	
regulator	
HK1	 hexokinase	1	 Cytoplasm	 kinase	
HMG20A	 high	mobility	group	20A	 Nucleus	 transcription	
regulator	
HMGA1	 high	mobility	group	AT-hook	1	 Nucleus	 transcription	
regulator	
HMHA1	 histocompatibility	(minor)	HA-1	 Cytoplasm	 transporter	
HNRNPLL	 heterogeneous	nuclear	ribonucleoprotein	L-like	 Other	 other	
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HRH4	 histamine	receptor	H4	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
HS6ST1	 heparan	sulfate	6-O-sulfotransferase	1	 Plasma	
Membrane	
enzyme	
HSPBAP1	 HSPB	(heat	shock	27kDa)	associated	protein	1	 Other	 other	
HVCN1	 hydrogen	voltage-gated	channel	1	 Plasma	
Membrane	
ion	channel	
HYAL2	 hyaluronoglucosaminidase	2	 Cytoplasm	 enzyme	
ID	 Description	 Location	 Family	
ID2	 inhibitor	of	DNA	binding	2,	dominant	negative	helix-
loop-helix	protein	
Nucleus	 transcription	
regulator	
IER5	 immediate	early	response	5	 Other	 other	
IFI35	 interferon-induced	protein	35	 Nucleus	 other	
IFIH1	 interferon	induced	with	helicase	C	domain	1	 Nucleus	 enzyme	
IFIT1	 interferon-induced	protein	with	tetratricopeptide	
repeats	1	
Cytoplasm	 other	
IFIT1B	 interferon-induced	protein	with	tetratricopeptide	
repeats	1B	
Cytoplasm	 other	
IFIT2	 interferon-induced	protein	with	tetratricopeptide	
repeats	2	
Cytoplasm	 other	
IFIT3	 interferon-induced	protein	with	tetratricopeptide	
repeats	3	
Cytoplasm	 other	
IFIT5	 interferon-induced	protein	with	tetratricopeptide	
repeats	5	
Plasma	
Membrane	
other	
IGFBP7	 insulin-like	growth	factor	binding	protein	7	 Extracellular	
Space	
transporter	
IKBIP	 IKBKB	interacting	protein	 Cytoplasm	 other	
IL1A	 interleukin	1,	alpha	 Extracellular	
Space	
cytokine	
IL1RN	 interleukin	1	receptor	antagonist	 Extracellular	
Space	
cytokine	
IL27	 interleukin	27	 Extracellular	
Space	
cytokine	
IMPA2	 inositol(myo)-1(or	4)-monophosphatase	2	 Cytoplasm	 phosphatase	
INTS6	 integrator	complex	subunit	6	 Nucleus	 enzyme	
IQCK	 IQ	motif	containing	K	 Other	 other	
IRF2	 interferon	regulatory	factor	2	 Nucleus	 transcription	
regulator	
IRF2BPL	 interferon	regulatory	factor	2	binding	protein-like	 Nucleus	 other	
IRF7	 interferon	regulatory	factor	7	 Nucleus	 transcription	
regulator	
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ISG15	 ISG15	ubiquitin-like	modifier	 Extracellular	
Space	
other	
ISG20	 interferon	stimulated	exonuclease	gene	20kDa	 Nucleus	 enzyme	
ITGAM	 integrin,	alpha	M	(complement	component	3	receptor	
3	subunit)	
Plasma	
Membrane	
transmembrane	
receptor	
ITGAX	 integrin,	alpha	X	(complement	component	3	receptor	4	
subunit)	
Plasma	
Membrane	
transmembrane	
receptor	
ITPR1	 inositol	1,4,5-trisphosphate	receptor,	type	1	 Cytoplasm	 ion	channel	
ITPRIPL2	 inositol	1,4,5-trisphosphate	receptor	interacting	
protein-like	2	
Other	 other	
JADE1	 jade	family	PHD	finger	1	 Nucleus	 other	
JDP2	 Jun	dimerization	protein	2	 Nucleus	 transcription	
regulator	
KAT5	 K(lysine)	acetyltransferase	5	 Nucleus	 transcription	
regulator	
KIAA0226	 KIAA0226	 Cytoplasm	 other	
KIAA0226L	 KIAA0226-like	 Other	 other	
KIAA0232	 KIAA0232	 Extracellular	
Space	
other	
KIAA0368	 KIAA0368	 Cytoplasm	 other	
KIAA1033	 KIAA1033	 Cytoplasm	 other	
KIAA1257	 KIAA1257	 Other	 other	
KIAA1467	 KIAA1467	 Other	 other	
KIF28P	 kinesin	family	member	28,	pseudogene	 Cytoplasm	 other	
KIF3B	 kinesin	family	member	3B	 Cytoplasm	 transporter	
KLF10	 Kruppel-like	factor	10	 Nucleus	 transcription	
regulator	
KLF3	 Kruppel-like	factor	3	(basic)	 Nucleus	 transcription	
regulator	
KLHDC7B	 kelch	domain	containing	7B	 Other	 other	
KLHL28	 kelch-like	family	member	28	 Other	 other	
KLHL6	 kelch-like	family	member	6	 Other	 other	
KLHL8	 kelch-like	family	member	8	 Nucleus	 other	
KNSTRN	 kinetochore-localized	astrin/SPAG5	binding	protein	 Cytoplasm	 other	
KPTN	 kaptin	(actin	binding	protein)	 Other	 other	
KRT14	 keratin	14	 Cytoplasm	 other	
KRT16P2	 keratin	16	pseudogene	2	 Other	 other	
KRT17	 keratin	17	 Cytoplasm	 other	
KRT33A	 keratin	33A	 Extracellular	
Space	
other	
KRTAP5-10	 keratin	associated	protein	5-10	 Other	 other	
LACTB	 lactamase,	beta	 Cytoplasm	 other	
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LAMP3	 lysosomal-associated	membrane	protein	3	 Plasma	
Membrane	
other	
LASP1	 LIM	and	SH3	protein	1	 Cytoplasm	 transporter	
LCE6A	 late	cornified	envelope	6A	 Other	 other	
LCMT1	 leucine	carboxyl	methyltransferase	1	 Cytoplasm	 enzyme	
LDHB	 lactate	dehydrogenase	B	 Cytoplasm	 enzyme	
LEP	 leptin	 Extracellular	
Space	
growth	factor	
LETM2	 leucine	zipper-EF-hand	containing	transmembrane	
protein	2	
Other	 other	
LGALS8	 lectin,	galactoside-binding,	soluble,	8	 Extracellular	
Space	
other	
LINC00173	 long	intergenic	non-protein	coding	RNA	173	 Other	 other	
LINC00211	 long	intergenic	non-protein	coding	RNA	211	 Other	 other	
LINC00310	 long	intergenic	non-protein	coding	RNA	310	 Other	 other	
LINC00334	 long	intergenic	non-protein	coding	RNA	334	 Other	 other	
LINC00461	 long	intergenic	non-protein	coding	RNA	461	 Other	 other	
LINC00487	 long	intergenic	non-protein	coding	RNA	487	 Other	 other	
LINC00877	 long	intergenic	non-protein	coding	RNA	877	 Other	 other	
LINC00930	 long	intergenic	non-protein	coding	RNA	930	 Other	 other	
LINC00957	 long	intergenic	non-protein	coding	RNA	957	 Other	 other	
LINC01262	 long	intergenic	non-protein	coding	RNA	1262	 Other	 other	
LMO2	 LIM	domain	only	2	(rhombotin-like	1)	 Nucleus	 other	
LNPEP	 leucyl/cystinyl	aminopeptidase	 Cytoplasm	 peptidase	
LOC100129550	 uncharacterized	LOC100129550	 Other	 other	
LOC100130539	 uncharacterized	LOC100130539	 Other	 other	
LOC100294362	 uncharacterized	LOC100294362	 Other	 other	
LOC100506023	 uncharacterized	LOC100506023	 Other	 other	
LOC100506036	 uncharacterized	LOC100506036	 Other	 other	
LOC100506801	 uncharacterized	LOC100506801	 Other	 other	
LOC100507131	 uncharacterized	LOC100507131	 Other	 other	
LOC100507501	 uncharacterized	LOC100507501	 Other	 other	
LOC101926887	 uncharacterized	LOC101926887	 Other	 other	
LOC101927027	 uncharacterized	LOC101927027	 Other	 other	
LOC101927207	 uncharacterized	LOC101927207	 Other	 other	
LOC101927522	 uncharacterized	LOC101927522	 Other	 other	
LOC101927759	 uncharacterized	LOC101927759	 Other	 other	
LOC101928092	 uncharacterized	LOC101928092	 Other	 other	
LOC101928173	 uncharacterized	LOC101928173	 Other	 other	
LOC101929128	 uncharacterized	LOC101929128	 Other	 other	
LOC101930017	 transcription	initiation	factor	TFIID	subunit	4-like	 Other	 other	
LOC101930333	 uncharacterized	LOC101930333	 Other	 other	
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LOC101930532	 uncharacterized	LOC101930532	 Other	 other	
LOC102723759	 uncharacterized	LOC102723759	 Other	 other	
LOC153684	 uncharacterized	LOC153684	 Other	 other	
LOC200830	 uncharacterized	LOC200830	 Other	 other	
LOC283177	 uncharacterized	LOC283177	 Other	 other	
LOC389765	 kinesin	family	member	27	pseudogene	 Other	 other	
LOC648987	 uncharacterized	LOC648987	 Other	 other	
LOC728554	 THO	complex	3	pseudogene	 Other	 other	
LPAR6	 lysophosphatidic	acid	receptor	6	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
LRG1	 leucine-rich	alpha-2-glycoprotein	1	 Extracellular	
Space	
other	
LRMP	 lymphoid-restricted	membrane	protein	 Cytoplasm	 other	
LRPAP1	 low	density	lipoprotein	receptor-related	protein	
associated	protein	1	
Plasma	
Membrane	
transmembrane	
receptor	
LRRC25	 leucine	rich	repeat	containing	25	 Other	 other	
LRRC37A2	 leucine	rich	repeat	containing	37,	member	A3	 Other	 other	
LRRC37A3	 leucine	rich	repeat	containing	37,	member	A3	 Other	 other	
LRRC4	 leucine	rich	repeat	containing	4	 Plasma	
Membrane	
other	
LSM2	 LSM2	homolog,	U6	small	nuclear	RNA	associated	(S.	
cerevisiae)	
Nucleus	 other	
LY6K	 lymphocyte	antigen	6	complex,	locus	K	 Nucleus	 other	
LYRM1	 LYR	motif	containing	1	 Cytoplasm	 other	
LYSMD1	 LysM,	putative	peptidoglycan-binding,	domain	
containing	1	
Other	 other	
LYSMD2	 LysM,	putative	peptidoglycan-binding,	domain	
containing	2	
Other	 other	
MAD2L1BP	 MAD2L1	binding	protein	 Nucleus	 other	
MADCAM1	 mucosal	vascular	addressin	cell	adhesion	molecule	1	 Plasma	
Membrane	
other	
MAL2	 mal,	T-cell	differentiation	protein	2	(gene/pseudogene)	 Plasma	
Membrane	
transporter	
MANSC1	 MANSC	domain	containing	1	 Other	 other	
MAP2K4	 mitogen-activated	protein	kinase	kinase	4	 Cytoplasm	 kinase	
MAP3K14	 mitogen-activated	protein	kinase	kinase	kinase	14	 Cytoplasm	 kinase	
MAP3K3	 mitogen-activated	protein	kinase	kinase	kinase	3	 Cytoplasm	 kinase	
MAPRE2	 microtubule-associated	protein,	RP/EB	family,	member	
2	
Cytoplasm	 other	
MASTL	 microtubule	associated	serine/threonine	kinase-like	 Cytoplasm	 kinase	
MB21D1	 Mab-21	domain	containing	1	 Cytoplasm	 other	
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MBD4	 methyl-CpG	binding	domain	protein	4	 Nucleus	 enzyme	
MCMBP	 minichromosome	maintenance	complex	binding	
protein	
Nucleus	 other	
MCU	 mitochondrial	calcium	uniporter	 Cytoplasm	 ion	channel	
MDK	 midkine	(neurite	growth-promoting	factor	2)	 Extracellular	
Space	
growth	factor	
MED21	 mediator	complex	subunit	21	 Nucleus	 transcription	
regulator	
MED28	 mediator	complex	subunit	28	 Nucleus	 other	
MED30	 mediator	complex	subunit	30	 Nucleus	 transcription	
regulator	
MEF2D	 myocyte	enhancer	factor	2D	 Nucleus	 transcription	
regulator	
MEGF9	 multiple	EGF-like-domains	9	 Other	 other	
MEMO1	 mediator	of	cell	motility	1	 Cytoplasm	 other	
MET	 MET	proto-oncogene,	receptor	tyrosine	kinase	 Plasma	
Membrane	
kinase	
METTL17	 methyltransferase	like	17	 Nucleus	 other	
MFAP1	 microfibrillar-associated	protein	1	 Extracellular	
Space	
other	
MFSD2A	 major	facilitator	superfamily	domain	containing	2A	 Plasma	
Membrane	
transporter	
MGRN1	 mahogunin	ring	finger	1,	E3	ubiquitin	protein	ligase	 Cytoplasm	 enzyme	
MIA3	 melanoma	inhibitory	activity	family,	member	3	 Cytoplasm	 other	
MICA	 MHC	class	I	polypeptide-related	sequence	A	 Plasma	
Membrane	
other	
MID1IP1	 MID1	interacting	protein	1	 Cytoplasm	 other	
MIS18BP1	 MIS18	binding	protein	1	 Nucleus	 other	
MKL1	 megakaryoblastic	leukemia	(translocation)	1	 Nucleus	 transcription	
regulator	
MKNK2	 MAP	kinase	interacting	serine/threonine	kinase	2	 Cytoplasm	 kinase	
MME	 membrane	metallo-endopeptidase	 Plasma	
Membrane	
peptidase	
MOB3A	 MOB	kinase	activator	3A	 Other	 other	
MOB3C	 MOB	kinase	activator	3C	 Other	 other	
MPDU1	 mannose-P-dolichol	utilization	defect	1	 Cytoplasm	 other	
MPZL2	 myelin	protein	zero-like	2	 Plasma	
Membrane	
other	
MRFAP1L1	 Morf4	family	associated	protein	1-like	1	 Other	 other	
MRPL16	 mitochondrial	ribosomal	protein	L16	 Cytoplasm	 other	
MRPL17	 mitochondrial	ribosomal	protein	L17	 Cytoplasm	 other	
MRPL24	 mitochondrial	ribosomal	protein	L24	 Cytoplasm	 other	
  212 
MRPS6	 mitochondrial	ribosomal	protein	S6	 Cytoplasm	 other	
MRVI1-AS1	 MRVI1	antisense	RNA	1	 Other	 other	
MSL1	 male-specific	lethal	1	homolog	(Drosophila)	 Nucleus	 other	
MSL2	 male-specific	lethal	2	homolog	(Drosophila)	 Nucleus	 other	
MT1A	 metallothionein	1A	 Cytoplasm	 other	
MT1B	 metallothionein	1B	 Cytoplasm	 other	
MT1E	 metallothionein	1E	 Other	 other	
MT1HL1	 metallothionein	1H-like	1	 Other	 other	
MT1L	 metallothionein	1L	(gene/pseudogene)	 Cytoplasm	 other	
MT1M	 metallothionein	1M	 Other	 other	
MT1X	 metallothionein	1X	 Other	 other	
MT2A	 metallothionein	2A	 Cytoplasm	 other	
MTL5	 metallothionein-like	5,	testis-specific	(tesmin)	 Cytoplasm	 other	
MTMR6	 myotubularin	related	protein	6	 Cytoplasm	 phosphatase	
MX1	 MX	dynamin-like	GTPase	1	 Cytoplasm	 enzyme	
MXI1	 MAX	interactor	1,	dimerization	protein	 Nucleus	 transcription	
regulator	
MYL12A	 myosin,	light	chain	12A,	regulatory,	non-sarcomeric	 Cytoplasm	 other	
N4BP2	 NEDD4	binding	protein	2	 Cytoplasm	 kinase	
NAA50	 N(alpha)-acetyltransferase	50,	NatE	catalytic	subunit	 Cytoplasm	 enzyme	
NACC2	 NACC	family	member	2,	BEN	and	BTB	(POZ)	domain	
containing	
Nucleus	 transcription	
regulator	
NAGK	 N-acetylglucosamine	kinase	 Cytoplasm	 kinase	
NAPA	 N-ethylmaleimide-sensitive	factor	attachment	protein,	
alpha	
Cytoplasm	 transporter	
NCAPD2	 non-SMC	condensin	I	complex,	subunit	D2	 Nucleus	 other	
NCK1	 NCK	adaptor	protein	1	 Cytoplasm	 kinase	
NCOA4	 nuclear	receptor	coactivator	4	 Nucleus	 transcription	
regulator	
NDE1	 nudE	neurodevelopment	protein	1	 Nucleus	 other	
NDEL1	 nudE	neurodevelopment	protein	1-like	1	 Nucleus	 other	
NEURL3	 neuralized	E3	ubiquitin	protein	ligase	3	 Other	 other	
NFASC	 neurofascin	 Plasma	
Membrane	
other	
NFATC3	 nuclear	factor	of	activated	T-cells,	cytoplasmic,	
calcineurin-dependent	3	
Nucleus	 transcription	
regulator	
NFX1	 nuclear	transcription	factor,	X-box	binding	1	 Nucleus	 transcription	
regulator	
NGFRAP1	 nerve	growth	factor	receptor	(TNFRSF16)	associated	
protein	1	
Cytoplasm	 other	
NKIRAS2	 NFKB	inhibitor	interacting	Ras-like	2	 Cytoplasm	 enzyme	
NKRF	 NFKB	repressing	factor	 Nucleus	 transcription	
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regulator	
NME1	 NME/NM23	nucleoside	diphosphate	kinase	1	 Cytoplasm	 kinase	
NME2	 NME/NM23	nucleoside	diphosphate	kinase	2	 Nucleus	 kinase	
NNMT	 nicotinamide	N-methyltransferase	 Cytoplasm	 enzyme	
NOMO1	 NODAL	modulator	1	 Plasma	
Membrane	
other	
NPAP1	 nuclear	pore	associated	protein	1	 Cytoplasm	 other	
NPRL2	 nitrogen	permease	regulator-like	2	(S.	cerevisiae)	 Cytoplasm	 kinase	
NPVF	 neuropeptide	VF	precursor	 Extracellular	
Space	
other	
NR2F6	 nuclear	receptor	subfamily	2,	group	F,	member	6	 Nucleus	 ligand-
dependent	
nuclear	
receptor	
NRBF2	 nuclear	receptor	binding	factor	2	 Nucleus	 transcription	
regulator	
NRDE2	 NRDE-2,	necessary	for	RNA	interference,	domain	
containing	
Other	 other	
NRIP3	 nuclear	receptor	interacting	protein	3	 Other	 other	
NRM	 nurim	(nuclear	envelope	membrane	protein)	 Nucleus	 other	
NSUN6	 NOP2/Sun	domain	family,	member	6	 Other	 enzyme	
NT5C2	 5'-nucleotidase,	cytosolic	II	 Cytoplasm	 phosphatase	
NT5C3A	 5'-nucleotidase,	cytosolic	IIIA	 Cytoplasm	 phosphatase	
NTNG2	 netrin	G2	 Plasma	
Membrane	
other	
NUB1	 negative	regulator	of	ubiquitin-like	proteins	1	 Nucleus	 other	
NUDT4	 nudix	(nucleoside	diphosphate	linked	moiety	X)-type	
motif	4	
Cytoplasm	 phosphatase	
NUMB	 numb	homolog	(Drosophila)	 Plasma	
Membrane	
other	
NUP62	 nucleoporin	62kDa	 Nucleus	 transporter	
NUPR1	 nuclear	protein,	transcriptional	regulator,	1	 Nucleus	 transcription	
regulator	
NXT1	 nuclear	transport	factor	2-like	export	factor	1	 Nucleus	 transporter	
OAZ2	 ornithine	decarboxylase	antizyme	2	 Cytoplasm	 other	
OLIG2	 oligodendrocyte	lineage	transcription	factor	2	 Nucleus	 transcription	
regulator	
OR51A4	 olfactory	receptor,	family	51,	subfamily	A,	member	4	 Plasma	
Membrane	
other	
OR51G2	 olfactory	receptor,	family	51,	subfamily	G,	member	2	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
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ORAI1	 ORAI	calcium	release-activated	calcium	modulator	1	 Plasma	
Membrane	
ion	channel	
OTULIN	 OTU	deubiquitinase	with	linear	linkage	specificity	 Cytoplasm	 peptidase	
OXR1	 oxidation	resistance	1	 Cytoplasm	 other	
P2RY12	 purinergic	receptor	P2Y,	G-protein	coupled,	12	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
P4HA1	 prolyl	4-hydroxylase,	alpha	polypeptide	I	 Cytoplasm	 enzyme	
PAICS	 phosphoribosylaminoimidazole	carboxylase,	
phosphoribosylaminoimidazole	succinocarboxamide	
synthetase	
Cytoplasm	 enzyme	
PAIP1	 poly(A)	binding	protein	interacting	protein	1	 Cytoplasm	 translation	
regulator	
PAPD5	 PAP	associated	domain	containing	5	 Nucleus	 enzyme	
PAPD7	 PAP	associated	domain	containing	7	 Nucleus	 enzyme	
PARP10	 poly	(ADP-ribose)	polymerase	family,	member	10	 Cytoplasm	 enzyme	
PARP12	 poly	(ADP-ribose)	polymerase	family,	member	12	 Nucleus	 other	
PARP4	 poly	(ADP-ribose)	polymerase	family,	member	4	 Cytoplasm	 enzyme	
PARP9	 poly	(ADP-ribose)	polymerase	family,	member	9	 Nucleus	 enzyme	
PATL1	 protein	associated	with	topoisomerase	II	homolog	1	
(yeast)	
Cytoplasm	 translation	
regulator	
PCED1B	 PC-esterase	domain	containing	1B	 Other	 other	
PCM1	 pericentriolar	material	1	 Cytoplasm	 other	
PCP2	 Purkinje	cell	protein	2	 Cytoplasm	 other	
PDGFRL	 platelet-derived	growth	factor	receptor-like	 Plasma	
Membrane	
kinase	
PDK1	 pyruvate	dehydrogenase	kinase,	isozyme	1	 Cytoplasm	 kinase	
PDSS1	 prenyl	(decaprenyl)	diphosphate	synthase,	subunit	1	 Cytoplasm	 enzyme	
PDZD8	 PDZ	domain	containing	8	 Extracellular	
Space	
other	
PEF1	 penta-EF-hand	domain	containing	1	 Cytoplasm	 other	
PELI2	 pellino	E3	ubiquitin	protein	ligase	family	member	2	 Cytoplasm	 other	
PER1	 period	circadian	clock	1	 Nucleus	 other	
PF4V1	 platelet	factor	4	variant	1	 Extracellular	
Space	
cytokine	
PGBD2	 piggyBac	transposable	element	derived	2	 Other	 other	
PHACTR2	 phosphatase	and	actin	regulator	2	 Other	 other	
PHF11	 PHD	finger	protein	11	 Other	 other	
PHF20	 PHD	finger	protein	20	 Nucleus	 other	
PHOSPHO1	 phosphatase,	orphan	1	 Extracellular	
Space	
enzyme	
PI4K2A	 phosphatidylinositol	4-kinase	type	2	alpha	 Cytoplasm	 kinase	
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PI4K2B	 phosphatidylinositol	4-kinase	type	2	beta	 Cytoplasm	 kinase	
PIGY	 phosphatidylinositol	glycan	anchor	biosynthesis,	class	Y	 Plasma	
Membrane	
other	
PIKFYVE	 phosphoinositide	kinase,	FYVE	finger	containing	 Cytoplasm	 kinase	
PIM1	 Pim-1	proto-oncogene,	serine/threonine	kinase	 Cytoplasm	 kinase	
PIM2	 Pim-2	proto-oncogene,	serine/threonine	kinase	 Other	 kinase	
PLA2G16	 phospholipase	A2,	group	XVI	 Nucleus	 enzyme	
PLEKHA4	 pleckstrin	homology	domain	containing,	family	A	
(phosphoinositide	binding	specific)	member	4	
Cytoplasm	 other	
PLEKHB2	 pleckstrin	homology	domain	containing,	family	B	
(evectins)	member	2	
Other	 other	
PLEKHM3	 pleckstrin	homology	domain	containing,	family	M,	
member	3	
Other	 other	
PLK2	 polo-like	kinase	2	 Nucleus	 kinase	
PLSCR2	 phospholipid	scramblase	2	 Other	 other	
PML	 promyelocytic	leukemia	 Nucleus	 transcription	
regulator	
PNMA5	 paraneoplastic	Ma	antigen	family	member	5	 Other	 other	
PNMA6A	 paraneoplastic	Ma	antigen	family	member	6A	 Cytoplasm	 other	
PNPT1	 polyribonucleotide	nucleotidyltransferase	1	 Cytoplasm	 enzyme	
POC5	 POC5	centriolar	protein	 Cytoplasm	 other	
POLB	 polymerase	(DNA	directed),	beta	 Nucleus	 enzyme	
POM121	 POM121	transmembrane	nucleoporin	 Nucleus	 other	
POMZP3	 POM121	and	ZP3	fusion	 Nucleus	 other	
POPDC2	 popeye	domain	containing	2	 Other	 other	
PPA1	 pyrophosphatase	(inorganic)	1	 Cytoplasm	 enzyme	
PPAPDC1B	 phosphatidic	acid	phosphatase	type	2	domain	
containing	1B	
Other	 phosphatase	
PPARD	 peroxisome	proliferator-activated	receptor	delta	 Nucleus	 ligand-
dependent	
nuclear	
receptor	
PPARG	 peroxisome	proliferator-activated	receptor	gamma	 Nucleus	 ligand-
dependent	
nuclear	
receptor	
PPBP	 pro-platelet	basic	protein	(chemokine	(C-X-C	motif)	
ligand	7)	
Extracellular	
Space	
cytokine	
PPFIA4	 protein	tyrosine	phosphatase,	receptor	type,	f	
polypeptide	(PTPRF),	interacting	protein	(liprin),	alpha	
4	
Plasma	
Membrane	
phosphatase	
PPIL1	 peptidylprolyl	isomerase	(cyclophilin)-like	1	 Plasma	 enzyme	
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Membrane	
PPM1D	 protein	phosphatase,	Mg2+/Mn2+	dependent,	1D	 Cytoplasm	 phosphatase	
PPM1K	 protein	phosphatase,	Mg2+/Mn2+	dependent,	1K	 Cytoplasm	 phosphatase	
PPP1R12A	 protein	phosphatase	1,	regulatory	subunit	12A	 Cytoplasm	 phosphatase	
PPP1R12B	 protein	phosphatase	1,	regulatory	subunit	12B	 Other	 phosphatase	
PRDX4	 peroxiredoxin	4	 Cytoplasm	 enzyme	
PRKAG2	 protein	kinase,	AMP-activated,	gamma	2	non-catalytic	
subunit	
Cytoplasm	 kinase	
PRKD2	 protein	kinase	D2	 Cytoplasm	 kinase	
PRMT2	 protein	arginine	methyltransferase	2	 Nucleus	 enzyme	
PRORY	 proline	rich,	Y-linked	 Other	 other	
PRPF38B	 pre-mRNA	processing	factor	38B	 Other	 other	
PRPS2	 phosphoribosyl	pyrophosphate	synthetase	2	 Cytoplasm	 kinase	
PRR12	 proline	rich	12	 Extracellular	
Space	
other	
PRSS16	 protease,	serine,	16	(thymus)	 Extracellular	
Space	
peptidase	
PRUNE	 prune	exopolyphosphatase	 Nucleus	 enzyme	
PSIP1	 PC4	and	SFRS1	interacting	protein	1	 Nucleus	 other	
PSMA4	 proteasome	(prosome,	macropain)	subunit,	alpha	type,	
4	
Cytoplasm	 peptidase	
PSMB6	 proteasome	(prosome,	macropain)	subunit,	beta	type,	
6	
Other	 peptidase	
PWWP2A	 PWWP	domain	containing	2A	 Other	 other	
PYGO2	 pygopus	family	PHD	finger	2	 Nucleus	 other	
RAB11FIP1	 RAB11	family	interacting	protein	1	(class	I)	 Cytoplasm	 other	
RAB13	 RAB13,	member	RAS	oncogene	family	 Plasma	
Membrane	
enzyme	
RAB20	 RAB20,	member	RAS	oncogene	family	 Cytoplasm	 enzyme	
RAB2A	 RAB2A,	member	RAS	oncogene	family	 Cytoplasm	 enzyme	
RAB36	 RAB36,	member	RAS	oncogene	family	 Cytoplasm	 enzyme	
RAB37	 RAB37,	member	RAS	oncogene	family	 Cytoplasm	 enzyme	
RAB8A	 RAB8A,	member	RAS	oncogene	family	 Plasma	
Membrane	
enzyme	
RACGAP1	 Rac	GTPase	activating	protein	1	 Cytoplasm	 transporter	
RAF1	 Raf-1	proto-oncogene,	serine/threonine	kinase	 Cytoplasm	 kinase	
RAPGEF6	 Rap	guanine	nucleotide	exchange	factor	(GEF)	6	 Plasma	
Membrane	
other	
RARA	 retinoic	acid	receptor,	alpha	 Nucleus	 ligand-
dependent	
nuclear	
receptor	
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RASGRP3	 RAS	guanyl	releasing	protein	3	(calcium	and	DAG-
regulated)	
Cytoplasm	 other	
RASSF1	 Ras	association	(RalGDS/AF-6)	domain	family	member	
1	
Nucleus	 other	
RBBP6	 retinoblastoma	binding	protein	6	 Nucleus	 enzyme	
RBCK1	 RanBP-type	and	C3HC4-type	zinc	finger	containing	1	 Cytoplasm	 transcription	
regulator	
RBM11	 RNA	binding	motif	protein	11	 Nucleus	 other	
RBM14	 RNA	binding	motif	protein	14	 Nucleus	 transcription	
regulator	
RBM20	 RNA	binding	motif	protein	20	 Nucleus	 other	
RBM47	 RNA	binding	motif	protein	47	 Other	 other	
RBM4B	 RNA	binding	motif	protein	4B	 Nucleus	 other	
RCBTB2	 regulator	of	chromosome	condensation	(RCC1)	and	
BTB	(POZ)	domain	containing	protein	2	
Cytoplasm	 other	
RCN1	 reticulocalbin	1,	EF-hand	calcium	binding	domain	 Cytoplasm	 other	
RCOR1	 REST	corepressor	1	 Nucleus	 transcription	
regulator	
RDH16	 retinol	dehydrogenase	16	(all-trans)	 Cytoplasm	 enzyme	
RELL1	 RELT-like	1	 Other	 other	
REXO1L2P	 REX1,	RNA	exonuclease	1	homolog	(S.	cerevisiae)-like	2	
(pseudogene)	
Other	 other	
RFC1	 replication	factor	C	(activator	1)	1,	145kDa	 Nucleus	 transcription	
regulator	
RFWD2	 ring	finger	and	WD	repeat	domain	2,	E3	ubiquitin	
protein	ligase	
Cytoplasm	 enzyme	
RGS14	 regulator	of	G-protein	signaling	14	 Cytoplasm	 other	
RGS18	 regulator	of	G-protein	signaling	18	 Cytoplasm	 other	
RGS2	 regulator	of	G-protein	signaling	2	 Nucleus	 other	
RHBDD2	 rhomboid	domain	containing	2	 Plasma	
Membrane	
other	
RHBDF2	 rhomboid	5	homolog	2	(Drosophila)	 Cytoplasm	 other	
RHOH	 ras	homolog	family	member	H	 Plasma	
Membrane	
enzyme	
RHOT1	 ras	homolog	family	member	T1	 Cytoplasm	 enzyme	
RIF1	 replication	timing	regulatory	factor	1	 Nucleus	 other	
RILP	 Rab	interacting	lysosomal	protein	 Cytoplasm	 other	
RIN2	 Ras	and	Rab	interactor	2	 Cytoplasm	 other	
RLF	 rearranged	L-myc	fusion	 Nucleus	 transcription	
regulator	
RMI1	 RecQ	mediated	genome	instability	1	 Nucleus	 other	
RNF139	 ring	finger	protein	139	 Cytoplasm	 enzyme	
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RNF213	 ring	finger	protein	213	 Cytoplasm	 enzyme	
RNF44	 ring	finger	protein	44	 Other	 other	
RPN1	 ribophorin	I	 Cytoplasm	 enzyme	
RPRD2	 regulation	of	nuclear	pre-mRNA	domain	containing	2	 Other	 other	
RPS27L	 ribosomal	protein	S27-like	 Cytoplasm	 translation	
regulator	
RPS6KA1	 ribosomal	protein	S6	kinase,	90kDa,	polypeptide	1	 Cytoplasm	 kinase	
RPS6KB2	 ribosomal	protein	S6	kinase,	70kDa,	polypeptide	2	 Cytoplasm	 kinase	
RRM1	 ribonucleotide	reductase	M1	 Nucleus	 enzyme	
RRM2B	 ribonucleotide	reductase	M2	B	(TP53	inducible)	 Nucleus	 enzyme	
RTF1	 Rtf1,	Paf1/RNA	polymerase	II	complex	component,	
homolog	(S.	cerevisiae)	
Nucleus	 other	
SAMD8	 sterile	alpha	motif	domain	containing	8	 Cytoplasm	 other	
SAMD9	 sterile	alpha	motif	domain	containing	9	 Cytoplasm	 other	
SAMD9L	 sterile	alpha	motif	domain	containing	9-like	 Extracellular	
Space	
other	
SAMHD1	 SAM	domain	and	HD	domain	1	 Nucleus	 enzyme	
SAP25	 Sin3A-associated	protein,	25kDa	 Other	 other	
SAP30	 Sin3A-associated	protein,	30kDa	 Nucleus	 transcription	
regulator	
SCAMP1-AS1	 SCAMP1	antisense	RNA	1	 Other	 other	
SCARB2	 scavenger	receptor	class	B,	member	2	 Plasma	
Membrane	
other	
SCARF1	 scavenger	receptor	class	F,	member	1	 Plasma	
Membrane	
transmembrane	
receptor	
SCHIP1	 schwannomin	interacting	protein	1	 Cytoplasm	 other	
SCRG1	 stimulator	of	chondrogenesis	1	 Extracellular	
Space	
other	
SCRN3	 secernin	3	 Other	 other	
SEC11A	 SEC11	homolog	A	(S.	cerevisiae)	 Cytoplasm	 peptidase	
SEC16A	 SEC16	homolog	A	(S.	cerevisiae)	 Cytoplasm	 phosphatase	
SEMA4A	 sema	domain,	immunoglobulin	domain	(Ig),	
transmembrane	domain	(TM)	and	short	cytoplasmic	
domain,	(semaphorin)	4A	
Plasma	
Membrane	
other	
SEMA6B	 sema	domain,	transmembrane	domain	(TM),	and	
cytoplasmic	domain,	(semaphorin)	6B	
Plasma	
Membrane	
other	
SERPINB1	 serpin	peptidase	inhibitor,	clade	B	(ovalbumin),	
member	1	
Cytoplasm	 other	
SERPINB5	 serpin	peptidase	inhibitor,	clade	B	(ovalbumin),	
member	5	
Extracellular	
Space	
other	
SESN3	 sestrin	3	 Extracellular	
Space	
other	
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SETD2	 SET	domain	containing	2	 Cytoplasm	 enzyme	
SETDB2	 SET	domain,	bifurcated	2	 Nucleus	 enzyme	
SGPL1	 sphingosine-1-phosphate	lyase	1	 Cytoplasm	 enzyme	
SGSH	 N-sulfoglucosamine	sulfohydrolase	 Cytoplasm	 enzyme	
SH2D3A	 SH2	domain	containing	3A	 Cytoplasm	 other	
SH2D3C	 SH2	domain	containing	3C	 Cytoplasm	 other	
SHFM1	 split	hand/foot	malformation	(ectrodactyly)	type	1	 Nucleus	 peptidase	
SIGIRR	 single	immunoglobulin	and	toll-interleukin	1	receptor	
(TIR)	domain	
Plasma	
Membrane	
transmembrane	
receptor	
SIGLEC1	 sialic	acid	binding	Ig-like	lectin	1,	sialoadhesin	 Plasma	
Membrane	
other	
SIGLEC14	 sialic	acid	binding	Ig-like	lectin	14	 Plasma	
Membrane	
other	
SIK1	 salt-inducible	kinase	1	 Nucleus	 kinase	
SLC15A2	 solute	carrier	family	15	(oligopeptide	transporter),	
member	2	
Plasma	
Membrane	
transporter	
SLC19A1	 solute	carrier	family	19	(folate	transporter),	member	1	 Plasma	
Membrane	
transporter	
SLC19A2	 solute	carrier	family	19	(thiamine	transporter),	member	
2	
Plasma	
Membrane	
transporter	
SLC22A5	 solute	carrier	family	22	(organic	cation/carnitine	
transporter),	member	5	
Plasma	
Membrane	
transporter	
SLC25A3	 solute	carrier	family	25	(mitochondrial	carrier;	
phosphate	carrier),	member	3	
Cytoplasm	 transporter	
SLC25A45	 solute	carrier	family	25,	member	45	 Cytoplasm	 transporter	
SLC27A3	 solute	carrier	family	27	(fatty	acid	transporter),	
member	3	
Cytoplasm	 transporter	
SLC38A2	 solute	carrier	family	38,	member	2	 Plasma	
Membrane	
transporter	
SLC40A1	 solute	carrier	family	40	(iron-regulated	transporter),	
member	1	
Plasma	
Membrane	
transporter	
SLC51A	 solute	carrier	family	51,	alpha	subunit	 Plasma	
Membrane	
transporter	
SLC5A3	 solute	carrier	family	5	(sodium/myo-inositol	
cotransporter),	member	3	
Plasma	
Membrane	
transporter	
SLC7A5	 solute	carrier	family	7	(amino	acid	transporter	light	
chain,	L	system),	member	5	
Plasma	
Membrane	
transporter	
SLFN13	 schlafen	family	member	13	 Nucleus	 enzyme	
SLX4	 SLX4	structure-specific	endonuclease	subunit	 Nucleus	 other	
SMIM3	 small	integral	membrane	protein	3	 Other	 ion	channel	
SMIM9	 small	integral	membrane	protein	9	 Other	 other	
SNAR-A3	 small	ILF3/NF90-associated	RNA	A3	 Other	 other	
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SNAR-B2	 small	ILF3/NF90-associated	RNA	B2	 Other	 other	
SNAR-D	 small	ILF3/NF90-associated	RNA	D	 Other	 other	
SNAR-F	 small	ILF3/NF90-associated	RNA	F	 Other	 other	
SNAR-G2	 small	ILF3/NF90-associated	RNA	G2	 Other	 other	
SNAR-H	 small	ILF3/NF90-associated	RNA	H	 Other	 other	
SNHG7	 small	nucleolar	RNA	host	gene	7	(non-protein	coding)	 Other	 other	
SNORD35B	 small	nucleolar	RNA,	C/D	box	35B	 Other	 other	
SNRK	 SNF	related	kinase	 Cytoplasm	 kinase	
SNRPD2	 small	nuclear	ribonucleoprotein	D2	polypeptide	
16.5kDa	
Nucleus	 other	
SNX1	 sorting	nexin	1	 Cytoplasm	 transporter	
SOCS2-AS1	 SOCS2	antisense	RNA	1	 Other	 other	
SOCS5	 suppressor	of	cytokine	signaling	5	 Extracellular	
Space	
cytokine	
SORL1	 sortilin-related	receptor,	L(DLR	class)	A	repeats	
containing	
Cytoplasm	 transporter	
SP100	 SP100	nuclear	antigen	 Nucleus	 transcription	
regulator	
SP140L	 SP140	nuclear	body	protein-like	 Other	 other	
SPAG4	 sperm	associated	antigen	4	 Cytoplasm	 other	
SPECC1L	 sperm	antigen	with	calponin	homology	and	coiled-coil	
domains	1-like	
Extracellular	
Space	
other	
SPHK1	 sphingosine	kinase	1	 Cytoplasm	 kinase	
SPHKAP	 SPHK1	interactor,	AKAP	domain	containing	 Cytoplasm	 other	
SPINK6	 serine	peptidase	inhibitor,	Kazal	type	6	 Extracellular	
Space	
other	
SPINT2	 serine	peptidase	inhibitor,	Kunitz	type,	2	 Extracellular	
Space	
other	
SPOPL	 speckle-type	POZ	protein-like	 Other	 other	
SPTA1	 spectrin,	alpha,	erythrocytic	1	 Cytoplasm	 other	
SQRDL	 sulfide	quinone	reductase-like	(yeast)	 Cytoplasm	 enzyme	
SRGAP2B	 SLIT-ROBO	Rho	GTPase	activating	protein	2B	 Other	 other	
SRGAP2C	 SLIT-ROBO	Rho	GTPase	activating	protein	2C	 Other	 other	
SSB	 Sjogren	syndrome	antigen	B	(autoantigen	La)	 Nucleus	 enzyme	
ST3GAL4	 ST3	beta-galactoside	alpha-2,3-sialyltransferase	4	 Cytoplasm	 enzyme	
ST3GAL4-AS1	 ST3GAL4	antisense	RNA	1	(head	to	head)	 Other	 other	
STAT1	 signal	transducer	and	activator	of	transcription	1,	
91kDa	
Nucleus	 transcription	
regulator	
STIM1	 stromal	interaction	molecule	1	 Plasma	
Membrane	
ion	channel	
STK38L	 serine/threonine	kinase	38	like	 Cytoplasm	 kinase	
STOML1	 stomatin	(EPB72)-like	1	 Other	 other	
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STRAP	 serine/threonine	kinase	receptor	associated	protein	 Plasma	
Membrane	
other	
STX17	 syntaxin	17	 Plasma	
Membrane	
transporter	
STXBP3	 syntaxin	binding	protein	3	 Plasma	
Membrane	
transporter	
SURF6	 surfeit	6	 Nucleus	 other	
TACC1	 transforming,	acidic	coiled-coil	containing	protein	1	 Nucleus	 other	
TAPT1	 transmembrane	anterior	posterior	transformation	1	 Plasma	
Membrane	
G-protein	
coupled	
receptor	
TBC1D10C	 TBC1	domain	family,	member	10C	 Nucleus	 other	
TCF20	 transcription	factor	20	(AR1)	 Nucleus	 transcription	
regulator	
TCP11L2	 t-complex	11,	testis-specific-like	2	 Other	 other	
TDRD6	 tudor	domain	containing	6	 Cytoplasm	 other	
TDRD7	 tudor	domain	containing	7	 Cytoplasm	 other	
TECPR2	 tectonin	beta-propeller	repeat	containing	2	 Other	 other	
TET3	 tet	methylcytosine	dioxygenase	3	 Nucleus	 other	
TEX2	 testis	expressed	2	 Other	 other	
TFAP2E	 transcription	factor	AP-2	epsilon	(activating	enhancer	
binding	protein	2	epsilon)	
Other	 other	
TFEC	 transcription	factor	EC	 Nucleus	 transcription	
regulator	
TGFBR2	 transforming	growth	factor,	beta	receptor	II	(70/80kDa)	 Plasma	
Membrane	
kinase	
TGM2	 transglutaminase	2	 Cytoplasm	 enzyme	
THBD	 thrombomodulin	 Plasma	
Membrane	
transmembrane	
receptor	
THRA	 thyroid	hormone	receptor,	alpha	 Nucleus	 ligand-
dependent	
nuclear	
receptor	
TICAM1	 toll-like	receptor	adaptor	molecule	1	 Nucleus	 other	
TINF2	 TERF1	(TRF1)-interacting	nuclear	factor	2	 Nucleus	 other	
TKT	 transketolase	 Cytoplasm	 enzyme	
TLDC2	 TBC/LysM-associated	domain	containing	2	 Other	 other	
TLR6	 toll-like	receptor	6	 Plasma	
Membrane	
transmembrane	
receptor	
TM2D2	 TM2	domain	containing	2	 Extracellular	
Space	
other	
TM4SF1	 transmembrane	4	L	six	family	member	1	 Plasma	 other	
  222 
Membrane	
TMEM123	 transmembrane	protein	123	 Plasma	
Membrane	
other	
TMEM126B	 transmembrane	protein	126B	 Other	 other	
TMEM140	 transmembrane	protein	140	 Other	 other	
TMEM255A	 transmembrane	protein	255A	 Extracellular	
Space	
other	
TMEM30B	 transmembrane	protein	30B	 Other	 other	
TMEM62	 transmembrane	protein	62	 Other	 enzyme	
TMEM81	 transmembrane	protein	81	 Other	 other	
TMLHE-AS1	 TMLHE	antisense	RNA	1	 Other	 other	
TMOD2	 tropomodulin	2	(neuronal)	 Cytoplasm	 other	
TMSB10	 thymosin	beta	10	 Cytoplasm	 other	
TMX4	 thioredoxin-related	transmembrane	protein	4	 Cytoplasm	 enzyme	
TNFRSF10A	 tumor	necrosis	factor	receptor	superfamily,	member	
10a	
Plasma	
Membrane	
transmembrane	
receptor	
TNFRSF10B	 tumor	necrosis	factor	receptor	superfamily,	member	
10b	
Plasma	
Membrane	
transmembrane	
receptor	
TNK2	 tyrosine	kinase,	non-receptor,	2	 Cytoplasm	 kinase	
TNK2-AS1	 TNK2	antisense	RNA	1	 Other	 other	
TOM1L2	 target	of	myb1-like	2	(chicken)	 Cytoplasm	 transporter	
TOPBP1	 topoisomerase	(DNA)	II	binding	protein	1	 Nucleus	 other	
TOR1A	 torsin	family	1,	member	A	(torsin	A)	 Cytoplasm	 enzyme	
TOR1AIP1	 torsin	A	interacting	protein	1	 Nucleus	 other	
TOR1B	 torsin	family	1,	member	B	(torsin	B)	 Cytoplasm	 enzyme	
TOX2	 TOX	high	mobility	group	box	family	member	2	 Nucleus	 transcription	
regulator	
TP53INP1	 tumor	protein	p53	inducible	nuclear	protein	1	 Nucleus	 other	
TPD52L1	 tumor	protein	D52-like	1	 Cytoplasm	 other	
TPI1P2	 triosephosphate	isomerase	1	pseudogene	2	 Other	 other	
TPK1	 thiamin	pyrophosphokinase	1	 Cytoplasm	 kinase	
TPM2	 tropomyosin	2	(beta)	 Other	 other	
TPT1-AS1	 TPT1	antisense	RNA	1	 Other	 other	
TRADD	 TNFRSF1A-associated	via	death	domain	 Cytoplasm	 other	
TRAFD1	 TRAF-type	zinc	finger	domain	containing	1	 Other	 other	
TRIM11	 tripartite	motif	containing	11	 Cytoplasm	 enzyme	
TRIM14	 tripartite	motif	containing	14	 Cytoplasm	 other	
TRIM21	 tripartite	motif	containing	21	 Nucleus	 enzyme	
TRIM26	 tripartite	motif	containing	26	 Cytoplasm	 other	
TRIM34	 tripartite	motif	containing	34	 Cytoplasm	 other	
TRIM5	 tripartite	motif	containing	5	 Cytoplasm	 enzyme	
TRIM56	 tripartite	motif	containing	56	 Cytoplasm	 enzyme	
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TRIM8	 tripartite	motif	containing	8	 Nucleus	 other	
TRIOBP	 TRIO	and	F-actin	binding	protein	 Nucleus	 other	
TSC22D3	 TSC22	domain	family,	member	3	 Nucleus	 transcription	
regulator	
TTC21A	 tetratricopeptide	repeat	domain	21A	 Extracellular	
Space	
other	
TTC26	 tetratricopeptide	repeat	domain	26	 Extracellular	
Space	
other	
TTC38	 tetratricopeptide	repeat	domain	38	 Cytoplasm	 other	
TUSC2	 tumor	suppressor	candidate	2	 Nucleus	 other	
TXN	 thioredoxin	 Cytoplasm	 enzyme	
UBE2W	 ubiquitin-conjugating	enzyme	E2W	(putative)	 Nucleus	 enzyme	
UBFD1	 ubiquitin	family	domain	containing	1	 Other	 other	
UBR2	 ubiquitin	protein	ligase	E3	component	n-recognin	2	 Nucleus	 enzyme	
UBXN7	 UBX	domain	protein	7	 Nucleus	 other	
UCK2	 uridine-cytidine	kinase	2	 Cytoplasm	 kinase	
UNC93B1	 unc-93	homolog	B1	(C.	elegans)	 Cytoplasm	 other	
UPP1	 uridine	phosphorylase	1	 Cytoplasm	 enzyme	
UQCRC1	 ubiquinol-cytochrome	c	reductase	core	protein	I	 Cytoplasm	 enzyme	
USP18	 ubiquitin	specific	peptidase	18	 Cytoplasm	 peptidase	
USP21	 ubiquitin	specific	peptidase	21	 Cytoplasm	 peptidase	
USP25	 ubiquitin	specific	peptidase	25	 Other	 peptidase	
USP3	 ubiquitin	specific	peptidase	3	 Cytoplasm	 peptidase	
USP41	 ubiquitin	specific	peptidase	41	 Other	 other	
USP49	 ubiquitin	specific	peptidase	49	 Other	 peptidase	
USPL1	 ubiquitin	specific	peptidase	like	1	 Extracellular	
Space	
other	
UTP14C	 UTP14,	U3	small	nucleolar	ribonucleoprotein,	homolog	
C	(yeast)	
Nucleus	 other	
VAT1	 vesicle	amine	transport	1	 Plasma	
Membrane	
transporter	
VNN3	 vanin	3	 Extracellular	
Space	
enzyme	
VPS26B	 vacuolar	protein	sorting	26	homolog	B	(S.	pombe)	 Cytoplasm	 transporter	
WAC	 WW	domain	containing	adaptor	with	coiled-coil	 Nucleus	 other	
WDR93	 WD	repeat	domain	93	 Other	 other	
WIPI2	 WD	repeat	domain,	phosphoinositide	interacting	2	 Cytoplasm	 other	
WRAP73	 WD	repeat	containing,	antisense	to	TP73	 Nucleus	 other	
XPO7	 exportin	7	 Nucleus	 transporter	
YAP1	 Yes-associated	protein	1	 Nucleus	 transcription	
regulator	
YME1L1	 YME1-like	1	ATPase	 Cytoplasm	 peptidase	
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YPEL2	 yippee-like	2	(Drosophila)	 Nucleus	 other	
YPEL3	 yippee-like	3	(Drosophila)	 Other	 other	
ZBP1	 Z-DNA	binding	protein	1	 Cytoplasm	 other	
ZBTB18	 zinc	finger	and	BTB	domain	containing	18	 Nucleus	 transcription	
regulator	
ZBTB33	 zinc	finger	and	BTB	domain	containing	33	 Nucleus	 other	
ZBTB34	 zinc	finger	and	BTB	domain	containing	34	 Nucleus	 other	
ZBTB43	 zinc	finger	and	BTB	domain	containing	43	 Nucleus	 other	
ZBTB47	 zinc	finger	and	BTB	domain	containing	47	 Other	 other	
ZCCHC2	 zinc	finger,	CCHC	domain	containing	2	 Cytoplasm	 other	
ZDHHC18	 zinc	finger,	DHHC-type	containing	18	 Cytoplasm	 enzyme	
ZEB2	 zinc	finger	E-box	binding	homeobox	2	 Nucleus	 transcription	
regulator	
ZER1	 zyg-11	related,	cell	cycle	regulator	 Other	 enzyme	
ZFP91	 ZFP91	zinc	finger	protein	 Nucleus	 transcription	
regulator	
ZFYVE26	 zinc	finger,	FYVE	domain	containing	26	 Cytoplasm	 other	
ZMYND10	 zinc	finger,	MYND-type	containing	10	 Cytoplasm	 other	
ZMYND8	 zinc	finger,	MYND-type	containing	8	 Nucleus	 transcription	
regulator	
ZNF106	 zinc	finger	protein	106	 Cytoplasm	 other	
ZNF18	 zinc	finger	protein	18	 Nucleus	 transcription	
regulator	
ZNF182	 zinc	finger	protein	182	 Nucleus	 other	
ZNF398	 zinc	finger	protein	398	 Nucleus	 transcription	
regulator	
ZNF552	 zinc	finger	protein	552	 Other	 other	
ZNF586	 zinc	finger	protein	586	 Other	 other	
ZNF614	 zinc	finger	protein	614	 Other	 other	
ZNF667	 zinc	finger	protein	667	 Nucleus	 other	
ZNF672	 zinc	finger	protein	672	 Other	 other	
ZNF684	 zinc	finger	protein	684	 Nucleus	 other	
ZNF775	 zinc	finger	protein	775	 Other	 other	
ZNF784	 zinc	finger	protein	784	 Other	 other	
ZNF814	 zinc	finger	protein	814	 Other	 other	
ZNFX1	 zinc	finger,	NFX1-type	containing	1	 Nucleus	 transcription	
regulator	
ZYG11B	 zyg-11	family	member	B,	cell	cycle	regulator	 Other	 other	
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